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Introduction 
 
DNA in living organisms is continuously subjected to chemical and physical 
assaults, of both environmental and endogenous origin. To minimize the damage and 
its genetic consequences several processes are active within a cell that sense and 
repair this damage. These processes are diverse in nature and able to manage a 
variety of DNA damage types. Figure 1 summarizes the types of damage that are 
commonly inflicted onto the DNA, their sources, and the relevant DNA repair 
mechanisms that engage in the removal of specific lesions (Hoeijmakers 2001). After 
unraveling the human genome sequence (Lander et al. 2001; Venter et al. 2001), 
150 enzymes have been recognized that could either be functionally linked to the 
recognition and repair of damaged DNA, or that showed sequence homology to 
known repair genes in other organisms (Wood et al. 2001; Wood et al. 2005). The list 
of genes becomes even larger if genes were included that are involved in the control 
of the cell cycle, DNA replication, and apoptosis, processes that are indirectly 
involved in stabilization of the genome. 
Cancer is a disease that results from uncontrolled cellular proliferation. As 
growth control of normal cells is tightly regulated by the genome, cancer is 
considered as a disease of the genes in somatic cells. The capacity of tumor cells to 
divide, invade, and metastasize requires the acquisition of at least three mutation 
events (Vogelstein & Kinzler 1993). However, the frequency of spontaneous 
mutations in healthy individuals is insufficient to explain the lifetime cancer risk (Loeb 
et al. 2008). Rather, it is thought that the accumulation of mutations is due to an initial 
defect in a process that maintains genetic stability, which would result in a condition 
referred to as a “mutator phenotype” that would greatly facilitate subsequent genetic 
hits. A cascade of mutations and epigenetic alterations may ultimately provide the 
cell with properties that characterize an aggressive metastasizing tumor (Loeb 1991). 
Support for the hypothesis is provided by the observation that most tumors are 
genetically unstable (Lengauer et al. 1998). Furthermore, the majority of the genetic 
instability disorders are characterized by predisposition to various types of 
malignancies. 
The genes defective in genetic instability disorders code for enzymes that help 
to maintain genomic integrity and are categorized as “caretaker genes”, a subclass of 
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tumor suppressor genes also referred to as “stability genes” (Vogelstein & Kinzler 
2004). Inactivation of these genes generates a mutator phenotype, which greatly 
increases the chances of growth regulatory genes to become altered by mutation. 
Some caretaker enzymes maintain genetic stability by direct interaction with DNA 
and repair of the damage, while others are involved in control of the cell cycle or 
activation of specialized machineries that facilitate repair. For example, the 
nucleotide excision repair system, which is defective in Xeroderma pigmentosum, 
Cockayne syndrome, and Trichothiodystrophy (Lehmann 2001), plays a direct role in 
the repair of ultraviolet light-induced DNA damage. On the other hand, for the repair 
of DNA double strand breaks resulting from ionizing radiation or chemicals, a 
cascade of reactions is required that delays the cell cycle and recruits repair factors. 
ATM (ataxia telangiectasia mutated) and ATR (ataxia telangiectasia related), which 
are defective in ataxia telangiectasia and Seckel syndrome, respectively (Rotman & 
Shiloh 1998; O'Driscoll et al. 2003), are among the early initiators of the cascade that 
stimulates cell cycle check points and damage repair via homologous recombination 
or end joining (Zhou & Elledge 2000; Khanna & Jackson 2001). The enzymes 
disrupted in the above-mentioned conditions together with those affected in other 
cancer-prone genetic instability disorders including Bloom syndrome, Werner 
syndrome, Rothmond Thomson syndrome, Nijmegen breakage syndrome, and 
Fanconi anemia (FA) (Table 1), appear to be involved in a complex web of 
interactions to maintain genomic stability (Surralles et al. 2004). Although the 
proteins found defective in FA patients interact with most of the proteins representing 
the other instability syndromes, the function of the pathway controlled by FA proteins 
is still poorly understood. 
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Figure 1. DNA damaging agents (top), typical consequential lesions (middle), and the 
relevant repair mechanisms (bottom). IR, ionizing radiation; HU, hydroxyurea; MMC, 
mitomycin C; HR, homologous recombination; NHEJ, non-homologous end joining. Adapted 
from Hoeijmakers 2001 
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Fanconi anemia 
 
The remainder of this introduction is devoted to the chromosomal instability 
disease Fanconi anemia (FA). A brief overview is given of the clinical aspects, 
including diagnosis and treatment, followed by a summary of the cellular phenotype 
and molecular aspects of the FA pathway. Lastly, the significance of the FA pathway 
in relation to the development of various malignancies is discussed. 
 
 
Clinical phenotype 
 
FA is a genetic syndrome named after Guido Fanconi who originally described 
a family in which three brothers suffered from aplastic anemia and congenital 
malformations (Fanconi 1927). The disorder is inherited in an autosomal recessive as 
well as in an X-linked-manner (Meetei et al. 2004a). Although FA is rare, about 5-25 
per million live births (Joenje & Patel 2001), it may vary among ethnic populations 
due to founder effects (Rosendorff et al. 1987; Verlander et al. 1995). Clinical 
features of FA become manifest as pre-and postnatal growth retardation, organ 
malformations (head, skin, skeleton, heart, and kidney), progressive bone marrow 
failure (BMF), and cancer predisposition (Alter et al. 2003; Rosenberg et al. 2008). 
The average life expectancy of FA patients is 25 years (range 0-50 years), and the 
main cause of death is due to progressive bone marrow failure that typically starts 
between 5 and 10 years of age. Other life-threatening complications include 
malignancies, mainly acute myeloid leukemia and squamous cell carcinoma. 
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Table 1. Genetic instability syndromes with hypersensitivity to DNA damage and 
predisposition to cancer 
 
Syndrome  Clinical 
presentation 
Genes Critical 
damaging 
agents 
Cellular process Type of 
neoplasia 
      
Ataxia telangiectasia neurodegeneration, 
immunodeficiency, 
premature aging, 
radiation sensitivity, 
cancer 
ATM Ionizing radiation DSB-recognition and repair 
(NHEJ+HR) 
Lymphoma 
AT-like syndromes 
(ATLD) 
cerebellar 
degeneration, 
radiation sensitivity 
Mre11, Rad50 Ionizing radiation DSB-recognition 
and repair (NHEJ+HR) 
Lymphoma 
Primary microcephaly microcephaly and 
mental retardation 
MCPH1, 3, 5, 
6 
- Chk1 signalling Mitosis - 
Bloom syndrome immunodeficiency, 
premature aging, 
cancer 
BLM UV light Helicase (HDR) All tumors 
Breast/ovarian cancer 
susceptibility 
Breast and ovarian 
cancer 
BRCA1, 
BRCA2 
Reactive oxygen 
species, 
crosslinking agents 
Recombinational repair 
(HDR) 
Breast and 
ovarian cancer 
Cockayne syndrome dwarfism, mental 
retardation, UV light 
sensitivity 
ERCC6, 8 UV light Helicase/Replication-
coupled 
– 
Fanconi anemia congenital 
abnormalities, bone-
marrow failure, 
cancer 
FANC-A, B, C, 
D1,D2,E, F, G, 
I, J, L, M, N 
Cross-linking 
agents, reactive 
oxygen species 
DSB-recognition and 
homology-directed 
recombinational repair 
(HDR) 
AML, squamous 
cell carcinomas 
Hereditary non-
polyposis colorectal 
cancer 
Colorectal cancer MSH2, MSH6, 
MLH1, PMS1,2 
Reactive oxygen 
species  
Mismatch-repair (MMR) Colorectal 
cancer 
Li-Fraumeni cancer p53 Ionizing radiation, 
chemicals 
Cell cycle arrest All tumors 
Nijmegen Breakage 
syndrome 
microcephaly and 
mental retardation, 
immunodeficiency, 
radiation sensitivity, 
cancer 
NBS1 Ionizing radiation DSB-recognition and repair 
(NHEJ+HR) 
Lymphoma 
Rapadilino syndrome Congenital 
malformations 
RecQ4 - Helicase - 
Rothmund-Thompson immunodeficiency, 
premature aging, 
cancer 
RecQ4 Bromodeoxyuridine, 
UV light 
Helicase Sarcoma 
Seckel syndrome Growth retardation, 
microcephaly with 
mental retardation 
ATR Ionizing radiation ATR-BRCA1-CHK1 
signaling 
Leukemia, 
Lymphoma 
Trichothiodystrophy  XPB, XPD, 
TTDA, TTDN1 
UV light Helicase/replication –
coupled repair 
 
Werner syndrome immunodeficiency, 
cancer 
WRN 4-nitroquinoline 1-
oxide 
Helicase/Exonuclease 
(NER) 
Sarcoma 
Xeroderma 
pigmentosum 
UV light sensitivity, 
skin aging, skin 
cancer 
XPA-XPG UV light Nucleotide excision repair 
(NER) 
Skin cancer 
 
Modified from Nevelinget et. al (Neveling et al. 2007a) 
DSB, double strand break; HR, homologous recombination; NHEJ, non-homologous end joining; 
HDR, homology directed repair, MMR, mismatch repair; NER, nucleotide excision repair. 
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Diagnosis 
 
The clinical suspicion of FA needs to be confirmed by examining the 
lymphocytes of the patient for sensitivity to DNA interstrand-cross-linking (ICL) 
agents, such as diepoxybutane (DEB) or Mitomycin C (MMC), in a chromosomal 
breakage assay (Auerbach & Wolman 1976; Cervenka et al. 1981). In this test FA 
cells exhibit dramatically increased levels of chromatid-type aberrations when 
compared to healthy control cells. However, the test is not always conclusive, since 
overlapping diseases exist that may also score positive in the test, such as Nijmegen 
breakage syndrome (Gennery et al. 2004; New et al. 2005). Furthermore, the 
interpretation of the chromosomal breakage test is sometimes complicated by the 
occurrence of genetic reversion in a fraction of the lymphocytes, leading to 
mosaicism in the blood (Lo Ten Foe et al. 1997). The ultimate diagnosis of FA 
requires a molecular analysis to demonstrate pathogenic mutations in a FA gene. 
Mutation analysis is strongly recommended as this may allow prenatal and pre-
implantation genetic diagnosis and help in establishing the mode of inheritance. A 
comprehensive screening approach for FA primarily based on mutation screening is 
described in chapter 2 of this thesis. 
Variation in the clinical manifestation of FA has been reported, which is mainly 
due to genetic heterogeneity based on multiple disease genes and different types of 
mutations. However, the genetic subtypes D1 (mutated in BRCA2/FANCD1) and N 
(mutated in PALB2/FANCN) are exceptional in being associated with a distinctly 
severe clinical phenotype with much poorer prognosis. Within genetic subtypes 
variation results from differences in severity associated with individual mutations. For 
example, the splice site mutation c.456+4A>T (formerly denoted as IVS4+4A>T) in 
the FANCC gene, which accounts for over 80% of all FA patients in Ashkenazi-
Jewish people (Whitney et al. 1993), is much more severe than the frame-shift 
mutation c.67delG (formerly denoted as 322delG) in the same gene, which is 
relatively prevalent in people of Dutch ancestry. Within subtype A, null mutations are 
more severe than mutations that allow near-full length protein expression (Faivre et 
al. 2000). Even within a single family, multiple affected individuals may show marked 
differences in clinical phenotype, suggesting some effect from modifier genes on the 
phenotypic manifestation of FA gene defects. Variation has even been reported in 
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affected identical twins, suggesting that also stochastic effects may play a role (Kwee 
et al. 1996). 
 
 
Treatment 
 
First-line treatment is based on the immediate life-threatening symptoms, such 
as critical organ malfunctions, which are treated by surgery. Also some skeletal 
abnormalities may be treated by surgery to improve the use of parts of the body that 
are malformed, such as the thumbs and arms. Other life-threatening symptoms in FA 
patients that need urgent attention are hematological abnormalities that become 
manifest as failure to form leukocytes, red blood cells, and platelets. Therefore, 
frequent monitoring is required to detect regression of the blood counts (Butturini et 
al. 1994). As a short-term treatment of the aplastic anemia, antibiotics are 
administered to battle infections, while blood transfusions are often necessary to 
increase the blood count to acceptable levels. Alternatively, hematopoietic growth 
factors and androgens are used to stimulate the formation of blood cells. However, 
the effects of these therapies may be poor (Guinan et al. 1994), while the use of 
androgens pose an increased risk of developing liver adenomas (Touraine et al. 
1993). 
Anemia in FA patients can be cured by of hematopoietic stem cell 
transplantation (HSCT). The first-choice donors are human leukocyte antigen-
identical (HLA) siblings (Guardiola et al. 1998), which can lead to success rates up to 
83% with minimal graft failure (Dufour et al. 2001; Tan et al. 2006; Farzin et al. 2007). 
In the past decades, unrelated donor transplants in FA have been disappointing 
because of treatment-related mortality mainly caused by graft failure, graft versus 
host disease, infections, and organ toxicity related to pre-transplant conditioning 
regimens. However, following the introduction of adapted conditioning regimens 
containing fludarabine (Kapelushnik et al. 1997) major improvements of unrelated 
HSCT in FA have been achieved, with increased survival rates ranging from 53% to 
96% (Guardiola et al. 1998; Yabe et al. 2006; Wagner et al. 2007). An attractive 
alternative approach to treat BMF of patients who lack a histocompatible sibling 
donor, is based on the ex vivo correction of the genetic FA defect in the bone marrow 
stem cells using lentiviral carriers to deliver the proficient FA gene (Galimi et al. 
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2002). So far, encouraging results have been achieved (Kelly et al. 2007), but the 
approach is still in the clinical experimental phase. 
Due to improved treatment protocols during the last decade, the life 
expectancy of FA patients has increased from a median age of 20 years to >30 
years. However, solid tumors in older patients represent a new major concern. 
Evidence has been presented that conditioning of FA patients for stem cell 
transplantation was associated with an increased risk of SCC of the head, neck and 
oesophagus (Rosenberg et al. 2003). Moreover, a comparative study for cancer risk 
in FA patients who did or did not receive transplants demonstrated a 4.4-fold higher 
risk in transplanted patients (Rosenberg et al. 2005). Due to the poor tolerance to 
radiotherapy and chemotherapy, the management of malignancies in FA patients 
remains challenging. 
Chapter 1 
 
17 
Cellular phenotype 
 
In addition to chromosomal breakage, a characteristic feature of FA cells is the 
prolonged progression through as well as complete arrest within the late S/G2 phase 
of the cell cycle (Dutrillaux et al. 1982; Akkari et al. 2001), which becomes even more 
pronounced when the cells are challenged with interstrand crosslink (ICL) agents 
(Seyschab et al. 1995; Kruyt et al. 1996). Indeed, the accumulation of 4n cells in 
response to ICLs has been proposed as a convenient alternative method to 
chromosomal breakage analysis for diagnosing FA patients (Bechtold et al. 2006). 
This cellular characteristic is also exploited to identify tumor cells that might have a 
defect in the FA/BRCA pathway (Chapter 8). 
Major processes involved in the repair of DNA damage in wild type cells takes 
place in the S and G2 phase (Lau & Pardee 1982), which suggests that FA cells 
activate a checkpoint to allow for repair of accumulated DNA damage. 
 
 
The FA pathway 
 
To date 13 FA subtypes have been identified for FA (Joenje & Patel 2001; 
Wang W. 2007). Each subtype is linked to a defect in a different disease gene (Table 
2). The encoded proteins work in concert in a distinct genomic maintenance pathway, 
called the FA/BRCA pathway (Figure 2). Most of the proteins (FANCA,-B,-C,-E,-F, -
G, -L, and –M) form a multiprotein complex that is required for the modification of 
FANCD2 and FANCI by monoubiquitination. FANCD2 and FANCI form a complex 
(ID-complex), and are interdependent in terms of stability and monoubiquitination 
(Smogorzewska et al. 2007). The catalytic subunit of the core complex is FANCL, 
which contains a PHD domain and has homology with other E3 ubiquitin ligases 
(Meetei et al. 2004b). Apart from the proteins found defective in FA patients, at least 
three additional FA-associated proteins, FAAP24, FAAP100 and HES1, have been 
identified that are considered essential components of the core complex for the 
modification of FANCD2 and FANCI (Ling et al. 2007; Ciccia et al. 2007; Tremblay et 
al. 2008). Furthermore, evidence for yet to be identified FA genes is discussed in 
Chapter 2. 
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In normal cells, the level of monoubiquitination of the ID-complex is intensified 
when cells are exposed to DNA damaging agents, such as cross-linking agents, 
ultraviolet, or ionizing radiation, or when the deoxyribonucleotide triphosphate pool is 
depleted by hydroxyurea, or when the DNA polymerase α and δ are inhibited by 
aphidicolin (Garcia-Higuera et al. 2001; Gregory et al. 2003; Howlett et al. 2005). 
This step is not influenced by FANCD1 (BRCA2), FANCJ (BRIP1), or FANCN 
(PALB2), so that these proteins are thought to operate downstream of the ID-
complex (Figure 2). Upon modification of the ID-complex, the FANCD2 subunit has 
been shown to co-localize in nuclear foci with many other proteins, including BRCA1 
(Garcia-Higuera et al. 2001), BRCA2 (Wang et al. 2004; Hussain et al. 2004), RAD51 
(Taniguchi et al. 2002; Hussain et al. 2004), proliferating cell nuclear antigen (PCNA) 
(Hussain et al. 2004), and Nijmegen breakage syndrome protein (NBS1) (Nakanishi 
et al. 2002). 
The FA core complex has been purified as part of a larger multiprotein 
complex that also contained the helicase defective in Bloom syndrome (BLM), 
replication protein A, and topoisomerase IIIα (Meetei et al. 2003), proteins that 
engage in DNA-processing activities. With the identification of FANCM, which 
contains a helicase and an endonuclease domain, it was suggested that the FA core 
complex interacts directly with DNA. This interaction could serve as an anchor to flag 
the sites of DNA damage that may result in the recruitment of specialized repair 
enzymes through modification of the ID-complex or to process the DNA for 
subsequent repair (Wang W. 2007). 
Also, the downstream proteins have been shown to form stable complexes 
with DNA-repair proteins. BRCA2 contains BRC-binding domains for RAD51, a RecA 
ortholog that has been shown to play a major role in homologous recombination 
(Wong et al. 1997; Kawabata et al. 2005). FANCJ was shown to co-
immunoprecipitate with BRCA1, topoisomerase II-binding protein 1 (TOPBP1), and 
the mismatch repair protein mutL homologue 1 (MLH1) (Greenberg et al. 2006). The 
link between FA and the mismatch repair system is also suggested by the interaction 
of FANCJ with the MutLα heterodimer, composed of post-meiotic increased 2 
(PMS2) and MLH1 (Peng et al. 2007). 
Activation and function of the FA pathway is thought to take place mainly in 
the S-phase of the cell cycle. Support for this argument is based on cell 
synchronization studies that showed the monoubiquitination of FANCD2 in early S-
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phase and progressing until it is deubiquitinated by USP1 at the exit of S-phase 
(Taniguchi et al. 2002; Nijman et al. 2005). Furthermore, fluorescent-tagged 
components of the core complex (FANCA, FANCC, and FANCG) were shown to 
localize as a complex in foci on chromatin at the beginning of the S-phase, and 
dissociate from the condensed chromosomes before mitosis (Mi & Kupfer 2005). 
During S-phase, in response to replication fork arrest, single-stranded DNA is bound 
by replication protein A (RPA) recruiting ATR and ATRIP, upon which the complex 
becomes engaged in the phosphorylation of multiple substrates (Zou & Elledge 
2003). The main substrate of ATR is checkpoint kinase 1 (CHEK1) (Pichierri & 
Rosselli 2004). Both ATR and CHEK1 together with ATR activators: RPA, ATRIP, 
NBS1, and HCLK2 (Zou & Elledge 2003; Stiff et al. 2005; Collis et al. 2007), have 
been implicated in the activation of the FA/BRCA pathway by facilitating 
phosphorylation of core complex components, FANCD2, FANCI, BRCA2 and 
FANCN (Yamashita et al. 1998; Qiao et al. 2004; Ho et al. 2006; Matsuoka et al. 
2007; Wang W. et al. 2007). 
Besides the involvement in DNA repair and cell cycle control, the FA/BRCA 
pathway has previously been assigned an important role in the defense against 
oxidative damage. Joenje et al. have demonstrated an oxygen-dependence of 
chromosomal breakage in FA cells (Joenje et al. 1981). In another study, FA cells 
were shown to accumulate in S and G2/M phase when exposed to an elevated 
oxygen tension (35% O2), while growth and cell cycle transit were normalized when 
the cells were cultured under a more physiological oxygen level (5% O2) (Schindler & 
Hoehn 1988). The involvement of FA proteins in the cellular response to oxidative 
stress was also suggested by an interaction of FANCC with NADPH cytochrome 
P450 reductase (Kruyt et al. 1998) and glutathione S-transferase (Cumming et al. 
2001), enzymes with recognized redox activities. Also FANCG has been found to 
interact with cytochrome P450 2E1 (Futaki et al. 2002). 
Despite extensive work to decipher the function of the FA proteins in response 
to ICLs and active oxygen species, the exact mechanism by which the FA/BRCA 
pathway counteracts the (geno) toxic effects from these agents is not fully 
understood. 
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Table 2. FA gene characteristics 
 
Gene Chromosome 
location 
exons Amino 
acids 
Molecular 
weight 
reference 
FANCA 16q24.3 43 1455 163 kD (Lo Ten Foe et al. 1996b) 
FANCB Xp22.31 14 859 95 kD (Meetei et al. 2004a) 
FANCC 9q22.3 14 558 63 kD (Strathdee et al. 1992) 
FANCD1 13q13.1 27 3418 384 kD (Howlett et al. 2002) 
FANCD2 3p25.3 44 1451 155 kD (Timmers et al. 2001) 
FANCE 6p21.3 10 536 60 kD (de Winter et al. 2000a) 
FANCF 11p14.3 1 374 42 kD (de Winter et al. 2000b) 
FANCG 9p13.3 14 622 70 kD (de Winter et al. 1998) 
FANCI 15q26.1 37 1268 140 kD (Smogorzewska et al. 2007; Dorsman et 
al. 2007; Sims et al. 2007) 
FANCJ 17q23.2 20 1249 150 kD (Litman et al. 2005; Levran et al. 2005; 
Levitus et al. 2005) 
FANCL 2p16.1 14 375 43 kD (Meetei et al. 2004b) 
FANCM 14q21.2 23 2048 250 kD (Meetei et al. 2005) 
FANCN 16p12.1 13 1188 140 kD (Reid et al. 2007; Xia et al. 2007) 
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Figure 2. A schematic depiction of the FA/BRCA pathway. Upon DNA replication stress, a 
multi-protein complex is formed consisting of FANCA, -B, -C, -E, -F, -G, -L, -M (FA core 
complex), which monoubiquitinates FANCD2 and FANCI, which form the ID complex. After 
this modification step, whereby FANCL acts as the ubiquitin ligase and UBE2T as the 
ubiquitin-conjugating enzyme, the ID complex co-localizes with BRCA2 (FANCD1) to sites of 
DNA damage. HES1, P24, and P100 are proteins that have been found to associate with the 
core-complex, but no FA patients have so far been identified with mutations in these genes. 
USP1, ubiquitin specific peptidase 1, is proposed to deubiquitinate FANCD2. 
UBE2T BRCA1 F 
C 
E 
D2 
ub 
D2 
G 
  A 
B 
L 
M 
N 
D1/BRCA2 
J 
ub 
FA core complex 
(upstream) 
ub 
BRCA1 
USP1 
P100 
downstream 
P24 
I 
I 
HES1 
UBE2
General introduction 
 
22 
FA gene mutations and cancer 
 
In view of the role that FA genes seem to play in avoiding deterioration of genetic 
information, FA gene defects are likely to promote cancer, which is already evident in 
the population of biallelic mutation carriers (FA patients). The cancer-promoting role 
of FA gene defects is less straightforward in the populations of heterozygous carriers 
and in individuals suffering from ‘sporadic’ cancer. The role of FA gene defects in the 
development of malignancies in these 3 populations is discussed below. 
 
 
Homozygous mutation carriers 
 
All FA patients face a high risk of developing cancer, in particular leukemia 
and squamous cell carcinomas. In fact, in about 25% of patients with FA who have 
cancer, the diagnosis of leukemia or a tumor preceded the diagnosis of FA (Alter 
2003a). Based on a literature review that included 1300 FA cases, 9% of patients 
had leukemia, mainly acute myeloid leukemia (AML), 7% had myelodysplastic 
syndrome (MDS), 5% had solid tumors, and 3% had liver tumors (Alter 2003a). The 
high incidence of liver tumors can likely be attributed to prolonged androgen 
treatment (Velazquez & Alter 2004). If FA patients outlive the severe complications of 
bone marrow failure and leukemia, the cumulative probability of developing a solid 
tumor is 76% at the age of 45 (Alter 2003a). Similar observations were made in a 
recent investigation, where a cohort of 181 individuals of mainly German nationality 
was studied (Rosenberg et al. 2003). The most common non-hematological 
malignancies in FA are squamous cell carcinomas (SCCs) of the head and neck, the 
vulva, and the cervix (Kutler et al. 2003), which occur at a much earlier age in FA 
patients than observed in the general population. 
A marked difference in life expectancy and cancer proneness is observed 
within FA subtypes. Patients with defective proteins that operate in the downstream 
part of the FA pathway, especially FANCD1/BRCA2 and FANCN/PALB2, have much 
more severe congenital abnormalities and a higher risk of malignancies than the 
other FA subtypes. Patients who carry bi-allelic mutations in BRCA2 present with an 
early onset of leukemia with a median age of 2.2 years, compared to 13.4 years in 
FA patients belonging to the ‘upstream’ complementation groups (Wagner et al. 
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2004). An assessment of 23 patients in 17 families with bi-allelic BRCA2 mutations 
identified 9 cases of various types of brain tumor (6 medulloblastoma, 2 glioblastoma 
multiforme, and 1 astrocytoma), 5 cases of Wilms tumor, 10 cases of leukemia (7 
AML, and 3 acute lymphoblastic leukemia, ALL). In 4 of those cases, multiple 
cancers were observed. Only one patient reached adulthood without developing 
cancer, which might be explained by a relatively mild mutation that was 
homozygously present in this patient (Reid et al. 2005). Patients belonging to the FA-
N subtype with mutations in the recently identified gene FANCN show similar severe 
clinical characteristics and childhood cancer proneness as patients in the FA-D1 
group. Eight FA-N patients have been described that suffered from brain tumors (5 
meduloblastoma, 1 neuroblastoma), Wilms tumor (3), AML (2), and one case of 
kaposiform hemangioendothelioma (Xia et al. 2007; Reid et al. 2007), a common 
vascular tumor of infancy (Mueller & Mulliken 1999). The close molecular connection 
of BRCA2 with FANCN in the DNA repair pathway may explain the overlap in tumor 
spectrum that is observed between these two patients groups. 
 
 
Heterozygous mutation carriers 
 
Given that FA cells are genetically unstable and are likely to develop into 
cancer cells, at least in homozygous mutation carriers, it is reasonable to 
hypothesize that loss of the wild type allele in a somatic cell of heterozygous 
mutation carrier may initiate a cascade of events leading to cancer, similar to the 
situation in carriers of a mutant Rb (gate-keeper) gene, who likely develop 
retinoblastoma upon inactivation of the wild-type allele (Knudson’s two hit model of 
carcinogenesis (Knudson, Jr. 1971)). In addition, malignancies might arise as a 
consequence of haplo-insufficiency (Santarosa & Ashworth 2004). A distinct cellular 
phenotype has been reported for lymphocytes from heterozygous carriers of 
mutations in BRCA1 or BRCA2 (Buchholz et al. 2002), suggesting that haplo-
insufficiency might represent a carcinogenic mechanism in itself. Alternatively, a 
dominant-negative characteristic of an altered enzyme could result in the obstruction 
of the DNA repair process, as described for several tumor suppressors, such as the 
transcription factor p53 (Ko & Prives 1996). Additional support for the hypothesis of 
haplo-insufficiency was obtained from experiments where FA heterozygous cells 
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were shown to accumulate more DNA breaks in response to irradiation than wild type 
control cells in a comet assay analysis (Djuzenova et al. 2001). In another study, the 
mean number of DEB-induced chromosomal breaks in FA heterozygous lymphocytes 
was found to be slightly but significantly higher compared to wild type control cells 
(0.13±0.06 versus 0.07±0.09) (Pearson et al. 2001), again suggesting that 
heterozygous FA mutations may be associated with an abnormal cellular phenotype. 
The question of whether family members of FA patients, which are obligatory 
carriers of a single FA gene mutation, would have a higher risk to develop cancer 
was addressed as early as in 1971. Although initially an increased incidence of 
cancer in relatives of FA patients was reported (Swift 1971), in a larger study that 
included 25 families the previous observation could not be confirmed (Swift et al. 
1980). Also no convincing evidence for an elevated cancer risk was found in another 
study describing relatives of 9 FA patients, where 7 cases of diverse cancers were 
observed, as compared with the 10.4 expected (P>0.05) (Potter et al. 1983). A recent 
comprehensive and rigorous study was reported by Berwick et al. (2007), which 
included 784 grandparents and 160 other relatives of FA patients, with a total of 404 
heterozygous carriers of mutations in all known FA genes, except FANCL, -M, and –
N. The general conclusion of the study was that heterozygous FA gene mutations do 
not confer an overall increased cancer risk. However, a 1.7-fold higher rate of breast 
cancer (BC) was observed among carrier grandmothers when compared to non-
carriers. The highest standardized increased risk (SIR, 2.4, 95% confidence interval 
[CI], 1.1–5.2) was found in grandmother carriers with FANCC mutations, of which the  
IVS4 mutation (c.711+4A>T ) was the most predominant (5 out of 8 FANCC mutation 
carriers). However, in a separate study including 42 Ashkenazi Jewish IVS4 mutation 
carriers, the alteration did not seem to result in an increased prevalence of 
malignancies (Baris et al. 2007). The overall results of the study by Berwick et al. 
(2008) provided family relatives of common FA patients with molecular support for no 
elevated risk of cancer with respect to the general population, with the possible 
exception of breast cancer. Furthermore, in a more recent study of 36 families 
consisting of 575 individuals from the UK, no overall increased cancer risk was 
observed in FA families as compared to the general population (Tischkowitz et al. 
2008a). 
An alternative approach to study whether FA gene mutations are associated 
with an increased risk of cancer, and hence act as tumor suppressor genes, is the 
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analysis of germ-line FA mutation prevalence in patients with an inherited form of 
cancer. In approximately 20-25% of families with hereditary breast cancer (BC), the 
disease can be mainly explained by mutations in BRCA1 and BRCA2 genes 
(Antoniou et al. 2001; Wooster & Weber 2003). A smaller fraction of familial BC can 
be caused by mutations in TP53 (Lalloo et al. 2003), PTEN (Ueda et al. 1998), 
STK11 (Giardiello et al. 2000a), ATM (Stankovic et al. 1998), or CHEK2 (CHEK2 
Breast Cancer Case-Control Consortium (The CHEK2 Breast Cancer Case-Control 
Consortium 2004). It was hypothesized that at least part of the remaining hereditary 
BCs might be explained by defects in yet-to-be-identified proteins that interact with 
proteins encoded by the known predisposition-causing genes. The identification of 
BRIP1 (BRCA1-Interacting Protein) (Cantor et al. 2001) and PALB2 (Partner And 
Localizer of BRCA2) (Xia et al. 2006) as the disease-causing genes in the FA-J and 
FA-N subtypes, respectively, triggered many researchers to investigate whether 
germ-line mutations in these genes may be associated with familial breast/ovarian 
cancer. In addition, FANCD2, which was found to functionally interact and co-localize 
with BRCA1 and BRCA2 in nuclear foci at sites of DNA damage, is to be considered 
a candidate for causing predisposition to BC (Garcia-Higuera et al. 2001; Wang et al. 
2004). 
Several studies have been conducted to evaluate the possible implication of 
FA genes in BC susceptibility and other cancers. Studies performed on hereditary 
cancers are summarized in Table 3. The involvement of an FA gene other than 
BRCA2, in BC susceptibility was first suggested when two germline mutations in 
FANCJ were detected in 65 individuals with early-onset breast cancer of whom the 
majority had a strong family history (Cantor et al. 2001). However, no FANCJ 
mutations were found in a panel of 340 BRCA1/2-negative familial or early-onset BC 
patients in the Swedish population (Luo et al. 2002). Absence of germ-line 
pathogenic alterations in FANCJ was also reported in the Finnish familial BC 
population (214 cases, (Karppinen et al. 2003)), in the North American population (21 
cases, (Rutter et al. 2003)), Australian population (75 cases, (Lewis et al. 2005), and 
in the French Canadian population (96 cases, (Guenard et al. 2008). Nonetheless, in 
a large study that included 1212 cases in the UK, 9 cases were identified that carried 
truncating mutations in FANCJ (Seal et al. 2006); the authors estimated that such 
mutations conferred a relative risk of 2 (95% CI = 1.2-3.2, P = 0.012). An association 
between FANCN mutations and elevated BC risk has been reported in a similar study 
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that included nearly 1000 familial BC patients from the UK. Truncating mutations 
were detected in 10/923 index cases, compared to 0/1084 controls (Rahman et al. 
2007). The calculated relative risk for FANCN mutation carriers for BC was 2.3-fold 
(95% CI = 1.4-3.9, P = 0.0025). After screening for FANCN mutations in 113 Finnish 
familial BC, a recurrent frameshift mutation, c.1592delT, was found to be present at 
significantly elevated frequency (Erkko et al. 2007). This specific mutation occurred in 
18 cases of 2059 unselected BCs. The contribution of FANCN mutations to BC 
susceptibility was also reported for the Ashkenazi Jewish population (Tischkowitz et 
al. 2007), French-Canadian populations (Foulkes et al. 2007),  Spanish population 
(Garcia et al. 2008), as well as for the Chinese population (Cao et al. 2008). 
However, mutations in FANCN do not seem to contribute to BC risk in the Icelandic 
population (Gunnarsson et al. 2008). A contribution to familial BC predisposition was 
also evaluated for the other FA genes, FANCA, FANCC, FANCF, FANCG, and 
FANCD2 in 88 cases from the UK, but this study did not reveal any disease-causing 
mutation (Seal et al. 2003). Absence of FANCD2 mutations was also reported in the 
Australian BC cohort (Lewis et al. 2005). So far there has been only one study 
investigating the involvement of the X-linked gene FANCB in BC predisposition, but 
none of the 95 analyzed Spanish cases was associated with mutations in this gene 
(Garcia et al. 2008). 
It is relevant to note that mutation screening of FANCD2 in the above-
mentioned studies was performed on genomic DNA. However, such an analysis is 
flawed as it may overlook certain alterations due to the presence FANCD2 
pseudogenes. Therefore, as long as the analysis has not been carried out on cDNA, 
it seems premature to conclude whether or not FANCD2 is implicated in the 
predisposition to BC, or to other cancers. 
Germ-line mutations in BRCA2 have also been linked to familial and sporadic 
cancers of the pancreas and the prostate (Swift 1971; Goggins et al. 1996; Ozcelik et 
al. 1997; Sigurdsson et al. 1997; Kern et al. 2002; Murphy et al. 2002; Tryggvadottir 
et al. 2007), which suggested the possible role of the other members of the FA/BRCA 
pathway in the development these tumors. The disruption of the coding sequence of 
FANCC and FANCG has been reported for a proportion of pancreatic cancers, which 
were selected for LOH at the 9q22.3 and 9p13 loci, respectively (van der Heijden et 
al. 2003). Subsequent examination of the FANCC deficient cell line and an additional 
FANCG mutated cell line demonstrated lack of FANCD2 monoubiquitination and 
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sensitivity to MMC, which could be restored by transduction of the relevant gene (van 
der Heijden et al. 2004). Interestingly, the identified FA gene mutations involved 
early-onset pancreatic cancer cases. Also, truncating FANCC mutations were 
identified in two early-onset cases after screening of 421 unselected pancreatic 
cases, which were not found in 658 controls (Couch et al. 2005). In a Finnish study 
where the FANCN founder mutation c.1592delT was screened in 639 prostate cancer 
cases (164 familial, and 475 unselected cases), one familial case was found positive 
(Erkko et al. 2007). Thus mutations in FANCC, FANCG and the FANCN genes seem 
to have a limited contribution to early-onset pancreatic cancer and familial prostate 
cancer, respectively. 
Altogether, mono-allelic mutations in most of the FA genes coding for the core 
complex proteins do not seem to have a major role in cancer predisposition, except 
mutations in FANCC, which were shown to be associated with a slightly elevated risk 
for cancers of the breast and pancreas. However, in addition to the well-established 
BC susceptibility gene BRCA2/FANCD1, it appears that a substantial role in the 
susceptibility to BC may be ascribed to mutations in the downstream FA genes 
FANCJ, and FANCN. Finally, the most recently identified FA gene, FANCI, which is 
considered a paralog of FANCD2, has not been tested for its potential connection 
with cancer in heterozygous carriers. There is also evidence for at least one as yet 
unidentified downstream FA gene based on a comprehensive mutation screening 
analysis (Chapter 3). To obtain a comprehensive insight into the role of FA/BRCA 
pathway defects in familial or early-onset cancer further analysis should include 
FANCI, FANCD2 (on cDNA) and other yet-to-be-discovered genes acting 
downstream in the pathway. 
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Table 3. FA gene mutation analysis in hereditary/familial cancer patients* 
 
* BRCA2 is not included  
§ screening for specific mutations, not entire gene 
¥ unselected cases 
& other types of cancer tested for the specific mutation, 476 colorectal (188a, 288u), 639 
prostate (164a, 475u).  
^ FANCC exons 2, 3, 7, and 10 not analyzed 
# FANCN mutations are responsible for 1% of Chinese women with early onset breast 
cancer. 
£ 4 mutation were identified of which 3 were considered germline mutations. 
€ 26 Ashkenazi Jewish, 22 Canadian, mixed ethnicity 
N.C: not calculated 
Cancer type Cases Region Gene(s) Relative risk Reference 
      
Breast 65 USA FANCJ N.C. (Cantor et al. 2001) 
 340 Sweden FANCJ Not significant (Luo et al. 2002) 
 88 UK FANC-A, -C, -D2, -E, 
-F, & -G 
Not significant (Seal et al. 2003) 
 41, 399§ Australia FANCD2 Not significant (Lewis et al. 2005) 
 83, 253§ Australia FANCJ Not significant (Lewis et al. 2005) 
 43, 888¥§& Finland FANCJ Not significant (Vahteristo et al. 2006) 
 1212 UK FANCJ 2-fold (Seal et al. 2006) 
 923 UK FANCN 2.3-fold (Rahman et al. 2007) 
 68 Canada€ FANCN 2.3-fold (Tischkowitz et al. 2007) 
 50 Canada FANCN 3.4-fold (Foulkes et al. 2007) 
 96 Canada FANCJ Not significant (Guenard et al. 2008) 
 95, 725§ Spain FANCB & FANCN >2-fold (Garcia et al. 2008) 
 360 China# FANCN N.C (Cao et al. 2008) 
 111, 638§ Iceland FANCN Not significant (Gunnarsson et al. 2008) 
      
Breast & ovarian 214 Finland FANCJ Not significant (Karppinen et al. 2003) 
 79 USA FANCJ Not significant (Rutter et al. 2003) 
 113, 2059¥§o Finland FANCN 11-fold, 4-fold (Erkko et al. 2007) 
      
Pancreas 44 USA FANCA Not significant (Rogers et al. 2004a) 
 38 USA FANCC^ &-G Not significant (Rogers et al. 2004b) 
 421¥ USA FANCC and FANCG Low for FANCC  (Couch et al. 2005) 
      
      
Prostate 95 USA FANCN Not significant (Tischkowitz et al. 2008b) 
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Sporadic cancer 
 
The term ‘sporadic cancer’ is commonly used to describe malignancies 
occurring in individuals at relatively old age and without a family history of cancer. 
However, the distinction from hereditary or ‘familial’ cancer is not absolute, because 
differences in genetic background may alter the penetrance of hereditary cancers, 
whereas exposure to similar environments or lifestyles may cause sporadic cancers 
to mimic familial cancers. In addition, familial/hereditary cancer cases may be 
misclassified as ‘sporadic’ due to circumstances such as small family size, lack of or 
inaccurate information on family members, or lack of susceptible gender in the case 
of sex-associated cancers like prostate or breast cancer (Trepanier et al. 2004). 
Thus, studies on sporadic malignancies are likely to be ‘contaminated’ with cases 
that are actually caused by inherited mutations. 
Several studies have reported on FA/BRCA pathway inactivation in sporadic 
malignancies of various origins. One out of 10 AML cell lines analyzed by Xie et al 
(Xie et al. 2000) lacked FANCF protein expression and was hypersensitive to MMC. 
The aberrant expression resulted from hypermethylation of the FANCF promoter 
region. Resistance to MMC was restored upon transfection with a FANCF-expressing 
construct (see Chapter 5 for details). A MMC-hypersensitive AML cell line with loss of 
FANCD2 monoubiquitination was reported in another study (Lensch et al. 2003). 
However, the MMC sensitivity in that cell line could only partially be rescued by 
ectopic expression of FANCA, while no evidence was found for inactivation of the 
FANCA gene by mutations or epigenetic silencing. 
Silencing of FANCF was also observed in 2 ovarian cancer cell lines 
(Taniguchi et al. 2003), which correlated with increased cisplatin sensitivity and lack 
of FANCD2 modification. In vitro selection for resistance to cisplatin restored FANCF 
expression, although the FANCF promoter region remained partially methylated. In 
the same study, analysis of primary material from 19 ovarian tumors showed 
promoter methylation in 4 cases. Furthermore, promoter methylation of FANCF was 
observed in 15% of HNSCC, and in 14% of non-small cell lung cancer (Marsit et al. 
2004), granulosa cell tumors (Dhillon et al. 2004), breast cancer (Wang et al. 2006; 
Wei et al. 2008), and bladder carcinoma (Neveling et al. 2007b). Recently, FANCN 
promoter methylation was found in two primary breast tumors from BRCA2 mutation 
carriers, four sporadic primary breast tumors, and four sporadic primary ovarian 
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tumors (Potapova et al. 2008). However, in these investigations primary archival 
material was used so that the observations could not be validated by functional 
studies. It should be pointed out, that the original observations by Taniguchi et al. 
(2003) have been contradicted by a recent study in which not a single case of 
FANCF silencing could be demonstrated amongst 106 ovarian tumors (Teodoridis et 
al. 2005), so that the clinical significance of FANCF silencing in sporadic ovarian 
cancer remains uncertain. Furthermore, FANCF promoter methylation could also not 
be confirmed for HNSCC (this thesis, chapter 7), where a panel of 22 patients was 
examined of whom 11 (50%) responded favorably to cisplatin containing treatment. 
The discrepancy between the results might be explained by the methylation detection 
method (MSP) used, which is prone to produce false positive results (Chapter 7). 
Sporadic cancers in which FA gene inactivation has been documented, are 
summarized in Table 4. In Chapter 6 of this thesis, evidence for FANCC and FANCL 
silencing in sporadic acute leukemia is reported, which was associated with MMC 
sensitivity. 
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Table 4. Evidence for FA gene inactivation in “sporadic” malignancies§ 
 
Aberration 
in tumor Gene 
Type of 
malignancy# cases
Functional 
testing 
Detection 
method(s) Reference 
Methylation BRCA2 Breast 9/18 - MSP (Cucer et al. 2008) 
  Granulosa 1/25 - MSP (Dhillon et al. 2004) 
       
 FANCC AML 1/143 - MS-MLPA, BS Chapter 6 
  ALL 3/97 - MS-MLPA, BS Chapter 6 
       
 FANCF AML 1 + BS, PE Chapter 5 
  Bladder 1/41 - MSP (Neveling et al. 2007b) 
  Bladder 1/23 + MSP, BS, PE (Neveling et al. 2007b) 
  Breast 13/75 - MSP (Olopade & Wei 2003) 
   1/120 - MSP (Wei et al. 2008) 
  Cervical 27/91 - MSP (Narayan et al. 2004) 
  Cervical 3/9^ - MSP, mRNA (Narayan et al. 2004) 
  Germ cell 
(male) 
4/70 - MSP, mRNA (Koul et al. 2004) 
  Granulosa 6/25 - MSP, mRNA (Dhillon et al. 2004) 
  HNSCC 13/89 - MSP (Marsit et al. 2004) 
  NSCLC 22/158 - MSP (Marsit et al. 2004) 
  Ovarian 4/19 - MSP (Taniguchi et al. 2003) 
   5/18 - MSP, PE, mRNA (Wang et al. 2006) 
  Ovarian$ 7/53 - MSP (Lim et al. 2008) 
  Ovarian 1/7 - MSP, PE, mRNA (Wang et al. 2006) 
   2 + MSP, BS, PE (Taniguchi et al. 2003) 
   1/9 - MSP, mRNA (Lim et al. 2008) 
       
 FANCL ALL 1/97 - MS-MLPA, BS Chapter 6 
       
 PALB2 Breast 4/60 - BS, mRNA (Potapova et al. 2008) 
  Ovarian 4/53 - BS, mRNA (Potapova et al. 2008) 
       
Mutation BRCA2  Ovarian 4/92* - PTT, M (Hilton et al. 2002) 
       
 FANCC Pancreatic$ 2/33¥ - M (van der Heijden et al. 2003) 
       
 FANCG Pancreatic$ 1/33 - M (van der Heijden et al. 2003) 
       
Absent 
mRNA 
BRCA2 Ovarian 
1/18 
- mRNA (Zikan et al. 2007) 
 BRCA2  Ovarian 12/92* - mRNA, MSP (Hilton et al. 2002) 
 
§ Except for the study by Hilton et al, all studies were done on patients without family history of cancer. 
# In the studies indicated in Italics only cell lines were used. 
^FANCF down regulation was found in three other cell lines without evidence for promoter 
methylation; all 6 cell lines were hypersensitive to MMC. 
*Cohort is composed of familial and sporadic cases (61% based on negative family history). In 12 
cases, BRCA2 mRNA was not detectable, of which one case showed BRCA2 promoter methylation. 
$ 11 unselected pancreatic cell lines and a selection of 22 tumors was made that showed loss of 
heterozygosity at 9q22.3 or 9p13 for mutation screening of FANCC or FANCG, respectively. Mutations 
were found in young-onset pancreatic cancer cases. 
¥Among the two FANCC mutations, c.839 A>T, p.D195V has previously been demonstrated to be non-
pathogenic (Lo Ten Foe et al. 1996a) 
Abbreviations: BS, bisulphite sequencing. M, DNA sequencing. MSP, methylation specific PCR. 
mRNA, undetectable messenger RNA. PE, protein undetectable by Western blotting. PTT, protein 
truncating test. HNSCC, squamous cell carcinoma of the head and neck region. NSCLC, non-small 
cell lung cancer. 
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Outline of the thesis 
 
The overall aim of this thesis is to examine the possible occurrence and significance 
of FA/BRCA pathway defects in sporadic cancer. Part of the work has focused on 
expanding our knowledge of the pathway through diagnostic mutation detection and 
gene identification procedures. In Chapter 2 a comprehensive mutation screening 
approach, in combination with functional assays, was used to determine the 
molecular defects in a group of 80 unselected FA cases. This study resulted in the 
identification of unclassifiable patients who were likely to represent new 
complementation groups, with defects in both the upstream and downstream parts of 
the FA/BRCA pathway. In one of the latter patients the gene could be identified as 
PALB2/FANCN, as described in Chapter 3, which extended the number of genes 
acting in the pathway to thirteen. Examination of large genetic rearrangements of 
PALB2/FANCN in familial breast cancer was performed in Chapter 4, but did not 
reveal the involvement of such aberrations in breast cancer predisposition. 
To explore the occurrence of FA pathway defects in sporadic cancer, the types of 
malignancy that are most commonly observed in FA patients were examined: 
leukemia and squamous cell carcinoma (SCC). Evidence for FA pathway inactivation 
by gene silencing was observed in AML (Chapter 5) and ALL (Chapter 6), albeit in a 
minority of the cases examined. In contrast to previous studies no FANCF promoter 
methylation was observed in a panel of head-and-neck SCC. A possible explanation 
for this discrepancy is explored in Chapter 7. In Chapter 8 various types of SCCs 
were screened for FA protein defects by various procedures, which led to the 
discovery of deficiencies in BRCA1 and -2 protein, again in a minority of the cases. 
The strength of our approach was that we used cell lines instead of primary tumor 
material (in contrast to most published studies), which enabled us to carry out 
functional experiments to confirm results from the DNA and expression studies. In 
Chapter 9 the results of our experiments are discussed from the perspective of their 
potential utility in the personalized treatment of cancer patients. 
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Abstract 
 
Fanconi anemia (FA) is a recessively inherited syndrome with predisposition to 
bone marrow failure and malignancies. Hypersensitivity to cross-linking agents 
is a cellular feature used to confirm the diagnosis. The mode of inheritance is 
autosomal recessive (12 subtypes) as well as X-linked (1 subtype). Most 
genetic subtypes have initially been defined as ‘complementation groups’ by 
cell fusion studies. Here we report a comprehensive genetic subtyping 
approach for FA that is primarily based on mutation screening, supplemented 
by protein expression analysis and by functional assays to test for 
pathogenicity of unclassified variants. Of 80 FA cases analyzed, 73 (91%) were 
successfully subtyped. In total, 92 distinct mutations were detected, of which 
56 were novel (40 in FANCA, 8 in FANCC, 2 in FANCD1, 3 in FANCE, 1 in 
FANCF, and 3 in FANCG). All known complementation groups were 
represented, except D2, J, L, and M. Three patients could not be classified 
because proliferating cell cultures from the probands were lacking. In cell lines 
from the remaining 4 patients immunoblotting was used to determine their 
capacity to monoubiquitinate FANCD2. In one case FANCD2 
monoubiquitination was normal, indicating a defect downstream. In the 
remaining 3 cases monoubiquitination was not detectable, indicating a defect 
upstream. In the latter 4 patients, pathogenic mutations in a known FA gene 
may have been missed, or these patients might represent novel genetic 
subtypes. We conclude that direct mutation screening allows a molecular 
diagnosis of FA in the vast majority of patients, even in cases where growing 
cells from affected individuals are unavailable. Proliferating cell lines are 
required in a minority (<15%) of the patients, to allow testing for FANCD2 
ubiquitination status and sequencing of FANCD2 using cDNA, to avoid 
interference from pseudogenes. 
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Introduction 
 
Fanconi anemia (FA, MIM# 227650) is an inherited bone marrow failure and cancer 
predisposition disorder with both autosomal recessive and X-linked modes of 
inheritance (Taniguchi & D'Andrea 2006; Levitus et al. 2006). Since clinical 
manifestations of FA are diverse and variable and since FA patients require special 
treatment, clinical suspicion should be confirmed at the cellular level, e.g. by a cross-
linking agent-induced chromosomal breakage test. Thirteen complementation groups 
(genetic subtypes) have been distinguished (A, MIM#607139; B, MIM#300515; C, 
MIM#227645; D1, MIM#605724; D2, MIM#227646; E, MIM#600901; F, MIM#603467; 
G, MIM#602956; I, MIM#609053; J, MIM#605882; L, MIM#608111; M, MIM#609644; 
N, MIM#610355). The largest complementation group is A (65%), and together with 
FA-B, -C, -E, -F, and –G accounts for over 90% of all FA cases (Levitus et al. 2006). 
Most FA proteins (FANCA, -B, -C, -E, -F, -G, -L, and –M) assemble into a 
multiprotein complex that activates the small form of FANCD2 (FANCD2-S) into the 
mono-ubiquitinated larger form (FANCD2-L). FANCD2-L is detected as a secondary 
band in a Western blot analysis. The modification directs this protein to sites of 
damaged chromatin where it interacts with other proteins, resulting in repair of the 
damage. The recently identified FANCI/KIAA1794 protein is also monoubiquitinated 
and appears to form a complex with FANCD2 (Xia et al. 2007; Sims et al. 2007; 
Dorsman et al. 2007; Smogorzewska et al. 2007). BRCA2/FANCD1 (Howlett et al. 
2002), BRIP1/FANCJ (Levitus et al. 2005), and PALB2/FANCN (Xia et al. 2007; Reid 
et al. 2007) are so far the only known components of the pathway that function 
downstream of the FANCD2 modification step. Although a positive cytogenetic test 
result is highly indicative for FA, molecular analysis is still required to demonstrate 
pathogenic mutations in a FA gene. This is essential for adequate clinical 
management, as this establishes the mode of inheritance, helps to assess prognosis 
and allows to exclude diseases with overlapping clinical symptoms.  
Retrovirus-mediated complementation of the cellular defect is an established method 
to classify FA patients according to genetic subtype, as a prelude for mutation 
analysis (Chandra et al. 2005; Casado AJ. et al. 2007). A prerequisite for such an 
assay is that growing, cross-linker sensitive, cells from the patient are available. 
Since these may not always be obtainable, the applicability of complementation tests 
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for genetic subtyping is limited. In addition, for some of the subtypes, such as B, D1, 
L, M, and N, complementing constructs are not yet available, leaving patients of 
these subtypes functionally unclassifiable. For such patients it is unclear whether 
they belong to one of the rarer known groups or represent a novel subtype.  
To avoid some of these drawbacks we developed a comprehensive classification 
strategy primarily based on direct mutation screening. Here we evaluate the results 
obtained from 80 FA patients. 
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Results and discussion 
 
The mutation screening strategy adopted for FA subtyping involved the following 
steps (Figure 1). (1) Screening of FANCA for deletions by MLPA, in parallel with 
sequencing the entire FANCA coding region; (2) – in case of a family with only male 
patient(s) – mutation screening of FANCB by MLPA and direct sequencing; (3) 
Screening of FANCC, -E, -F, and –G, simultaneously, by DHPLC and sequencing of 
aberrant fragments. Up to this point a (provisional) molecular diagnosis was obtained 
for >85% of the patients. For the remaining patients, further analysis was carried out 
provided that growing cells from the proband were available. 
Western blotting was used to visualize whether two FANCD2 isoforms were present 
at normal levels. [In cases where both FANCD2-S and -L bands appear to be absent 
or very weak, FANCD2 should be sequenced, from cDNA; however, no such cases 
were encountered in the patient group reported here.] When only the short (non-
ubiquitinated) isoform of FANCD2 was present, FANCI, FANCL, and FANCM were 
sequenced. If no mutations were detected, this was taken as evidence for a novel 
subtype with a defect upstream in the FA pathway. 
When both FANCD2 isoforms were present at normal levels, BRCA2/FANCD1 was 
screened by MLPA, denaturing gradient gel electrophoresis (DGGE), and 
sequencing. If negative, BRIP1/FANCJ and PALB2/FANCN  were sequenced. If 
negative again, the patient was considered to be mutated in a novel FA gene acting 
downstream of FANCD2 ubiquitination, to be confirmed by additional research 
(Figure1). 
As summarized in Table 1 and Figure 2, detection of sequence alterations allowed 
the classification of 73 patients (91%) as belonging to one of the following 8 groups: 
A (48), B (2), C (9), D1 (2), E (3), F (1), G (6), I (1) and N (1) (Figure 3). In the 
autosomal FA genes biallelic mutations were detected, except in FANCA (4x), 
FANCD1 (1x), FANCE (1x), FANCF (1x), and FANCI (1x), where extensive additional 
efforts would be required to identify the second mutation. Out of the 93 distinct 
sequence alterations found, 56 (60%) have not been reported before. 
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Figure 1. Scheme for the molecular diagnosis of patients who tested positive for FA in a 
chromosomal breakage test. For the majority of FA patients (86%) a diagnosis is reached 
based on the analysis of genomic DNA from the patients themselves or their parents (above 
dotted line). For the remaining patients proliferating cell cultures are needed to allow for 
Western blot analysis of FANCD2 and sequencing of FANCD2 at the level of cDNA. *, 
FANCB is sequenced if the patient is a male. #, FANCD2 transcript is sequenced to detect 
splice aberrations. 
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Table 1. Results from screening 80 FA patients for sequence variants in the 13 
known FA genesa 
 
1 or 2 mutations detected 
Effect Case Subtype Mutation 1 Mutation 2 
1 2 
Reference Comments 
1 A c.3746T>C c.709+5G>A p.L1249P A N/(Lo et al. 1996b) 1: possibly hypomorphic 
2 A c.862G>T c.2051T>C p.E288X p.L684P (Wijker et al. 1999)/(Levran et 
al. 2005) 
 
3 A ex11_33del c.2851C>T D p.R951W N/(Levran et al. 2005)  
4 A c.275C>A c.3624C>T p.S92X A N/N splicing error demonstrated on cDNA 
5 A ex1_30del c.629T>G D p.L210R (Wijker et al. 1999)/N 2: pathogenic by functional test 
6 A c.3920delA c.4083_4084insG B B (Wijker et al. 1999)/N  
7 A ex1_31del c.3788_3790del D C N/(Levran et al. 1997)  
8 A ex15_23del c.1115_1118del d B N/(FAB consortium 1996)  
9 A c.1115_1118del c.2870G>A B p.W957X (FAB consortium 1996)/N  
10 A c.1464C>G  c.2632G>C p.Y488X A N/(Wijker et al. 1999)  
11 A c.2282T>A NF p.V761E -- N FA-A by cell fusion analysis, second 
allele not expressed 
12 A ex29del c.1164_1165del D B N/(Wijker et al. 1999)  
13 A ex6_8del ex11_21del d D N/N  
14 A c.4036G>A c.710-
143_144insCT 
p.A1346T A N/N 1: pathogenic status uncertain  
2: predicted splicing error* 
15 A ex16_17del c.1034_1035del d B (Levran et al. 1997)/(Levran 
et al. 2005) 
 
16 A ex31_33del c.100A>T D p.K34X N/N  
17 A ex7_20del c.3558_3559insG d B (Morgan et al. 1999)/(Savino 
et al. 1997) 
 
18 A c.3520_3522del c.3520_3522 del b b (Levran et al. 1997)  
19 A c.2853-19del19 c.2853-19del19 A A (Levran et al. 1997)  
20 A ex4_5del c.3788_3790del D b N/(Levran et al. 1997)  
21 A c.987_990del c.2638C>T B p.R880X (Levran et al. 1997)/N  
22 A ex22_28del ex22_28del D D (Lo et al. 1996b)  
23 A c.2535_2536del c.2604_2609del B b (Levran et al. 1997)/(Levran 
et al. 2005) 
 
24 A ex18_23del c.3788_3790del d C N/(Levran et al. 1997)  
25 A c.3391A>G NF p.T1131A -- (Levran et al. 1997)  
26 A c.2606A>C NF p.E869P -- N 1: pathogenic by functional test 
27 A c.2535_2356del c.1979T>C B p.L660P (Levran et al. 1997)/N 2: pathogenic by functional test 
28 A c.2826_2844dup19 c.3239+82T>G B A N/N predicted splicing error* 
29 A c.3558_3559insG c.987_990del B B (Savino et al. 1997)/(Levran 
et al. 1997) 
 
30 A c.2736_2737insA c.2736_2737insA B B N  
31 A c.3021_3027del c.4069_4083del B B N/(Levran et al. 1997)  
32 A c.790C>T c.2535_2536del p.E264X B (Savino et al. 1997)/(Levran 
et al. 1997) 
 
33 A NF NF -- -- N exon 11 skipping detected on cDNA 
34 A c.3788_3790del c.3558_3559insG b B (Levran et al. 1997)/(Savino 
et al. 1997) 
 
35 A ex4_5del c.1115_1118del D B N/(FAB consortium 1996)  
36 A c.3348+5G>A c.3788_3790del A b N/(Levran et al. 1997) predicted splicing error* 
37 A c.3558_3559insG c.2852G>A B p.R951Q (Savino et al. 1997)/ (Levran 
et al. 2005) 
 
38 A c.2807A>G c.2807A>G p.E936G A (Levran et al. 2005) exon 29 skipping detected on cDNA 
39 A c.3602_3604del ex18_21del b D N/N  
40 A c.3971G>T c.4199G>A p.P1324L p.R1400H (Morgan et al. 1999)/N 1: pathogenic by functional test 
2: possibly hypomorphic 
41 A ex27_36del c.3391A>G D p.T1131A N/(Levran et al. 1997)  
42 A c.173_174insA c.427-2A>G B A N/ N predicted splicing error* 
43 A ex1_43del c.2807A>G D p.E936G (Centra et al. 1998)/(Levran 
et al. 2005) 
2: exon 29 skipping detected on cDNA 
44 A c.2527T>G c.2527T>G p.Y843D p.Y843D N Y conserved in Xenopus, pathogenic 
status uncertain 
45 A c.128T>A c.2151+2_3insG p.L43X A N/N predicted splicing error* 
46 A c.3788_3790del c.4130C>G b p.S1377X (Levran et al. 1997)/N  
47 A c.1470G>A c.2851C>T p.Q490Q p.R951W N/(Levran et al. 2005) 1: predicted splicing error 
48 A ex15del ex15del d d N  
49 B c.811_812insT -- B -- (Meetei et al. 2004) Gene is X-linked 
50 B c.1650delT -- B -- (Meetei et al. 2004) Gene is X-linked 
51 C c.376_377del c.844-1G>C B A N/N predicted splicing error* 
52 C c.553C>T c.1639C>T p.R185X p.R547X N/N  
53 C c.67delG c.844-1G>C B A (Strathdee et al. 1992)/N predicted splicing error* 
54 C c.356_360del c.356_360del B B N  
55 C c.450_451insA c.1390C>T B p.E464X N/N  
56 C c.65G>A c.65G>A p.W22X p.W22X (Gibson et al. 1996)  
57 C c.65G>A c.65G>A p.W22X p.W22X (Gibson et al. 1996)  
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58 C c.1390C>T c.996G>A p.E464X A N/N 2: predicted splicing error 
59 C c.67delG c.67delG B B (Gibson et al. 1993)  
60 D1 c.9901_9902insA NF B -- N  
61 D1 c.1538_1541del c.1538_1541del B B N  
62 E c.1111C>T c.1111C>T p.R371W p.R371W N FANCE protein not expressed 
63 E c.551C>A NF p.P184Q -- N P conserved in mouse, pathogenic 
status uncertain 
64 E c.91C>T c.91C>T p.Q31X p.Q31X N  
65 F c.825G>A NF A  N predicted splicing error* 
66 G c.1077-2A>G c.1077-2A>G A A (Demuth et al. 2000)  
67 G c.1077-2A>G c.1077-2A>G A A (Demuth et al. 2000)  
68 G c.1077-2A>G c.1077-2A>G A A (Demuth et al. 2000)  
69 G c.1077-2A>G c.1077-2A>G A A (Demuth et al. 2000)  
70 G c.1528C>T c.1528C>T p.E510X p.Q510X N  
71 G c.271_272del c.620delT B B N/N  
72 I c.2509G>T NF p.E837X -- (Sims et al. 2007) FA-I by cell  fusion analysis 
73 N c.1802T>A ex 1_10 del pY551X d (Xia et al. 2007)  
No mutations detected  
Effect Case Subtype Mutation 1 Mutation 2 
1 2 
Reference Comments 
74 ? NF NF -- --  No cell line available 
75 ? NF NF -- --  No cell line available 
76 ? NF NF -- --  No cell line available 
77 ? NF NF -- --  No FANCD2-L 
78 ? NF NF -- --  No FANCD2-L 
79 ? NF NF -- --  No FANCD2-L 
80 ? NF NF -- --  FANCD2-L present 
 
a Description of the mutations is based on cDNA sequence, +1 corresponding to the A of the 
ATG translation initiation codon of the reference sequence. NF, mutation not found; N, new 
mutation, not reported before; A, altered splicing of pre-mRNA; B, micro-deletion/insertion, 
out-of-frame; b, micro-deletion/insertion, in-frame; D, exon(s) deletion, out-of-frame; d, 
exon(s) absent by MLPA, breakpoints unknown. Some of the novel missense mutations were 
functionally tested and found pathogenic (boldface); the status of the two underlined 
variants was uncertain, because some functional activity was present in a transfection assay, 
suggesting that these mutations might be hypomorphs. 
* According to http://www.fruitfly.org/seq_tools/splice.html and 
http://www.cbs.dtu.dk/services/NetGene2/. 
Genetic subtyping of Fanconi anemia 
 
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mutations in FANC-A, -B, -C, -D1, -E, -F, -G, -I, and –N. The open reading frames 
with their exon structures are drawn roughly to scale. Most mutations occur in FANCA, a 
large proportion of which are deletions (horizontal bars), as detected by MLPA. Polymorphic 
variants are not indicated. 
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Most novel mutations were considered pathogenic because of their severity, such as 
frameshifts and deletions. For missense mutations the pathogenic consequences are 
often uncertain. Some of these unclassified variants were tested for pathogenicity by 
assessing their ability to complement the cellular FA defect in a deficient cell line. Of 
6 FANCA missense variants tested, 4 failed to completely restore MMC resistance 
and were thus considered pathogenic. Two variants (c.3746T>C / p.L1249P and 
c.4199G>A / p.R1400H in FANCA) exhibited a level of activity similar to wild type, 
suggesting non-pathogenicity of these mutations. However, we cannot exclude that 
these mutations are hypomorphic and that overexpression has compensated for 
potential instability of the mutant protein. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Genetic subtyping of 80 unselected FA patients. Seventy three patients were 
assigned to 9 subtypes: A: 58; B: 2; C: 9; D1: 2; E: 3; F: 1; G: 6; I: 1; N: 1. In this cohort no 
patients were found in groups D2, J, L, and M. Of the remaining 7 patients, 3 were 
unclassifiable because available material was unsuitable for further analysis. Cell lines from 
the remaining four patients were analyzed for the presence of monoubiquitinated FANCD2, 
which was detected in only one case. The latter 4 patients might represent novel 
complementation group(s). 
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protein level was not possible. These patients could thus not be classified. From the 
remaining 4 patients cultured cells were used to examine their FANCD2 
ubiquitination status by Western blotting. Three patients expressed only non-
ubiquitinated FANCD2, suggesting a defect upstream in the FA/BRCA pathway. 
These patients may thus represent (a) novel complementation group(s). The 
remaining patient expressed both FANCD2 isoforms, indicating a defect downstream. 
No sequence alterations in FANCD1, -J, or -N were found, suggesting the possible 
existence of a novel FA protein that functions downstream in the FA/BRCA pathway. 
However, the possibility that pathogenic mutations in a known FA gene were missed 
can not be excluded completely. The ultimate diagnosis of the four unclassified 
patients therefore remains uncertain until pathogenic mutations have been 
demonstrated in their disease-causing genes. 
The mutation screening strategy presented here proved to be efficient in the 
molecular diagnosis of FA patients. Of the 73 successfully diagnosed patients 69 
(94%) were classified by analysis of genomic DNA from the patients. Six of the 
variants identified (6%) required functional testing to assess their pathogenicity. In 
seven patients mutations were found in only one allele (3 in FANCA, 1 in FANCD1, 1 
in FANCE, 1 in FANCF, and 1 in FANCI). Mutations on the second allele had either 
been missed or were absent due to reverse mosaicism, a relatively common event in 
FA (Waisfisz et al. 1999). For these cases complementation testing is required to 
confirm whether the identified sequence variants reside in the disease-causing 
genes. 
Complementation group FA-A is by far the largest group, accounting for about 65% 
of the FA cases (Faivre et al. 2000). Because of the high frequency of large deletions 
encountered in FANCA (Morgan et al. 1999) deletion screening by MLPA as an initial 
step in the mutation screening approach is highly efficient, as this allows the 
classification of approximately 25% of unselected FA patients. MLPA did not only 
detect large deletions but also detected some micro-deletions, such as the relatively 
common micro-deletion c.3788-3790delTCT, which is observed in approximately 5% 
of the all FA-A patients (Levran et al. 1997). A novel micro-deletion c.3021-3027del7 
as well as the previously described mutation c.4069-4082del15 (Levran et al. 2005) 
were also detected. Moreover, the missense mutation c.2807A>G (p.E936Q) 
apparently interfered with the amplification of the exon 29-specific probe and was 
thus detected as an aberration by MLPA. Further examination of this substitution on 
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the cDNA level showed aberrant splicing, resulting in skipping of exon 29. 
Examination of cDNA is sometimes essential to determine the pathogenicity of 
certain variants. For example, c.2632G>C in FANCA has been reported as 
nonpathogenic (Wijker et al. 1999). However, cDNA analysis demonstrated a 33-bp 
deletion of exon 28 sequence, so that this mutation is probably pathogenic by 
causing aberrant splicing. 
We conclude that our comprehensive mutation screening approach offers a highly 
effective method for the ultimate diagnosis of the great majority of FA patients. In a 
minority of cases functional tests, such as retroviral complementation or transfection, 
are required to help assess the pathogenic status of novel unclassified missense 
variants. With an ever expanding database of already characterized sequence 
variants the requirement for additional functional tests will gradually diminish. 
 
 
Materials and Methods 
 
Patients, cells, and DNA. Patients were referred for mutation screening, after the FA 
diagnosis had been established by a chromosomal breakage test. Genomic DNA 
was obtained from blood, skin, B lymphoblastoid cell lines (LCLs), or fibroblasts, 
according to standard protocols. Where applicable, cDNA was synthesized from total 
RNA isolated from cycloheximide-treated cells using SuperscriptTM II RNase H 
reverse transcriptase (Invitrogen), and Oligo dT priming (Roche) according to 
standard protocols. This study was approved by the VUmc Institutional Review 
Board. 
 
MLPA Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was used 
to detect deletions or amplifications in the FANCA, FANCB, FANCD1, and FANCN 
genes. MLPA is a rapid quantitative method for the detection of deletion/amplification 
of up to 40 specific DNA fragments in a single PCR reaction (Schouten et al. 2002). 
The MLPA kits, developed in collaboration with the manufacturer (MRC-Holland BV, 
Amsterdam) detect aberrations in FANCA, FANCB, FANCD1, and FANCN; details 
are available at http://www.mrc-holland.com. Briefly, target DNA was denatured for 5 
min at 98 °C, 3 µl of the probe mix was added, after which the mixture was heated for 
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1 min at 98 °C and incubated at 60 °C overnight (16 hr); after addition of ligase the 
mixture was incubated at 54 °C for 15 min. Ligase was subsequently inactivated at 
98 °C for 5 min. Next, 10 µl was transferred to PCR mix containing PCR buffer, 
deoxynucleotide triphosphates, Taq polymerase, and one unlabeled and one 
carboxyfluorescein-labeled PCR primer, which are complementary to the universal 
primer sequence. The PCR reaction was carried out for 33 cycles (30 s at 95 °C, 30 s 
at 60 °C, and 60 s at 72 °C). The fragments were analyzed on an ABI model 310 
capillary sequencer (Applied Biosystems) using genescan-TAMRA 500 size standard 
(Applied Biosystems). Description of the deletions was limited to the affected exons. 
No attempts were made to determine the exact breakpoints of deletions at the 
genomic DNA level. 
 
PCR. Genomic fragments representing all exons of FANCA, –B, –C, –E, –F, –G, and 
–J, (GenBank accession numbers: NM_000135.2, NM_152633.2, NM_000136.2, 
NM_021922.2, NM_022725.2, NM_004629.1, NM_032043.1, respectively) were 
amplified by PCR. Primers were designed to include flanking intronic regions and to 
generate amplicons ranging between 200 and 450 bp, ensuring optimal results when 
analyzed by Denaturing High-Performance Liquid Chromatography (dHPLC). 
FANCD1, -D2, -I, -L, and –M were analyzed from cDNA, in cases where a cell line 
was available (GenBank accession numbers: NM_000059.3, NM_033084.3, 
EF469766.1, NM_018062.2, NM_020937.1, respectively). Experimental details are 
available upon request. 
 
Mutation screening by DHPLC. PCR products were separated, after a denaturation at 
98 ºC and a gradual renaturation at a final temperature of 37 ºC, by DHPLC on the 
WAVE HT system (Transgenomics, USA) using an acetonitrile gradient (Rischewski 
& Schneppenheim 2001). Analysis was at three column temperatures according to 
predictions by the Wavemaker software (Transgenomics, USA). 
 
Sequencing and description of mutations. Independent PCR fragments, derived from 
genomic DNA or cDNA, were sequenced using the BigDye Terminator Cycle 
Sequencing V3.1 Ready Reaction kit (Applied Biosystems), and analyzed on an ABI 
PRISM 3100 Genetic Analyzer. The same primer sets were used for PCR and 
sequencing. With the exception of large deletions (see MLPA) all sequence variants 
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were described according to current nomenclature rules 
(http://www.hgvs.org/mutnomen) using the following GenBank reference sequences: 
FANCA, NM_000135.2; FANCB, NM_152633.2; FANCC, NM_000136.2; FANCD1, 
NM_000059.2; FANCE, NM_021922.2; FANCF, NM_022725.2; FANCG, 
NM_004629.1; FANCI, NM_018193.2; FANCN, NM_024675.3.  
 
Construction of mutants. The complete wild type cDNAs of Flag-tagged FANCA and 
HA-tagged FANCE were cloned into the episomal expression vector pMEP4 
(Invitrogen). The FANCA mutations, Leu210Arg and Leu274Pro were generated by 
site-directed mutagenesis using the QuickChangeII mutagenesis kit (Clontech) on a 
KpnI – KpnI  fragment from pMEP4 FANCA-Flag subcloned into pBluescript. The 
primers used for Leu210Arg were: forward, 5’ 
CTGTGGGATCGTGGCGCTTCAGGAATCTGTG 3’, reverse, 3’ 
GACACCCTAGCACCGCGAAGTCCTTAGACAC 5’. The primers used for Leu274Pro 
were: forward, 5’ GTACTGCAGAGGATGCCGATTTTTGCACTTGACGC 3’, reverse 
3’ CATGACGTCTCCTACGGCTAAAAACGTGAACTGCG 5’. After mutagenesis and 
sequencing, the mutant KpnI – KpnI  fragment was cloned into pMEP4 FANCA-Flag. 
The FANCA mutations, Leu660Pro and Glu869Pro were generated by site-directed 
mutagenesis using the QuickChangeII mutagenesis kit on a KpnI – SalI  fragment 
from pMEP4 FANCA-Flag subcloned into pBluescript. The primers used for 
Leu660Pro were: forward, 5’ GCACTGGGAGAGCCTAGAGCCTCCATGACAG 3’, 
reverse 3’ CGTGACCCTCTCGGATCTCGGAGGTACTGTC 5’. The primers used for 
Glu869Pro were: forward, 5’ 
CTCCAGGGCTTATTAAAAAGTTTCCGTTCCTCATGTTCAG, reverse 3’ 
GAGGTCCCGAATAATTTTTCAAAGGCAAGGAGTACAAGTC. After mutagenesis 
and sequencing the mutant KpnI – SalI  fragment was extended at the 5’ and 3’ ends 
with wild type FANCA sequence and cloned into pMEP4 to generate mutant FANCA-
Flag constructs. 
The FANCA mutations Leu1249Pro, Pro1324Leu, and Arg1400His were obtained by 
digestion of cDNA derived from patient cell lines with SalI and HindIII and 
subsequently cloned in pBluescript. The 5’ ends of the inserts were then extended 
with a SalI - HindIII fragment from pDR FANCA-Flag. The construct was digested 
with KpnI – HindIII and cloned in pMEP4 FANCA-Flag. Mutated insert cDNAs were 
verified by DNA sequencing. 
Genetic subtyping of Fanconi anemia 
 
62 
 
Functional tests. Some missense variants were tested for pathogenic status by 
transfection, essentially as described (Lo et al. 1996a). Briefly, lymphoblastoid cell 
lines derived from FA patients lacking functional FANCA protein were used for 
functional complementation to assess the pathogenicity of mutations in FANCA. Cells 
were cultured at 37 °C in RPMI1640 medium (Gibco) containing 10% Fetal Bovine 
Serum (FBS, Gibco) and supplemented with 200 µg/ml hygromycin, for transfected 
cells. A suspension of 5 million cells in 0.8 µl serum-free RPMI1640 were transfected 
by electroporation using BTX’s Electro Square Porator ECM830 at 900V with a pulse 
length of 333 µs (3 pulses with an interval of 100 ms). The cells were then transferred 
to flasks containing 8 ml RPMI1640 with 10% FBS and cultured for 2 days before 
they were cultured on selection medium. 
 
Western blotting. The antibodies used for detection of FANCD2 were affinity-purified 
rabbit polyclonal antibodies raised against FANCD2 mouse monoclonal antibody 
(FI17, Santa Cruz Biotechnologies, Santa Cruz, California, USA). For direct Western 
blot, cells were resuspended in lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 
1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, supplemented with 
proteinase inhibitors aprotinin, pepstatin, leupeptin and pefablock). Protein lysates 
corresponding to 500,000 cells or the indicated amounts of protein, as determined 
with a Bio-Rad (Hercules, CA) protein assay, were denatured at 70 °C and loaded on 
a 3-8% NuPAGE Tris-Acetate gradient gel (Invitrogen, Carlsbad, California, USA). 
After electrophoresis, proteins were transferred to an Immobilon-P membrane 
(Millipore, Bedford, Massachusetts, USA). The membrane was blocked with 5% fat-
free milk in TBST (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) and 
incubated with rabbit polyclonal or mouse monoclonal antibodies against FANCD2 
(1:500) overnight. To visualize FANCD2, blots were incubated with horseradish 
peroxidase-labelled secondary antibodies (Dako Diagnostics, Glostrup, Denmark) 
and detected using the ECL Western blot analysis system (Amersham Pharmacia 
Biotech, UK). Detection of other FA proteins by direct Western blot has been 
described elsewhere (de Winter et al. 2000). 
 
Cell fusion. Polyethylene glycol (PEG)-induced fusions were carried out as described 
(Joenje et al. 1995), using as fusion partners the hygromycin (H) or G418/neomycin 
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(N) marked cell line EUFA592, representing the complementation group I. The cell 
fusion procedure entailed mixing 2 x 107 lymphoblasts from each fusion partner. After 
centrifugation (250 x g for 5 minutes) and resuspension in serum-free medium, the 
cells were divided into 4 equal portions for 4 parallel fusion experiments. After 
centrifugation, cell fusion was induced by gentle resuspension of the cells in 1 ml of a 
solution containing 50% PEG (type 1000; Merck, Darmstadt, Germany) in serum-free 
medium. After 1 minute, the samples were carefully mixed with 4 ml of serum-free 
medium, followed 2 minutes later by another 4 ml of serum-free medium, after which 
the cells were left at room temperature for 20 minutes. The cells were then washed 
once by centrifugation at 111 x g and resuspended in 10 ml of complete medium. 
After recovery at 37 °C for 48 hours, selection medium was added. In successful 
experiments outgrowth of the hybrids typically occurred after 2-5 weeks. Success 
rates were typically 80%-90%.  
 
Mitomycin C-induced growth inhibition test. The growth-inhibiting effect of mitomycin 
C (MMC) was assessed by growing the transfected cells in the presence of various 
concentrations of MMC over a period of time that allowed cells without addition of 
drug to undergo at least three population doublings, as described previously (Joenje 
et al. 1995). IC50 values are defined as the concentration of MMC causing 50% 
inhibition of growth. 
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Abstract 
 
The Fanconi anemia and BRCA networks are considered interconnected, as 
BRCA2 gene defects have been discovered in individuals with Fanconi anemia 
subtype D1. Here we show that a defect in the BRCA2-interacting protein 
PALB2 is associated with Fanconi anemia in an individual with a new subtype. 
PALB2-deficient cells showed hypersensitivity to cross-linking agents and 
lacked chromatin-bound BRCA2; these defects were corrected upon ectopic 
expression of PALB2 or by spontaneous reversion. 
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Introduction 
 
Fanconi anemia is a recessive chromosomal instability syndrome with both 
autosomal and X-linked inheritance. Clinical features are diverse and include 
progressive bone marrow dysfunction and an extremely elevated cancer risk. Cells 
derived from individuals with Fanconi anemia are hypersensitive to growth inhibition 
and chromosomal breakage induced by DNA cross-linking agents such as mitomycin 
C (MMC) and diepoxybutane. Eleven distinct genes have been identified that, when 
defective, can cause Fanconi anemia, and all Fanconi anemia gene products are 
thought to function in a common network of genome maintenance (Taniguchi & 
D'Andrea 2006; Levitus et al. 2006). At least eight Fanconi anemia proteins form a 
nuclear ‘core complex’ that catalyzes the activation of the Fanconi anemia D2 protein 
(FANCD2) by monoubiquitination. BRCA2 (also known as FANCD1) and BRIP1 (also 
known as FANCJ) function downstream and/or independently of this modification 
step (Howlett et al. 2002; Levitus et al. 2005). 
This study began with a search for a gene defect in an unclassified individual with 
Fanconi anemia, EUFA1341, who showed normal monoubiquitination of FANCD2 
and in whom we did not detect pathogenic sequence alterations in BRCA2 and 
FANCJ. As no further Fanconi anemia subtypes are known to operate downstream of 
FANCD2 activation, we suspected this individual of representing a new Fanconi 
anemia complementation group, designated subtype N. PALB2 (partner and localizer 
of BRCA2) is a recently discovered protein that interacts with BRCA2 and is 
important in determining the localization and stability of BRCA2 in the nucleus (Xia et 
al. 2006). HeLa cells in which PALB2 expression is reduced by short interfering RNA 
show an increased sensitivity to MMC, a hallmark of Fanconi anemia (Xia et al. 
2006). Therefore, we considered PALB2 a candidate for the protein defective in 
EUFA1341. 
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Results and discussion 
 
As an initial test for a possible PALB2 defect, we visualized PALB2 by protein blotting 
using antibodies raised against a central region of PALB2 (amino acids 601–880). In 
contrast to cells from individuals with Fanconi anemia subtype D1 or subtype I and in 
contrast to control cells, we did not detect full-length PALB2 in EUFA1341 
lymphoblasts and fibroblasts (Figure 1a). The amount of BRCA2 in EUFA1341 
lymphoblasts was much lower than in control cells (Figure 1b), consistent with the 
previous observation that PALB2 promotes BRCA2 stability in the nucleus (Xia et al. 
2006). The lack of full-length PALB2 protein and the reduced amount of BRCA2 
suggested the existence of sequence alterations in the gene encoding PALB2. 
Notably, in a phenotypically reverted (MMC-resistant) subline of EUFA1341 
lymphoblasts (designated ‘EUFA1341(R)’), we found a normal amount of BRCA2 
without the reappearance of full-length PALB2 (Figure 1b). 
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Figure 1 Phenotype of PALB2-deficient cells from an individual with Fanconi anemia is 
corrected by ectopic expression of PALB2. (a) Immunoblotting with an antibody against 
residues 601-880 of PALB2 demonstrated the absence of full-length PALB2 from whole-cell 
extracts of lymphoblasts and fibroblasts of individual EUFA1341. (b) The amount of BRCA2 
is low in EUFA1341 lymphoblasts and normal in reverted EUFA1341(R) lymphoblasts. (c) 
EUFA1341 fibroblasts stably transduced with empty pOZC vector or pOZC-PALB2 were 
analyzed for PALB2, BRCA2 and Rad51 expression by immunoblotting whole-cell extract 
(WCE). (d) The same cells as in c were fractionated into S100 (soluble, containing 
cytoplasmic and nucleoplasmic proteins) and P100 (pellet, containing chromatin, nuclear 
matrix and insoluble proteins). Unlike in WCE and S100, amounts of BRCA2 and Rad51 
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were grossly reduced in P100 of EUFA1341 fibroblasts and were restored upon 
reintroduction of PALB2. (e) EUFA1341 fibroblasts had a reduced capability to form MMC-
induced Rad51 foci, which was restored by introduction of PALB2 or PALB2D4. (f) 
EUFA1341 fibroblasts showed a substantially increased sensitivity to MMC that was 
corrected by introduction of PALB2 or PALB2D4 but not by introduction of PALB2 (Y551X) or 
empty (pOZC) vector. The data presented are the averages of three independent 
experiments performed in duplicate. This research was carried out with written informed 
consent and after approval by the Institutional Review board of the VU Medical Center. 
 
 
Four lines of evidence showed that a loss of PALB2 function caused Fanconi anemia 
in individual EUFA1341. First, although total BRCA2 was not reduced in EUFA1341 
fibroblasts (Figure 1c), the protein was mislocalized, being grossly depleted from the 
nuclear pellet (P100) fraction (Figure 1d). Consequently, Rad51 focus formation 
induced by MMC treatment was impaired in these fibroblasts (Figure 1e). Second, 
introduction of wild-type PALB2 into these cells normalized (i) the association of 
BRCA2 with the chromatin/nuclear matrix fraction (Figure 1d), (ii) the ability to form 
Rad51 foci (Figure 1e) and (iii) the sensitivity to MMC (Figure 1f). Third, we found 
pathogenic mutations in the gene encoding PALB2 in EUFA1341. Sequencing of 
genomic DNA as well as cDNA from EUFA1341 uncovered an apparently 
homozygous or hemizygous nonsense mutation in exon 4, leading to the amino acid 
change Y551X (primers are listed in Table 1). As we detected this mutation only in 
the mother of this individual, EUFA1341 was probably compound heterozygous for a 
deletion on the paternal allele in the region of the exon 4 mutation. This was 
confirmed by multiplex ligation-dependent probe amplification (MLPA) analysis 
(Schouten et al. 2002) (Figure 2). Fourth, cDNA sequencing and MLPA analysis of 
the reverted cells uncovered a secondary sequence alteration that restored part of 
the PALB2 ORF and could explain recovery of PALB2 activity (Figure 2). The 
corrective alteration deleted the premature stop-containing exon 4 from the mRNA, 
resulting in an in-frame fusion of exons 3 and 5 (Figure 2a). Subsequent genomic 
sequencing showed a 5,962-bp deletion between Alu repeats in introns 3 and 4 of 
the maternal allele that was probably generated by spontaneous Alu-mediated 
recombination (Batzer & Deininger 2002). Although genetic reversion of somatic cells 
has been attributed to several distinct genetic mechanisms (Waisfisz et al. 1999), the 
above-noted results indicate that Alu-mediated recombination in cis can be added to 
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this list. Given the role of PALB2 in efficient homologous recombination (Xia et al. 
2006), it remains to be determined whether Alu-mediated recombination is enhanced 
in PALB2-deficient cells (for example, by promoting single-strand annealing as a 
compensatory event for reduced homologous recombination). 
 
 
 
 
Figure 2. Deletion screening by MLPA. The left three panels show the analysis of genomic 
DNA isolated from control, EUFA1341and reverted EUFA1341(R) cells. The control probe 
(C) recognizing DNA sequences on 1p22 served as the reference to which the PALB2 peaks, 
indicated with numbers 2 to 6, were compared. In EUFA1341 cells, one copy of exons 2, 3, 
4, 5 and 6 was lost, whereas in EUFA1341(R) cells, the second copy of exon4 was also lost. 
The right two panels show the same analysis for genomic DNA from the mother and the 
father isolated from whole blood. The maternal alleles did not display deletions, as expected, 
whereas the paternal DNA displayed the loss of one copy of exons 2 to 6. The horizontal line 
indicates the height of the control peak and is included to facilitate the comparison with the 
PALB2 peaks. Arrows indicate lost exons. Extension of the MLPA kit with probes for the 
additional exons revealed that in EUFA1341 a deletion of exon 1 till 10 is present. 
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Figure 2. PALB2 protein analysis in EUFA1341 and EUFA1341(R) lymphoblasts. (a) We 
detected a premature stop (1802T-A, Y551X) in the cDNA and genomic DNA from 
EUFA1341 and found an in-frame deletion of exon 4 in cDNA from EUFA1341(R). This 
cDNA encodes a variant of PALB2 (PALB2D4) in which residues 1–70 are fused to residues 
562–1186. (b) Whole-cell extracts of HSC93 (wild-type), EUFA1341 and EUFA1341(R) 
lymphoblasts were immunoprecipitated with antibodies to PALB2 residues 1–200 (lanes 1–3 
and 7–9) or 601–880 (lanes 4–6 and 10–12) and analyzed by protein blotting with antibodies 
against BRCA2 (lanes 1–12), PALB2 residues 1–200 (lanes 1–6) or 601–880 (lanes 7–12). 
Antibody a1–200 immunoprecipitated a protein (’X’; lane 2) in EUFA1341 cells that was 
detected when the same antibody was used for protein blotting, but BRCA2 was not 
coimmunoprecipitated. Both a1–200 and a601–880 immunoprecipitated a slightly larger 
protein (‘Y’; lanes 3, 6, 9 and 12) in EUFA1341(R). This protein reacted with both antibodies 
in protein blots and coimmunoprecipitated BRCA2. In addition, a601–880 recognized protein 
‘Z’ (lane 11) in EUFA1341 cells. (c) We loaded the same immunoprecipitates as in lanes 2 
and 12 of b along with recombinant PALB2 (Y551X) or PALB2D4, generated in HEK293T 
cells. These recombinant proteins migrated at the same position as proteins X and Y. The 
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identity of protein Z is unknown. (d) HEK293T cells were transfected with the indicated 
plasmids. Immunoprecipitation with anti-Flag M2 agarose beads showed that recombinant 
PALB2D4 efficiently binds BRCA2. 
 
 
Further studies showed the existence of truncated PALB2 proteins in primary and 
reverted EUFA1341 cells. Using immunoprecipitation and protein blotting, we 
detected truncated PALB2 lacking residues encoded by exon 4 (protein ‘Y’) in 
EUFA1341(R) cells, whereas a protein comprising only the first 550 residues of 
PALB2 (protein ‘X’) was present in primary EUFA1341 cells (Figure 2b, c). In contrast 
to the truncated protein in the primary cell line, the truncated PALB2 protein from the 
reverted cells did interact with BRCA2 (Figure 2b, d), which provides an explanation 
of why BRCA2 levels were restored in these cells. This protein also re-established 
MMC-induced Rad51 focus formation (Figure 1e) and corrected the MMC-
hypersensitive phenotype of EUFA1341 cells (Figure 1f). Our results show that a 
shortened PALB2 protein with a large internal deletion is functional, whereas the N-
terminal 550 residues of PALB2 cannot function alone. These data link mutations in 
PALB2 to the new Fanconi anemia subtype N and justify FANCN as an alias for this 
gene. Like many other individuals with Fanconi anemia, individual EUFA1341 
presented with skin, thumb, heart and kidney abnormalities and growth retardation 
(Methods). In addition, this individual developed anemia at a very early age and died 
at the age of 2 from an aggressive, rare type of endothelial cancer, a kaposiform 
hemangioendothelioma (Mueller & Mulliken 1999; Chang 2003). Similar to Fanconi 
anemia associated with biallelic mutations in BRCA2, Fanconi anemia caused by 
mutations in PALB2 might represent an extreme variant of this disorder, with respect 
to the severity of the clinical phenotype, time of anemia onset and cancer 
susceptibility (Alter et al. 2007). As PALB2 is critical for the function of BRCA2 in 
DNA repair and tumor suppression (Xia et al. 2006), it could, in principle, also be a 
tumor suppressor protein. Several family members of individual EUFA1341 indeed 
developed tumors, and some of these tumors fall into the recently proposed BRCA2 
tumor spectrum (Figure 3) (Lorenzo & Hemminki 2004; Friedenson 2005). Further 
studies are necessary to assess the potential role of PALB2 mutations in sporadic 
and familial (childhood) cancer in non–Fanconi anemia populations. 
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Figure 3. Pedigree of patient EUFA1341 and cancer cases in the family (including age at 
diagnosis) Individuals II:3 and III:2 are carriers for the non-sense mutation Y551X, individuals 
II:2, III:1 and IV:2 are carriers for the large genomic deletion. Material from individuals I:1, I:2, 
I:3, I:4, I:5, I:6, I:7, I:8 and II:1 was not available. 
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Materials and methods 
 
Affected individual EUFA1341. The female patient was born after an uneventful 
pregnancy (40 wks), with low birth weight (1820 g; 27 days of incubator) and a length 
of 42 cm. Congenital abnormalities: microcephaly (head circumference 28.5 cm), 
hypertelorism, short neck, heart defect, long bone-less thumb on the right hand, 
hypoplastic thumb on the left hand, imperforate anus, ectopic right kidney, café-au-
lait spots, epicanthus. The patient developed aplastic anemia at 2 and died at 2 years 
and 4 months from a kaposiform hemangioendothelioma in the left retroocular cavity 
that had invaded the brain. Cytogenetic investigation of stimulated T-lymphocytes 
revealed a normal 46, XX karyotype. Spontaneous chromatid breaks were observed 
in approximately 50% of the cells (0.9 breaks per cell, on average). Breakage was 
increased by adding diepoxybutane or mitomycin C at 100 ng/ml. This resulted in >10 
break events per cell in 100% of the cells examined, thereby confirming an FA 
diagnosis. 
 
Cell lines. All Epstein Barr virus-immortalized B cell lines from blood samples and 
SV40-transformed fibroblasts from skin biopsies were established according to 
standard procedures. The research was carried out after approval by the Institutional 
Review board of the VU Medical Center that adhered to local ethical standards, and 
was initiated only after the relevant informed consents had been obtained. 
Lymphoblastoid cells were propagated in RPMI supplemented with 10 % fetal calf 
serum (FCS), while fibroblasts were grown in a mixture of F10 (HAM) and Dulbecco's 
modified Eagle's medium (DMEM) (1:1) containing 10 % FCS. HEK293T cells were 
grown in DMEM supplemented with 10% FCS. To generate EUFA1341 cells stably 
expressing PALB2, PALB2 mutants or control cells, fibroblasts were infected with 
amphotropic pOZC-PALB2, pOZC-PALB2 (Y551X), pOZC-PALB2∆4 or pOZC 
retrovirus. After 72 hours, cells were selected using paramagnetic M-450 Dynabeads 
(Dynal Biotech) coated with anti-IL-2 receptor antibody (Upstate, #05-170). 
 
Plasmids and transient transfections. The retroviral PALB2 cDNA vector, pOZC-
PALB2, has been described (Xia et al. 2006). To generate an expression vector 
encoding PALB2 (Y551X), codon 551 was replaced with a nonsense codon in pOZC-
Chapter 3 
 
79 
PALB2 by site-directed mutagenesis using the QuickChange (Stratagene) method. 
To construct pOZC-PALB2∆4, exon 4-deleted PALB2 cDNA was first obtained by 
PCR and then cloned into pOZC. By omitting or including a stop codon at the end of 
the PALB2 coding sequence (before the C-terminal FLAG-HA tags), both tagged and 
untagged versions were generated. Transient transfections were carried out in 6-well 
plates using FuGENE 6 (Roche) for 30 hours. 
 
Western blotting and immunoprecipitation. Polyclonal PALB2 antibodies, α1-200 and 
α601-880, have been described (Xia et al. 2006). BRCA2 and Rad51 antibodies were 
purchased from Calbiochem (Ab-1, #OP95) and BD Pharmingen (#551922), 
respectively. Anti-α-tubulin, anti-FLAG M2 and M2-agarose beads were purchased 
from Sigma. For initial PALB2 detection (Figure 1), whole cell extracts of 
lymphoblasts and fibroblasts were prepared in lysis buffer (50 mM Tris-HCl, pH7.4, 
450 mM NaCl, and 1% Triton X-100 supplemented with protease and phosphatase 
inhibitors) and the supernatants (each derived from 500,000 cells) were analysed by 
Western blotting. Cell fractionation was carried out as described (Xia et al. 2006). In 
all other experiments, cell extracts were prepared with NETN420 (Xia et al. 2006). 
Immunoprecipitation was performed overnight at 4ºC. Tris-Acetate (3-8%) gels 
(Figure 1) and Tris-Glycine (4-12%) gels (Figure 2) from Invitrogen were used for 
protein separation. 
 
Immunofluorescence. Fibroblasts were treated with 2.4 µg/ml MMC for 1 hour, and 
the medium was then replaced. Cells were fixed 12 hr after MMC treatment, and 
Rad51 focus formation was analyzed by immunofluorescence using the 
aforementioned polyclonal Rad51 antibody (BD Pharmingen, #551922). 
Immunostaining was performed as described (Xia et al. 2006). 
 
Mitomycin C sensitivity assay. Fibroblast lines were seeded at 1,000 cells per well in 
96-well plates. Four hours later, MMC-containing medium was added to achieve the 
desired final MMC concentrations. Cells were incubated with the drug for 5 days, and 
their survival rates were measured using a CellTiter Glo kit (Promega) following the 
manufacturer’s instructions. 
 
 
Fanconi anemia is associated with a defect in PALB2 
 
80 
Multiplex ligation-dependent probe amplification (MLPA) analysis. To detect deletions 
in exon 2, 3, 4, 5, and 6 of the PALB2 gene, synthetic oligonucleotide probes were 
designed according to standard procedures of MRC-Holland (http://www.mrc-
holland.com) (Schouten et al. 2002; Stern et al. 2004). Sequences of the probes are 
available on request. Annealing and ligation of the probes were performed as 
described (Schouten et al. 2002). The ligation products were amplified by the 
addition of 5 µl of the aforementioned ligation mixture to 20 µl of PCR mixture 
containing PCR buffer, dNTPs, SALSA polymerase and PCR primers (one unlabeled 
and one D4-labeled) at 60°C as described (Schouten et al. 2002). PCR products 
were analyzed in an ABI PRISM 310 fragment analyzer (Applied Biosystems), and 
the data were analyzed using GeneScan analysis software Version 3.7 (Applied 
Biosystems). 
 
Amplification of PALB2 sequences. Total RNA was isolated from cycloheximide-
treated lymphoblastoid cell lines using a total RNA isolation kit (Macherey-Nagel) 
followed by cDNA synthesis using 10 pmol oligo-dT20 primers and Superscript II RT 
polymerase (Invitrogen). Genomic DNA was isolated from whole blood or 
lymphoblastoid cell lines with a Blood mini kit (Qiagen). The PCR reactions for 
amplification of PALB2 cDNA and genomic fragments were carried out using 
Platinum Taq polymerase (Invitrogen). Sequences of the primers are depicted in 
Table 1. To determine the deletion in the reverted EUFA1341 cell line, long-range 
PCR was performed on genomic DNA using the Elongase system (Invitrogen). DNA 
sequence analysis. PCR fragments were treated with Shrimp Alkaline Phosphatase 
and Exonuclease I for 30 min at 37°C and 15 min at 80°C according to the 
manufacturer’s instructions (Amersham Biosciences). Sequencing reactions were 
carried out using 10 pmol of primer and the Big Dye terminator cycle sequencing kit 
(Applied Biosystems) in the Gene Amp PCR system 9700 (Applied Biosystems). 
Samples were analyzed in an ABI 3100 DNA analyzer (Applied Biosystems). 
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Table 1: Primers used for mutation screening 
 
Primers for PALB2 coding exons 
Exon Primer Sequence 5’-3’ Amplicon 
size 
 Forward Reverse  
1 ACAGCGCGGCTCTCCTTTAG ATACTGCTGCCCTCGGACTG 410 
2+3 GTAGATTGTTATGGACCAGTGCTACT GTCTATTGCTAGTCATTATCTTCACAC 511 
4A TCTGCCTGAATGAAATGTCACTGA GGTCTTCTTAGGAATGTATCAACACC 645 
4B CAGATTCTCCAGAACCAGTTACAGAA TTTTCTGCAGAAAGAGGAGAGGTT 559 
4C CTCCCAGTGACACTCTTGATGGC GGTGACTTCTTCCTTGGACCTGT 572 
5A TTAAATCTAGGAGATCCTATTCTCTTTG GTATAAAGTAATATGGATGAAGAAAGGC 531 
5C AGAAATGGAGGACTTAGAAGAGGAC CATGCTGTTTACATTCACTAAGGC 586 
6 GCTGCTGTTATAAGAGGAAATAAAGACA GGGAAAAATAACCAATCCAAATCTG 344 
7 GCTCTTTCTTTTCACCTGCATAAGA TGGGTATATGGGTGCTCACTATACA 492 
8 CCTTGTACAGTGAGAATACAAAAGAATGTGA TAGGTTATTACCTGCACTTAAAACCA 270 
9 AAAAAAGTGAACCTAGTCCTTTAATATT GCTCAAACTTCTGCCTTGGC 581 
10 ATATTATGCAGTTCAACAATGCGG ACCTGGGTGATAGGAGGAGACTC 386 
11 ACCTCCTAAGACATGCTATGATGAATAA GCCAGAAAATTTACCAAGCAATCA 379 
12 CAGAGCCTATCGGTCATTGCTT TCTGGGGTTTGACTCAAGTCCA 438 
13 TTTAATTGTTTTTTGGATATGTAATCTGAA AAATATTTATTGCCATTTGAAGCTTTAT 549 
 
 
Primers for PALB2 cDNA 
 
Position* Primer Sequence 5’-3’ Amplicon 
size 
 Forward Reverse  
-142-402 TCAGCTGATCGCGCACTGAG GGTCACTGACCCTGTGGGGA 545 
160-1797 AACAAGATTGTTTGTCTCAGCAGG AACTCAGCATTCCATCCCTATGA 1638 
160-795 AACAAGATTGTTTGTCTCAGCAGG GAATGTGTTCAAGGTGCTGACTACTAC 636 
671-1257 ACCAACTGCCCAACCAGAAA GGCAATTGGACATGCTTCGT 587 
1116-1797 GAGATTCTAAGTCAACCTAAGAGTCTTAGC AACTCAGCATTCCATCCCTATGA 682 
1620-2571 AGGTCCAAGGAAGAAGTCACCTC CCAATTGTAGGTTGCCTGGG 952 
1620-2185 AGGTCCAAGGAAGAAGTCACCTC GGGAAAGCAGGTGAACACATGT 566 
2071-2571 GCCAGCATACAAAGACGGGC CCAATTGTAGGTTGCCTGGG 501 
2431-3334 CACCCATTGAGTCATTCACTTTTAA ATTTCAGAATAGGCTTTGTGACAGAC 769 
3050-3727 TGAGGTCCAAGGGATGCAAG CCAAGATCAGTGGTGCTACCATC 678 
 
*Position relative to the translation start has been indicated 
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Abstract 
 
Pathogenic sequence alterations in the Fanconi anemia genes BRIP1/FANCJ 
and PALB2/FANCN have been implicated in the predisposition to breast 
cancer. However, in most of the published studies genetic alterations such as 
large deletions/amplifications may have been missed by the sequencing 
methods used. We used multiplex ligation-dependent probe amplification 
(MLPA) to analyze 734 cases of non-BRCA1/2 familial breast cancer patients 
from the Dutch population for such genetic alterations in BRIP1/FANCJ, 
PALB2/FANCN, and FANCD2. No aberrations were detected, suggesting that in 
this population large deletion/amplification within these genes do not 
significantly contribute to breast cancer predisposition in familial cases. 
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Introduction 
 
Breast cancer (BC) is the most common malignancy in women worldwide. It is 
estimated that 5-10% of all BCs may be caused by germline mutations in breast 
cancer susceptibility genes (Rahman & Scott 2007; Oldenburg et al. 2007). BRCA1 
and BRCA2 are the major known BC susceptibility genes accounting for 
approximately 16% of the familial BC cases (Anglian Breast Cancer Study Group 
2000). Other BC susceptibility genes include ATM (Renwick et al. 2006), PTEN 
(Lynch et al. 1997), CASP8 (Cox et al. 2007), CHEK2 (The CHEK2 Breast Cancer 
Case-Control Consortium 2004), LKB1/STK11 (Giardiello et al. 2000), TGFß1 
(Dunning et al. 2003) and TP53 (Malkin et al. 1990). However to date, the majority of 
familial BCs can not be attributed to mutations in one of known susceptibility gene(s). 
Fanconi anemia (FA) is a recessively inherited chromosomal instability syndrome 
with autosomal or X-linked mode of inheritance, and is characterized by an increased 
susceptibility to several forms of malignancies (Joenje & Patel 2001; Alter 2003). The 
disease is caused by mutations in one of the 13 genes so far identified. The FA gene 
products interact in a common pathway whereby most of the proteins (FANCA,-B,-C,-
E,-F, -G, -L, and –M) form a multiprotein complex that is required for the 
monoubiquitination of FANCD2 and FANCI. However, this modification step is not 
influenced by FANCD1 (BRCA2), FANCJ (BRIP1), or FANCN (PALB2), and hence 
these proteins are thought to act downstream of this process. FANCD2 and FANCI 
form a protein complex (ID complex), which translocates to DNA damage sites where 
it co-localizes with the downstream FA proteins, BRCA2/FANCD1, BRIP1/FANCJ, 
and PALB2/FANCN and other proteins that are involved in the recognition and repair 
of DNA damage, such as BRCA1, ATM, NBS, and RAD51 (Wang 2007). 
The discovery of the breast cancer susceptibility gene BRCA2 as the gene defective 
in the Fanconi anemia (FA)-D1 complementation group (Howlett et al. 2002), the 
identification of BRIP1 (BRCA1 Interacting Protein) (Bridge et al. 2005; Levran et al. 
2005; Levitus et al. 2005) and PALB2 (Partner And Localizer of BRCA2) (Reid et al. 
2007; Xia et al. 2007) as the genes responsible for the FA-J and FA-N 
complementation groups, respectively, triggered many to investigate whether 
heterozygous carriers for a mutation in one of the FA genes are predisposed to 
breast cancer. To date, only mutation in the “downstream” FA genes have been 
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found to significantly elevate the risk of developing breast cancer. Heterozygous 
mutations in BRIP1/FANCJ and PALB2/FANCN appear to increase the risk 2- and 
2.3-fold, respectively (Seal et al. 2006; Rahman et al. 2007). Risk assessment has 
been based on sequence alteration screening analysis of these genes in familial 
breast cancer (FBC) cases lacking mutations in BRCA1/2. However, pathogenic 
germline mutations in BRIP1/FANCJ are very rare as exemplified by the observation 
that these were not detected in several studies using FBC cases from the Swedish 
(Luo et al. 2002), Finnish (Karppinen et al. 2003), North American (Rutter et al. 
2003), Australian (Lewis et al. 2005), and (French-) Canadian (Guenard et al. 2008) 
populations. In addition, mutations in PALB2/FANCN do not seem to contribute to BC 
risk in the population of Iceland (Gunnarsson et al. 2008). 
Furthermore, FANCD2 mutations, have been suggested to play a role in the 
development of breast cancer based on observations of Fancd2 knockout  mice, 
which demonstrated a high incidence of epithelial tumors, including mammary and 
ovarian tumors (Houghtaling et al. 2003). However, in humans a significant 
contribution of FANCD2 mutations to FBC could not be established (Seal et al. 2003; 
Lewis et al. 2005). 
Interestingly, one of the eight FA-N patients described in literature carried a 
pathogenic nucleotide substitution on one allele and a large genomic deletion 
encompassing exon 1 through 10 of PALB2/FANCN on the other allele (figure 1). 
The latter aberration is not detectable by standard sequencing methods applied for 
PALB2/FANCN mutation screening in most studies published to date (Erkko et al. 
2007; Rahman et al. 2007; Garcia et al. 2008; Cao et al. 2008; Gunnarsson et al. 
2008; Tischkowitz et al. 2008). Hence, we hypothesized that heterozygous large 
deletion/amplification mutations in the downstream FA genes (FANCJ and FANCN) 
and FANCD2 may contribute to the risk of breast cancer in familial cases. In this 
study we tested this hypothesis by analyzing gDNA of a large cohort of non-BRCA1/2 
FBC patients for large genomic alterations in FANCD2, BRIP1/FANCJ, and 
PALB2/FANCN using Multiplex Ligation-dependent Probe Amplification (MLPA). 
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Results and discussion 
 
In the current study, we analyzed a total of 734 Dutch BRCA1/2 negative familial 
breast cancer (FBC) patients for large genomic deletions/amplifications in FANCD2, 
BRIP1/FANCJ, and PALB2/FANCN using MLPA. We failed to detect deletions or 
amplifications in any of these genes. Absence of PALB2/FANCN large 
deletions/amplifications was also demonstrated in two previous studies where 600 
FBC cases of French-Canadian ancestry (Foulkes et al. 2007) and 61 index patients 
of Finnish breast and/or ovarian cancer families (Pylkas et al. 2008) were analyzed. 
The MLPA kits used for the analysis contained probes targeted against all the exons 
of BRIP1/FANCJ and PALB2/FANCN. Due to the presence of FANCD2 
pseudogenes, only a number of FANCD2 exons could be analyzed (see materials 
and methods section) by MLPA. 
Large deletions encompassing multiple exons will be detected by the used MLPA 
kits, but subtle deletions/amplifications in the intronic region and of FANCD2 exons of 
which no probes were present in the MLPA kit could have been missed. In addition, 
genetic rearrangements such as inversions are not detectable by MLPA. However, 
our results show that large genetic deletions/amplifications of multiple exons of the 
analyzed genes are unlikely to contribute significantly to the BC risk in the Dutch 
population. 
As the only patient so far described with a large deletion in PALB2 is of Argentinian 
nationality, this mutation might be derived from a founder within this particular 
population and it might be of interest to test FBC cases from this population for this 
large deletion. Alternatively, large deletion mutations in PALB2 may be very rare and 
the analysis of an even larger cohort of FBCs may be necessary to determine the 
contribution of such aberrations to breast cancer risk. 
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Figure 1. MLPA analysis. A large deletion spanning exon 1 through 10 of the PALB2 gene in 
the FA-N patient EUFA1341 was used as a positive control (Xia et al. 2007). Signals of 
capillary electrophoresis patterns of wild type DNA (light) and EUFA1341 DNA (dark) are 
depicted whereby the Probes detecting PALB2 exons are indicated at the bottom. The 
arrows indicate the heterozygously deleted exons. 
x1 
 
x9 x10  x12 x7 x11 x4 x6 x8 x3 x5 x2 exons 
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Materials and methods 
 
Familial breast cancer patients 
BRCA1/2 negative breast cancer (BC) patients were included in this study who met 
the criteria described previously (Verhoog et al. 2001). Briefly, women were selected 
for the study when a single patients within a family was affected by breast cancer 
before the age of 40, or if affected by breast and ovarian cancer (OC), or if two first– 
or second degree relatives were affected by BC (one of them diagnosed before the 
age of 45), or if two first– or second degree relatives of whom one affected by OC 
and the other affected by BC before the age of 50, or if two first– or second degree 
relatives were affected by OC, or if three first– or second degree relatives were 
affected by either BC or OC. 
 
MLPA 
Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was used to 
detect deletions or amplifications in the FANCD2, BRIP1/FANCJ, and 
PALB2/FANCN genes. MLPA is a rapid quantitative method for the detection of 
deletion/amplification of up to 40 specific DNA fragments in a single PCR reaction 
(Schouten et al. 2002). The SALSA MLPA kits, P057 and P240 (MRC-Holland BV, 
Amsterdam) were used for the detection of exon insertions/deletions in FANCD2 
(exons: 1, 2, 4, 9, 12, 17, 19, 23, 28, 32, 35, 41, 43) and PALB2/FANCN (all exons), 
and BRIP1/FANCJ (all exons), respectively; details are available at http://www.mrc-
holland.com. Briefly, target DNA was denatured for 5 min at 98 °C, 3 µl of the probe 
mix was added, after which the mixture was heated for 1 min at 98 °C and incubated 
at 60 °C overnight (16 hr); after addition of ligase, the mixture was incubated at 54 °C 
for 15 min. Ligase was subsequently inactivated at 98 °C for 5 min. Next, 10 µl was 
transferred to PCR mix containing PCR buffer, deoxynucleotide triphosphates, Taq 
polymerase, and one unlabeled and one carboxyfluorescein-labeled PCR primer, 
which are complementary to the universal primer sequence. The PCR reaction was 
carried out for 33 cycles (30 s at 95 °C, 30 s at 60 °C, and 60 s at 72 °C). The 
fragments were analyzed on an ABI model 3730 capillary sequencer (Applied 
Biosystems) using genescan-LIZ500 size standard (Applied Biosystems). 
GeneMarker 1.6 software (SoftGenetics) was used for fragment analysis. 
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DNA obtained from EUFA1341, containing a heterozygous deletion of exon 1 through 
exon 10 in PALB2/FANCN (Xia et al. 2007) was used as a positive control for the 
PALB2/FANCN MLPA analysis (Figure 1). 
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Abstract 
 
Fanconi anemia (FA) is a chromosomal instability disorder associated with a 
high risk of acute myeloid leukemia (AML). Previous work has shown that the 
AML cell line CHRF-288, derived from a sporadic AML-M7 patient, does not 
express FANCF protein and exhibits a cellular FA phenotype. We show that 
this phenotype is corrected by a FANCF-expressing plasmid and that the 
absence of FANCF protein is explained by hypermethylation of the promoter 
region of the FANCF gene. As FANCF is localized in a hot-spot region for 
somatic hypermethylation (11p15), FANCF silencing might be an early step in 
sporadic carcinogenesis, including leukemogenesis. 
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Introduction 
 
Fanconi anemia (FA) is a recessively inherited syndrome characterized by excessive 
chromosomal breakage, both spontaneous and induced by DNA cross-linking agents 
such as mitomycin C (MMC). The disease is associated with a high risk of various 
malignancies, most notably acute myeloid leukemia (AML) (D'Andrea & Grompe 
2003). FA is genetically heterogeneous, comprising at least eight complementation 
groups. The genes FANCA, FANCC, FANCD2, FANCE, FANCF and FANCG are 
defective in the corresponding complementation groups (Joenje & Patel 2001), while 
the breast cancer susceptibility gene, BRCA2, is mutated in FA-D1 patients (Howlett 
et al. 2002). All FA proteins, along with the BRCA1 protein, are thought to function in 
an integrated pathway that maintains genomic stability. Consequently, even a single 
defective component would disrupt the pathway leading to chromosomal breaks and 
gross rearrangements. 
We hypothesized that inactivation of the FA/BRCA pathway might be an early step in 
the development of sporadic malignancies, in particular those that also occur 
frequently in FA, such as AML. We previously reported (Xie et al. 2000) that the AML 
cell line CHRF-288 (originally described by Witte et al, 1986) lacked the FANCF 
protein and was hypersensitive to MMC. We now show that the cellular phenotype of 
CHRF-288 cells was corrected upon introduction of a FANCF-containing expression 
plasmid and present evidence that FANCF in CHRF-288 is inactivated by epigenetic 
silencing. 
 
 
 
Results and discussion 
 
The cellular phenotype of CHRF-288 cells was corrected upon transfection with the 
FANCF expression plasmid. Growth inhibition by MMC was restored to a level similar 
to that observed in wild type cells (Fig 1). Furthermore, after transfection of CHRF-
288 cells the spontaneous and MMC-induced chromosomal breakage decreased 
from 0.6 and 3.9 to 0.1 and 1.6 breaks/cell, respectively (results not shown). At the 
molecular level, CHRF-288 had no detectable FANCF protein and FANCF antibodies 
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failed to co-precipitate FANCA protein, similar to what is observed in lymphoblasts 
from an FA complementation group F patient. However, CHRF-288 cells transfected 
with a plasmid expressing FANCF clearly had (exogenous) FANCF that co-
precipitated with FANCA, indicating a correction at the level of FA protein complex 
formation. 
Sequencing of the entire FANCF coding region in CHRF-288 cells did not identify any 
mutation. We therefore tested for gene silencing by methylation. Extensive 
methylation of the upstream sequence was detected, which was unmethylated in 
blood and bone marrow from healthy individuals and another AML cell line, ML-2. 
The 38 CpG dinucleotides that were studied represent 75% of all CpG sites in the 
predicted CpG island. Eight plasmid clones from CHRF-288 were sequenced and 
methylation was scored for each CpG site (Fig 2). The average frequency of CpG 
dinucleotide 
 
 
 
 
 
Figure 1. (A) FANCF protein expression in stably 
transfected cell lines. HSC93 and EUFA698 are 
lymphoblastoid cell lines from a healthy control 
and an FA-F patient, respectively. CHRF-288, 
AML cell line. FANCF protein was not detected in 
EUFA698 and CHRF-288, but was clearly 
present after transfection with a FANCF-expressing plasmid. After immunoprecipitation with 
anti-FANCF antibodies, both FANCA and FANCF were co-precipitated in wild type and 
complemented cells. (B) Functional correction of CHRF-288 cells shown by MMC-induced 
growth inhibition. Cells were cultured in the presence of MMC for 5 d and evaluated for 
growth. HSC93, wild type lymphoblasts; CHRF-288 +F, CHRF-288 cells transfected with 
 
A 
B
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FANCF-containing expression plasmid. 
 
 
 
Figure 2. Methylation of the CpG island in the FANCF promoter region, demonstrated by 
bisulphite sequencing. Methylation status at known CpG dinucleotide positions in eight 
plasmids cloned from CHRF-288 and two normal control samples. Closed circles indicate 
methylated CpGs. 
 
 
 
methylation in this region was 75% with 16/38 CpG dinucleotides being methylated in 
all clones analyzed. Genotyping of DNA from the parents with closely linked 
polymorphic markers confirmed the presence of both FANCF alleles in the patient’s 
cell line (results not shown). Furthermore, the promoter sequence in the mother’s 
DNA was unmethylated, indicating that the methylation of the maternal allele in 
CHRF-288 cells was not inherited but had occurred de novo. The possibility that the 
methylation arose during establishment of the CHRF-288 cell line rather than in the 
primary tumor cannot be excluded. We then investigated sporadic cases of adult 
AML, but did not find any further examples of methylation of FANCF (36 patients 
examined). However, FANCF silencing by hypermethylation has been reported in a 
subset of ovarian tumor cell lines and in four of 19 primary ovarian tumors (Taniguchi 
et al. 2003), suggesting that this phenomenon may be of more general significance. 
FANCF silencing might be considered a candidate-mechanism underlying the state 
of genomic instability that is assumed to be rate-limiting in the origin of many types of 
malignancy. FANCF is localized in a chromosomal region known to be a hot spot for 
gene silencing through methylation in a variety of malignancies (de Bustros et al. 
1988; Schwienbacher et al. 2000; Rush et al. 2001). Although FANCF silencing in 
CHRF-288 cells seems stable, demethylation may cause re-activation of FANCF 
expression. Indeed, Taniguchi et al (2003) showed in an ovarian tumor cell line that 
the cellular FA phenotype associated with epigenetic FANCF silencing could revert in 
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vitro as a result of demethylation. The possibility of reversion complicates the 
assessment of tumors in which FANCF methylation has played a critical role. 
Although it will be difficult to prove such a course of events for FA pathway-
dependent carcinogenesis, our data and those of Taniguchi et al (2003) suggest that 
FANCF gene silencing may contribute to genomic instability in two very different 
types of malignancy. 
 
 
Materials and methods 
 
Patient cell lines and DNA samples. The lymphoblast cell line EUFA698 was derived 
from a FA type F patient (de Winter et al. 2000). The cell line CHRF-288 was derived 
from the leukemic blasts of a patient with megakaryoblastic leukemia (Witte et al. 
1986); genomic DNA isolated from blood samples from the parents and a healthy 
sibling were analyzed to ensure presence of both FANCF alleles in the AML cell line. 
Written consent was obtained from the individuals involved or their legal 
representatives to carry out the studies reported here. 
 
FANCF expression. FANCF protein was immunoprecipitated from whole cell extracts 
with guinea-pig antiserum against GST-FANCF1-245 and visualized by Western 
blotting with rabbit antiserum against GST-FANCF1-374. Co-precipitated FANCA was 
detected with rabbit FANCA antiserum 89. Blots were re-probed with anti-flag 
monoclonal M2 (Sigma, Zwijndrecht, The Netherlands) to show flag-tagged FANCF. 
FA-F lymphoblasts (EUFA698) were stably transfected with FANCF in expression 
vector pCMV-sport6; CHRF-288 cells were stably transfected with FANCF-flag in 
pCEP-4. Functional correction of CHRF-288 cells was analyzed by MMC-induced 
growth inhibition, as described by Joenje et al (Joenje et al. 1995). Parallel cultures 
were evaluated for spontaneous and MMC-induced chromosomal breakage. 
 
FANCF methylation analysis. The sodium bisulphite conversion technique (Clark et 
al. 1994), was used to analyze the methylation status of the FANCF CpG island. 
Following sodium bisulphite conversion of genomic DNA, polymerase chain reactions 
to amplify the FANCF CpG island sequences were performed (details available on 
request). The amplicon (469 bp in length and predicted to contain 38 CpG 
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dinucleotides) was analyzed using an ABI 310 Genetic Analyzer (Applied 
Biosystems, Warrington, UK). Further analysis, to determine the degree of 
methylation, was performed by generating plasmid clones using a TopoTA cloning kit 
(Invitrogen, Paisley, UK) according to the manufacturer’s instructions and sequencing 
as above. 
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Abstract 
 
Objective: Inactivation of the FA-BRCA pathway results in chromosomal 
instability. Fanconi anemia (FA) patients have an inherited defect in this 
pathway and are strongly predisposed to the development of acute myeloid 
leukemia (AML). Studies in sporadic cancers have shown promoter methylation 
of the FANCF gene in a significant proportion of various solid tumors. 
However, only a single leukemic case with methylation of one of the FA-BRCA 
genes has been described to date, i.e. methylation of FANCF in cell line CHRF-
288. We investigated the presence of aberrant methylation in 11 FA-BRCA 
genes in sporadic cases of leukemia. 
Methods: We analyzed promoter methylation in 143 AML bone marrow samples 
and 97 acute lymphoblastic leukemia (ALL) samples using methylation-specific 
multiplex ligation-dependent probe amplification (MS-MLPA). Samples with 
aberrant methylation were further analyzed by bisulphite sequencing and 
tested for mitomycin C sensitivity using Colony Forming Units assays. 
Results: MS-MLPA showed promoter methylation of FANCC in one AML and 
three ALL samples, while FANCL was found methylated in one ALL sample. 
Bisulphite sequencing of promoter regions confirmed hypermethylation in all 
cases. In addition, samples with hypermethylation of either FANCC or FANCL 
appeared more sensitive towards mitomycin C in Colony Forming Units 
assays, compared to controls. 
Conclusion: Hypermethylation of promoter regions from FA-BRCA genes does 
occur in sporadic leukemia, albeit infrequently. Hypermethylation was found to 
result in hypersensitivity towards DNA cross-linking agents, a hallmark of the 
FA cellular phenotype, suggesting that these samples displayed chromosomal 
instability. This instability may have contributed to the occurrence of the 
leukemia. In addition, this is the first report to describe hypermethylation of 
FANCC and FANCL. This warrants the investigation of multiple FA-BRCA 
genes in other malignancies. 
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Introduction 
 
The FA-BRCA pathway is thought to be essential for specific DNA repair processes 
(Niedernhofer et al. 2005; Levitus et al. 2006). Cells, which are defective for one of 
the FA-BRCA genes, display genomic instability and are hypersensitive to DNA 
cross-linking agents. This cellular phenotype is associated with increased cancer risk 
as observed in patients with Fanconi anemia (FA) [OMIM#227650]. These patients 
are characterized by a diversity of clinical symptoms including an increased risk to 
develop malignancies in particular myelodysplastic syndrome and acute myeloid 
leukemia (AML), but also solid tumors. In the past years a number of papers have 
reported on the potential role of acquired disturbances in the FA-pathway in sporadic 
cancers (Lyakhovich & Surralles 2006; Taniguchi & D'Andrea 2006). 
Hypermethylation of the FANCF promoter has been described to occur in various 
tumor types such as those of the ovaries (Olopade & Wei 2003), cervix (Narayan et 
al. 2004), lungs and oral cavity (Marsit et al. 2004). Also in AML the occurrence of 
inherited and somatic abnormalities in the FA-BRCA genes has been studied 
(Condie et al. 2002; Lensch et al. 2003; Tischkowitz et al. 2003; Tischkowitz et al. 
2004). Only in a small proportion of cases data was provided showing that these 
abnormalities were indeed associated with functional inactivation of the FA-BRCA 
pathway. In an adult AML sample functional abnormality was suggested but in this 
case the molecular mechanism remained unidentified (Lensch et al. 2003). FANCF 
was found hypermethylated in the leukemic CHRF-288 cell line resulting in 
hypersensitivity towards DNA cross-linking agents (Tischkowitz et al. 2003). 
However, 36 additional AML patient samples appeared to be negative for FANCF 
hypermethylation suggesting that this is not a common event in leukemia. This was 
recently substantiated by Meyers et al., who found no evidence for hypermethylation 
of either the FANCF or FANCB gene in a total of 33 AML and 48 acute lymphoblastic 
leukemia (ALL) samples (Meyer et al. 2006). Here we report results from a study 
exploring aberrant methylation of 11 FA-BRCA genes (FANCA, FANCB, FANCC, 
FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCJ/BRIP1, FANCL and 
FANCM) in sporadic acute leukemia, using the recently described Methylation 
Specific (MS)-MLPA (Nygren et al. 2005) technique. 
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Results 
 
MS-MLPA 
Using MS-MLPA with probes directed against 11 FA-BRCA genes we first analyzed 
119 unselected adult AML bone marrow samples and 20 pediatric AML samples 
selected on the basis of an FA-AML like karyotype (complex rearrangements see 
materials and methods). Aberrant promoter methylation of the FANCC gene was 
detected in a single adult patient with biphenotypic AML (Fig. 1). Methylation was 
also present in the relapse sample from this patient. To test whether FA-BRCA gene 
methylation was associated with the specific leukemic phenotype, four additional 
biphenotypic AML samples, 15 adult ALL samples and 82 pediatric ALL samples 
were analyzed. One adult ALL sample showed FANCL promoter methylation, while 
FANCC promoter methylation was found in three pediatric ALL samples. All four 
patients had been diagnosed as having BCP-ALL with a hyperdiploid phenotype. In 
the biphenotypic subgroup we did not detect additional methylated cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Detection of aberrant methylation by MS-MLPA. MS-MLPA products were 
analyzed by capillary electrophoresis (CE). Profiles in red correspond with the undigested 
samples and blue with digested samples. MS-MLPA profiles are from (a) control genomic 
DNA without aberrant methylation, (b) SssI CpG methyltransferase treated control genomic 
b
a
c
d
e
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DNA showing methylation of all target sequences, (c) genomic DNA derived from the CHRF-
288 cell line, which shows FANCF promoter methylation (blue peaks indicated by arrows), 
(d) genomic DNA from an AML sample without methylation and (e) genomic DNA from an 
AML sample showing FANCC promoter methylation (blue peaks indicated by arrows). 
 
Sodium bisulphite sequencing 
Sodium bisulphite sequencing confirmed hypermethylation in all cases (Fig. 2). 
Analysis of the FANCC promoter region from the adult biphenotypic AML sample 
(patient 1) at diagnosis and the corresponding relapse, showed equally dense 
methylation patterns. Similarly, FANCC hypermethylation was observed in the two 
pediatric ALL samples (patients 3 and 4). A third sample showed only partial 
methylation of the FANCC promoter region (patient 2). The methylation status of 
FANCL was determined in the adult ALL sample (patient 5) and showed dense 
methylation (Fig. 2b). No methylation of these genes was found in genomic DNA 
from control CD34+ cells. 
 
Mitomycin C sensitivity 
A CFU assay was performed to evaluate whether hypermethylation was associated 
with increased sensitivity towards mitomycin C (MMC), a hallmark of cells defective in 
the FA-BRCA pathway. From two pediatric ALL samples with FANCC 
hypermethylation no colonies were obtained in the CFU assay. The other four 
methylated samples were on average 6.9-fold more sensitive to MMC (median IC50 
4.6 nM) than controls (median IC50 32.1 nM), see Fig. 3, an extent of hypersensitivity 
commonly observed in cells carrying biallelic FA gene defects. This suggests that the 
observed hypermethylation in these samples indeed is associated with an FA-like 
cellular phenotype of DNA cross-linker sensitivity. 
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Figure 2. Bisulphite sequence analysis of the FANCC and FANCL promoter regions in 
primary leukemic samples. (a) Upper part: schematic representation of the FANCC gene’s 
promoter region. The 33 assessed CpGs are situated upstream of exon 1, between the 
arrows; the translation start is in exon 2 (not shown). In the lower parts of the figure each row 
represents an individually cloned and sequenced allele following sodium bisulphite DNA 
modification, black and open circles representing methylated and unmethylated CpGs, 
respectively. Sequence data for a number of CpGs were ambiguous, indicated by an x. 
Arrows indicate sequences complementary to the primers used (patient 1, adult diagnosed 
with biphenotypic AML, patients 2, 3 and 4, pediatric patients diagnosed with ALL). (b) 
Methylation status of the 23 assessed CpGs in the promoter region of the FANCL gene, 
represented as described above. The translation start of the FANCL gene is located in the 
first exon (patient 5, adult diagnosed with ALL). 
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Figure 3. Mitomycin C (MMC) sensitivity in Colony Forming Units (CFU) assay. Number of 
colonies scored following a 7-day culture in Methocult culture medium with increasing 
concentrations (5, 10 and 50 nM) of MMC, expressed as percentage of the number of scored 
colonies in the untreated (0 nM MMC) fraction. Open symbols, patients with FA-BRCA gene 
promoter methylation (patient 1, biphenotypic AML, FANCC methylated; patient 3, pediatric 
ALL, FANCC methylated; patient 5, adult ALL, FANCL methylated). Black symbols, controls 
(control 1, biphenotypic adult AML, control 2, primary adult AML, control 3, primary pediatric 
ALL, controls 4 and 5, primary hyperdiploid adult ALL). 
 
 
Discussion 
 
This is the first report showing epigenetic alterations of the FANCC and FANCL 
promoter regions in malignant cells. Furthermore, we show here for the first time 
evidence for FA-BRCA gene hypermethylation in primary sporadic leukemia 
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samples. We had anticipated to enrich for AML samples carrying a defect in the FA-
BRCA pathway by selecting pediatric AML samples with cytogenetic abnormalities 
that are frequently found in FA patients (Kutler et al. 2003; Tischkowitz & Dokal 
2004). However, no aberrant FA-BRCA gene methylation was detected in these 
samples using MS-MLPA for the detection of methylation in 11 FA-BRCA genes. In a 
larger series of sporadic leukemia samples, a relative higher incidence of FA-BRCA 
gene methylation was observed in ALL samples (4/97) compared to AML samples 
(1/143). This is somewhat surprising, since ALL is rarely observed in FA-patients 
(Kutler et al. 2003) except for the FA subtype associated with a defect in the 
FANCD1/BRCA2 gene (Alter et al. 2007). If methylation of the FA-BRCA genes is 
causally involved in the occurrence of sporadic leukemia our data suggest that this 
accounts for a small proportion of these cases. On the other hand the presented data 
may be an underestimate due to a number of reasons. First, MS-MLPA detects the 
presence of methylation only for a limited number of CpGs. Samples which are 
methylated but in which these specific CpGs are not will be missed. Second, 
silencing of the FA-BRCA pathway is predicted to be only necessary temporarily for 
the accumulation of tumorigenic alterations. Loss of FANCF methylation in vitro has 
been shown to occur (Taniguchi et al. 2003). Third, we have analyzed 11 of the 13 
genes known to cause Fanconi anemia. Not included were the recently identified 
FANCN/PALB2 (Reid et al. 2007; Xia et al. 2007) and FANCI (Smogorzewska et al. 
2007; Sims et al. 2007; Dorsman et al. 2007) genes. 
In conclusion, FA-BRCA gene hypermethylation is observed in a small portion of 
primary sporadic acute leukemia samples. These samples appeared hypersensitive 
to DNA cross-linking agents. The data suggests that methylation of these genes 
resulted in chromosomal instability which may have contributed to the accumulation 
of oncogenic alterations eventually leading to leukemia. Since the role of cross-
linking agents in the treatment of leukemias is limited in general, determining FA-
BRCA gene hypermethylation may have clinical consequences, as such leukemias 
are predicted to be particularly sensitive to regimens containing the cross-linking 
agents cyclophosphamide, cisplatin, or busulfan. 
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Materials and methods 
 
Sample characteristics. Samples were obtained from the cell banks of the VU 
medical center, the AML-BFM Study Group and the DCOG. Snap frozen cell pellets 
of bone marrow samples obtained from newly diagnosed adult AML patients (n = 
119, median blast cell percentage was 66%, range 4–97%) together with 15 adult 
ALL (B-cell precursor (BCP)-ALL; n = 10, T-cell ALL; n = 5, median blast cell 
percentage of adult ALL samples was 85%, range 10–99%) samples were randomly 
selected. Additionally, 20 pediatric AML samples with a complex karyotype, defined 
as 2 or more random aberrations, or loss of chromosome 5 or 7, or the long arms of 
these chromosomes, were studied, as well as 4 biphenotypic leukemic samples. For 
the analysis of 82 newly diagnosed pediatric ALL patients (BCPALL; n = 67, T-cell 
ALL; n = 15, median blast cell percentage of pediatric ALL samples was 94%, range 
16–100%) cytospin slides were selected at random. All specimens were collected 
with informed consent according to institutional guidelines and in accordance with the 
Helsinki Declaration of 1975. Control CD34+ cells were derived from healthy 
volunteers. 2.2. DNA isolation and treatment Genomic DNA from cell pellets was 
isolated using QIAamp® DNA Blood Minikit (Qiagen, Valencia, CA, USA) according 
to the manufacturer’s recommendations. DNA from cytospin slides was isolated 
using phenol, chloroform and isoamylalcohol (PCI; 25:24:1). Methylated DNA was 
obtained by treating control genomic DNA with SssI CpG methyltransferase (M.SssI, 
New England Biolabs) according to the manufacturer’s recommendations. 
 
MS-MLPA. MS-MLPA reagents were kindly provided by MRC Holland, Amsterdam, 
The Netherlands (www.mlpa.com). Target DNA was diluted in TE buffer (10 mM Tris-
HCl, pH 8.5, 1 mM EDTA) to a concentration of 100 ng/µl in a total volume of 5 µl and 
denatured for 10 min at 98◦C. MS-MLPA was performed as previously described 
(Nygren et al. 2005). Probes were designed such that these were targeted to the 
CpG islands within the promoter regions of 11 FA-BRCA genes and contained a 
recognition site for the methylation-sensitive restriction enzyme HhaI. The probe mix 
contained single probes directed to FANCA, FANCD2, FANCG, two probes directed 
to different sites of FANCB, FANCC, FANCD1/BRCA2, FANCE, FANCJ/BRIP1, 
FANCL and FANCM and three probes directed to different sites of FANCF. In 
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addition to the 11 FA-BRCA genes, probes were included for BRCA1, ATM, MLH1, 
XPA, WRN, BLM and NBS1. For quantification of the levels of methylation seven 
control probes lacking HhaI sites were also included. Probe sequences are shown in 
Table 1. 
 
 
 
 
Table 1 
FA-BRCA probe mix 
Size 
(bp) 
Gene Chr 
pos 
Probe 1 Probe 2 
130 FLJ22301* 01q44 GGTGAACCTGGCCACAGCTCACC CTGGAACAGCCACAATGTCTGCCCCTTAGAGAAGAACCCATG 
136 FANCF 11p15 GCGAAAGGAAGCGCGGAGACGTTCAT GACTGGCATCATCTCGCACGTGGTTCCGGAAATTCTCGGTACATG 
142 BRCA1 17q21 CCCCTTGGTTTCCGTGGCAACGGA AAAGCGCGGGAATTACAGATAAATTAAAACTGCGACT 
148 BRCA2 13q12.3 CGGGTTAGTGGTGGTGGTAGTGGGTT GGGACGAGCGCGTCTTCCGCAGTCCCAGTCCAGCGTGGCATG 
154 MLH1* 03p22.1 GGAGGGAGGCCTGAAGTTGATTCAGATCCA AGACAATGGCACCGGGATCAGGGTAAGTAAAACCTCAAAGTAG 
160 ATM 11q23 GCGGAGACCGCGTGATACTGGAT GCGCATGGGCATACCGTGCTCTGCGGCTGCTTGGCCATG 
166 MLH1 03p22.1 CGTTGAGCATCTAGACGTTTCCTTGGCTCT TCTGGCGCCAAAATGTCGTTCGTGGCAGGGGTTATTC 
175 BRCA2* 13q12.3 CAGCTGGCTTCAACTCCAATAATATTCAA AGAGCAAGGGCTGACTCTGCCGCTGTACCAATCTCCTGTAAAAGAAT 
184 FANCB Xp22.31 CCAGACCCAGGCGTCCGCATT GGATTGGGCGGTGCGGCGGCGCTTCTGTCCGCCTCATG 
211 FANCB Xp22.31 CCGGACCCGGAAGCCGCCTCT GAGGCCCGGGGACCGAGCGCCCGTGTGCAGGCATG 
220 FANCE 06p21.3 CGCGTCCGGTGTCGCCATGCC GGGGCACGGGTGCCGCGCCGCCCCCTACTCTGGT 
229 RELA 11q13 GCTTGTAGGAAAGGACTGCCG GGATGGCTTCTATGAGGCTGAGCTCTGCCCG 
238 FANCF 11p15 CTGCTCTCTCTGCGCCTGCTGGA GAACCGGGCCCTCGGGGATGCAGCTCGTTACCACCTGGCATG 
247 FANCF 11p15 GTCGCCGTCTCCAAGGTGAAAGCGGAA GTAGGGCCTTCGCGCACCTCATGGAATCCCTTCTGCAGCACCTCATG 
256 FANCM 14q21.3 CTGCCGGAGACTCATGCGCATTAT TAAGGCGTTACTCTAAATATGGTCCCCGGTGCGGTTCCGGCATG 
265 XPA 09q22.3 GGCAGGCCACCCCGAGCCCCT TAACTGCGCAGGCGCTCTCACTCAGAAAGGCCGCTGGGTGCATG 
274 FANCA 16q24.3 CAGGGAGCCGCCGCCGGGGCT GTAGGCGCCAAGGCCATGTCCGACTCGTGGG 
283 FANCD2* 03p25.3 GGTGTGGCCAAGTGGGGATAAAGA GAAGAGCAACATCTCTAATGACCAGCTCCATGCTCTGCTCCATG 
292 FANCC 09q22.3 CGCCGGGGCTTCCGCGCGAAA CCGGGAACACTGGAGCAGTACCGACTCCGCTCGCCTAGAA 
301 BRCA2 13q12.3 CGGGAGAAGCGTGAGGGGACAGATTTGTG ACCGGCGCGGTTTTTGTCAGCTTACTCCGGCCAAAAAAGA 
310 BRIP1 17q23.2 CTAAGAACAGGCCTGCGCTCAAAGGA GGTAAGGATAGGCTCCCTCCTCAGGTTTTCTGCCCCATG 
319 WRN 08p12 CTTGTACTCGGCAGCGCGGGAAT AAAGTTTGCTGATTTGGTGTCTAGCCTGGATGCCTGGGCATG 
328 FANCC 09q22.3 TGACACGTGTGCGCGCGCGCGGCT CCACTGCCGGGCGACCGCGGGAAAATTCCAAAAAAACTCA 
337 ATM* 11q23 CAGAGTCAGAGCACTTTTTCCGATGC TGTTTGGATAAAAAATCACAAAGAACAATGCTTGCTGTTGTGGACTACATG 
346 BLM 15q26.1 GGCGGGGTCGCCGTACAGCGC CGGGAGGGACGCGTATCTCCAAAGCCCAATCAGAGTC 
355 FANCL 02p14 GCGTCCGAGCGCCAGCGGACT GCGCATGTGCAGGACCCAGCAGGTCTAGAGCTTTTCTGTGCATG 
364 FANCM 14q21.3 CTGCTGGCAAAGGCGCCTTGG AGCTGCCAGGGCTCTGAGGTCGCTCAGTTCCGGAGCTCATG 
373 FANCD2 03p25.3 CGGTGATGGGCGAGCTTCTCTTCA CCGGGGCGCAGTTGCTTCTCTCTGACGTCGCCTC 
382 NBS1 08q21 CAACCACCAGGTGGCGGGCAA GCGCCCAAGTCGCACTCCCGCCTCATCCAAGGCAGCCCATG 
391 NF1* 17q11.2 CTCCCCTACCACTGGCCACTGTAACA GTGGACGAACTCGCCACGGATCCGCAAGCCAAGTGCAGAAGCATG 
400 FANCL 02p14 CCATGGCGGTGACGGAAGCGAGCCTGT TGCGCCAGTGCCCCCTGCTTCTGCCCCAGAACCGGTCGCATG 
409 FANCE 06p21.3 CACCGCCGCGTCAGGGACGGC GCTGGAGTCCTCCGTTCCCCTCAGCCTCTGAGCT 
418 WRN 08p12 GCAGCGAGGGCCTCCACGCAT GCGCACCGCGGCGCGCTGGGCGGGGCTGGATCATG 
427 XPA 09q22.3 CCCGGATGACAAGAGAGCAGGTAGTT AGGCGGGTACTCCGTGTCCGCGCATACCCAGACTCCGCCATG 
436 BRIP1 17q23.2 CTCGACTCCCAGCGCCCAATA GCCCAGCGAGCTCGACCAATCACCCGCCAAGGCCCATG 
445 TNFRSF7* 12p13 GAAAGTCCTGTGGAGCCTGCA GAGCCTTGTCGTTACAGCTGCCCCAGGGAGG 
454 FANCG 09p13 GCGGTAACTGGAGACGAGGGCGC TCCGTAATCGTCCATCCTTTCTCTGCTCACTGTCGAGC 
463 MLH1 03p22.1 CTGCTGAGGTGATCTGGCGCAGA GCGGAGGAGGTGCTTGGCGCTTCTCAGGCTCCTCCTCTCATG 
472 NBS1 08q21 CATGCCGACCGCAGGCGCCGT ATCCGCGCTCGTCTAGCAGCCCCGGTTACGCGGTTGCCATG 
481 CASR* 03q21 CCAGTGCCTGTAACAAGTGCCCAGATGACT TCTGGTCCAATGAGAACCACACCTCCTGCATTGCCAAGGACATG 
 
Indicated are the size of the expected PCR product in base pairs (bp), corresponding genes, 
chromosomal location, and probe sequences. In the probe sequences HhaI recognition sites 
are underlined. Control probes for genes lacking HhaI sites are indicated by asterisks. 
 
 
Sodium bisulphite sequencing. One µg of genomic DNA was converted by sodium 
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bisulphite using the EZ DNA Methylation Gold kitTM (ZYMO Research Corporation, 
Orange, CA) to confirm the aberrant methylation status. Bisulphite-treated genomic 
DNA was amplified by PCR using primers FANCC-F 5’-
TTTTATATTTTGAATAGAATATGGAAGAAG- 3’ and FANCC-R 5’-
CAATACATTCTAAAACCTAACTAAC- 3’ for FANCC, or FANCL-F 5’-
TTAGTTTTGTGGATTTGAGGGTAAT-3’ and FANCL-R 5’-
TAAAACAAAAACAAAAAACACTAAC- 3’ for FANCL. PCR products were subcloned, 
isolated and analyzed by sequencing. 
 
CFU assay and mitomycin C (MMC) sensitivity. To determine the number of Colony-
Forming Units present in the total bone marrow of AML and ALL patients, samples 
were plated in duplicate in Methocult culture medium (Stemcell Technologies Inc., 
Vancouver, BC) at a concentration of 40,000, 100,000 and 400,000 cells/well. 
Colonies were counted after 7 days (37◦C, 5% CO2, full humidity). MMC sensitivity 
was assessed by adding various concentrations of MMC (0, 5, 10 and 50 nM) to the 
cultures. Colonies were expressed as mean values from duplicate cultures and 
denoted as a percentage of the number of colonies in the wells without MMC. 
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Abstract 
 
Hypermethylation of the Fanconi anemia gene, FANCF, has been reported to 
occur in an appreciable proportion of malignancies, including 15% of head-
and-neck squamous cell carcinomas. This feature is claimed to be a useful 
tumor marker predicting a favorable response to cisplatin-based treatment 
protocols, since cells with a defective FA/BRCA pathway are hypersensitive to 
cross-linking agents, such as cisplatin. We examined the promoter methylation 
status of FANCF in paraffin-embedded oral tumor material from a cohort of 22 
patients, of whom 11 (50%) had responded favorably to a cisplatin-containing 
treatment regimen. No evidence for silencing of FANCF was obtained in any of 
these tumors. This result is in clear contradiction with published data. We 
provide evidence that the methylation-specific PCR method as used routinely 
to probe for FANCF methylation is flawed and liable to produce false-positive 
results. We suggest that the discrepancy between our results and those 
previously reported may be partly explained by this effect and that the 
occurrence of FANCF silencing in head-and-neck cancer may in fact be less 
frequent than suggested, if existing at all. 
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To the Editor, 
 
Fanconi anemia (FA) is a recessively inherited genetic disorder with a strong 
predisposition to malignancies, in particular acute myeloid leukemia (AML) and 
squamous cell carcinoma (SCC) (Joenje & Patel 2001; Alter 2003). Thirteen FA 
genes are known today (FANCA, -B, -C, D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, 
-M, and –N/PALB2) (Levitus et al. 2006; Meijer 2007; Dorsman et al. 2007; Wang 
2007), whose products act in the ‘FA/BRCA pathway’ to protect the genome against 
spontaneous as well as cross-linker-induced chromosomal breakage and 
rearrangements. Genomic instability is thought to be the underlying cause of cancer 
predisposition in FA patients as well as in other chromosomal instability and 
premature-ageing diseases (Hoehn et al. 2008). It has been hypothesized that FA 
gene defects might also play a role in sporadic cancer (Jacquemont & Taniguchi 
2006; Meijer 2007). In sporadic malignancies, loss of DNA stability and tumor 
suppressor gene function is often based on (a combination of) DNA sequence 
alterations, deletions, and promoter methylation. For FANCF, methylation of the 
promoter sequence has been reported for a proportion of several types of cancer, 
including leukemia (Tischkowitz et al. 2003; Hess et al. 2008) and cancer of the 
breast (Olopade & Wei 2003; Wei et al. 2008), ovary (Taniguchi et al. 2003; Dhillon 
et al. 2004; Wang et al. 2006; Lim et al. 2008), bladder (Neveling et al. 2007), cervix 
(Narayan et al. 2004), testis (Koul et al. 2004), lung (Marsit et al. 2004), and head-
and-neck (Marsit et al. 2004). All of these studies were based on a methylation-
specific PCR assay (‘MSP’), described in detail by Taniguchi et al. (Taniguchi et al. 
2003) and discussed in more general terms by Derks et al. (Derks et al. 2004). 
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Using the recently developed method of ‘methylation-specific multiplex ligase-
mediated probe amplification’ or ‘MS-MLPA’ (Nygren et al. 2005) we carried out a 
survey of FANCF promoter methylation in a panel of 25 cell lines derived from 
squamous cell carcinomas of various origins including the head-and-neck. We were 
unable to ascertain any convincing example of FANCF silencing, except in CHRF-
288 leukemia cells, which were used as positive controls (Tischkowitz et al. 2003). 
Because cell lines, due to culturing-artifacts, may not in every respect represent the 
initial tumor, we analyzed archival formalin-fixed paraffin-embedded HNSCC tumor 
material to retrospectively examine the possible relevance of FANCF silencing for 
tumor response to treatment regimens containing cisplatin. Twenty-two tumors from 
patients treated with cisplatin-containing chemoradiation were analyzed using MSP. 
Eleven tumors had shown sensitivity towards this treatment regimen; this subgroup 
was expected to be enriched for cases with FANCF methylation. However, no 
FANCF promoter methylation was observed in any of the 22 tumors, while formalin-
fixed paraffin-embedded CHRF-288 cells, which served as a positive control, clearly 
showed methylation (Figure 1). Our results represent a marked difference from those 
previously reported (0 positives out of 22 tested versus the reported 13 positives out 
of 89 tested; p< 0.07, 2-tailed Fisher’s exact test). 
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Figure 1. Bisulphite concentration-dependent variation in results obtained by MSP. MSP 
carried out on DNA isolated from FANCF-methylated CHRF-288 cells, and from 
unmethylated HSC93 wild type control cells (both formalin-fixed and paraffin embedded), 
after treatment with various concentrations of sodium bisulphite. An amplification product 
was generated with the M primers using methylated DNA even when the bisulphite 
concentration was down to 10% of the prescribed concentration (EZ DNA methylation kit, 
Zymo research). Using unmethylated DNA as a template, the PCR does not generate an 
amplification product when reducing the bisulphite concentration to 50%. Unmethylated DNA 
treated with 10% and 25% of the prescribed concentrations of sodium bisulphite, however, 
appeared to produce a PCR product with the M primers that will be interpreted as 
methylation-positive, but in fact is false-positive and due to suboptimal bisulphite treatment of 
the DNA. 
 
We next analyzed FANCF promoter methylation using a MS-MLPA test (MRC-
Holland, Amsterdam, The Netherlands). This test has the advantage over MSP that 
methylation is determined at multiple promoter sites simultaneously, while at the 
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same time deletions can be observed. However, this screen did not reveal any case 
of FANCF promoter methylation or homozygous deletion. Thus, so far our results 
have failed to provide evidence for FANCF inactivation underlying a favorable 
response to cisplatin-containing treatment regimens of head-and-neck SCCs. 
 
The discrepancy between our results and those published earlier may be explained, 
at least in part, by experimental details that could critically influence the results to be 
obtained with MSP (see (Derks et al. 2004) for a review of the MSP method). 
First, Marsit et al. (2004), who followed the PCR conditions as described by 
Taniguchi et al. (2003), used 44 PCR cycles to amplify the (bisulphite-modified) 
promoter sequences, whereas we used 34 cycles, which is in compliance with Derks 
et al. (2004), who recommend not to exceed 35 cycles. The use of too many cycles 
may carry a risk of producing false-positive amplification products. 
Second, since the yields of microdissected material may be low and highly variable, 
we used carrier DNA to standardize the amount of template for bisulphite treatment 
and to facilitate precipitation, as recommended (Derks et al. 2004). Whether carrier 
DNA has been used in the reported studies has not been specified. 
Third, bisulphite is known to be chemically unstable and may thus be a variable 
component of the reaction mixture if not used freshly-made. The MSP assay 
essentially relies on the conversion of unmethylated cytosine residues into uracil by 
sodium bisulphite treatment and the use of primers that specifically amplify either 
unmethylated (U) or methylated (M) DNA. However, DNA isolated from formalin-fixed 
paraffin-embedded specimens is often of relatively poor quality, which might interfere 
with efficient bisulphite modification of unmethylated cytosines. We hypothesized that 
incomplete conversion of cytosine bases could cause false-positive results by PCR 
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amplification, as most amplification protocols allow few mismatches in the annealing 
primers. We mimicked suboptimal conditions by applying a range of bisulphite 
concentrations and determined the amplification of methylated and unmethylated 
promoter region of FANCF using primers identical to those used in published studies 
(Taniguchi et al. 2003; Marsit et al. 2004). A concentration-dependent result of the 
PCR reaction was observed for the amplification of methylated and unmethylated 
DNA with M and U primers, respectively (Figure 1). Remarkably, a PCR product was 
generated with unmethylated DNA using M primers at bisulphite concentrations that 
were 10% and 25% of the prescribed concentration. Moreover, when 10% of 
bisulphite was used for conversion, only the M- and no U-PCR product was 
generated with unmethylated control DNA, in which case the sample was to be 
scored as fully methylated for FANCF. 
Our results revealed that the method as often applied in the assessment of FANCF 
promoter methylation, is liable to produce false-positive results when suboptimal 
conditions are used. Suboptimal conditions might exist particularly when using 
archival formalin-fixed paraffin-embedded material. We suggest that the discrepancy 
between our results and those reported by Marsit et al. (Marsit et al. 2004) may be 
partly explained by this effect and that the occurrence of FANCF silencing in head-
and-neck cancer may in fact be less frequent than suggested, if existing at all. 
In conclusion, the molecular basis underlying a favorable response of HNSCC 
patients to cisplatin treatment is not related to silencing of FANCF. In addition, the 
reported MSP-results that have led to conclusions regarding FANCF promoter 
methylation in tumor samples of various origins need to be considered with great 
caution in view of the possibility for the MSP assay to produce false-positive results. 
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Abstract 
 
Given that Fanconi anemia (FA) patients are strongly predisposed to develop 
squamous cell carcinomas, we addressed the question of whether squamous 
cell carcinomas (SCCs) occurring in the general population may be 
characterized by an impairment of the FA/BRCA pathway. We examined this 
pathway in 25 cell lines derived from head-and-neck (15), vulva (7), and cervix 
(3) SCCs. Western blotting was used to probe for (1) monoubiquitinated 
FANCD2, and (2) FA proteins known to act downstream of FANCD2 
monoubiquitination: BRCA2/FANCD1, BRIP1/FANCJ, and PALB2/FANCN; 
BRCA1, a known FANCD2 interactor, was also included. All cell lines appeared 
to be able to modify FANCD2 by monoubiquitination, indicating that the 
upstream part of the FA pathway was intact. However, the downstream-acting 
protein BRCA2 appeared undetectable in one HNSCC and one vulva carcinoma 
cell line, while BRCA1 was undetectable in two additional cell lines. These four 
cell lines were hyper-responsive to MMC-induced arrest in the G2 phase of the 
cell cycle, a phenotype consistent with a deficiency in the FA/BRCA pathway. 
We then screened the remaining 21 cell lines and found 12 more that showed a 
similar hypersensitive response. Thus, amongst 25 SCC cell lines, 16 (64%) 
responded in a FA-like fashion. In 4 of these the FA phenotype was associated 
with BRCA1 or BRCA2 deficiency, but in 12 the molecular defect remains 
undefined. We speculate that deficiencies of as yet unidentified FA proteins 
acting downstream in the pathway may be responsible for their abnormal 
response.
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Introduction 
 
Fanconi anemia (FA) is a recessively inherited genetic disorder with diverse clinical 
features, including developmental anomalies, progressive bone marrow failure and a 
strong predisposition to malignancies, in particular acute myeloid leukemia (AML) 
and squamous cell carcinoma (SCC) (Joenje & Patel 2001; Alter 2003). Cells derived 
from FA patients are hypersensitive to DNA cross-linking agents, such as mitomycin 
C (MMC) and cisplatin. To date, 13 FA complementation groups (FA-A, -B, -C, -D1, -
D2, -E, -F, -G, -I, -J, -L, -M, and -N) have been defined and the corresponding 
disease genes have been cloned (Joenje & Patel 2001; Wang 2007). The proteins 
encoded by these genes act in concert to support a complex genome maintenance 
pathway that is required for error-free DNA replication, especially in the presence of 
DNA damage due to cross-linking agents. Apart from the proteins found defective in 
FA patients at least three additional FA-associated proteins, FAAP24, FAAP100, and 
HES1, have been identified that are considered essential for the FA pathway to 
function, even though thus far no FA patients are known with pathogenic mutations in 
these genes (Ciccia et al. 2007; Ling et al. 2007; Tremblay et al. 2008). A key 
reaction in the FA pathway is the monoubiquitination of FANCD2 and FANCI, which 
together form a complex (I-D2) (Smogorzewska et al. 2007). Proteins acting 
upstream of this step are FANCA, -B, -C, -E, -F, -G, -L, -M, FAAP24, FAAP100, and 
HES1, which are assembled in a multiprotein ‘core complex’. Proteins acting 
downstream of the I-D2 complex are FANCD1/BRCA2 (Howlett et al. 2002), 
FANCN/PALB2 (Xia et al. 2006; Reid et al. 2007), and FANCJ/BRIP1 (Levran et al. 
2005; Levitus et al. 2005; Bridge et al. 2005). BRCA1, which is known to associate 
with FANCJ and FANCD2, and which when defective generates a FA-like cellular 
phenotype, is likely to play a role in the pathway as well. The existence of at least 
one additional as yet unidentified downstream-acting gene has been implicated on 
the basis of a recent comprehensive mutation screening study (Ameziane et al. 
2008). 
FA patients have an approximately 500-fold increased risk of developing SCC (Kutler 
et al. 2003; Alter 2003), most notably tumors of the oral cavity and gynecological 
tumors (Carvalho et al. 2002), which occur several decades earlier in FA patients 
than in the general population. Tumor cell lines derived from oral tumors obtained 
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from FA patients were found indistinguishable from those derived from sporadic 
tumor patients in showing highly complex karyotypes with a high proportion of whole-
arm translocations (Hermsen et al. 2001) in addition to numerous gains and losses 
that also characterize sporadic HNSCC (van Zeeburg et al. 2005). 
We hypothesized that (a proportion of) sporadic SCCs may originate from precursor 
cells with an acquired defect in the FA/BRCA pathway due to somatic inactivation, 
such as gene silencing or mutation. Indeed, previous studies have reported 
FA/BRCA pathway inactivation due to gene silencing in sporadic malignancies of 
various origins. Silencing of FANCF has been reported in ovarian cancer (Taniguchi 
et al. 2003), and in one megakaryocytic AML cell line (Tischkowitz et al. 2003), while 
FANCC and FANCL promoter methylation has been reported in five other cases of 
sporadic leukemia (Hess et al. 2008). Promoter methylation was apparently 
associated with a functional FA/BRCA pathway defect as demonstrated by cellular 
hypersensitivity to MMC and, in some cases of FANCF silencing, by correction of the 
FA phenotype by ectopic expression of FANCF. In addition, hypermethylation of 
FANCF has been reported for a proportion of primary material from head-and-neck 
and lung tumors (Marsit et al. 2004), granulosa cell tumors (Dhillon et al. 2004), 
breast tumors (Wei et al. 2008), and bladder carcinoma (Neveling et al. 2007). 
However, in these studies paraffin-embedded material was used, which is not 
suitable for examining the functional consequences of the observations. 
To ascertain the possible occurrence of FA/BRCA pathway defects in sporadic 
cancer we chose to study solid tumors that are known to occur frequently in FA 
patients: SCCs from the oral cavity and vulva/cervix. Instead of archival material we 
used cell lines established from such tumors, enabling us to correlate molecular 
findings with cellular phenotypes. Cell lines after being established from head-and-
neck tumors have been shown to faithfully reproduce critical properties of the primary 
tumor material (Martin et al. 2008). To characterize our tumor cell lines we utilized 
protein analysis by Western blotting, mRNA expression analysis, promoter 
hypermethylation and deletion analysis, and mutation screening. Tests for functional 
FA/BRCA pathway defects, applied in a subset of cases, included MMC-induced 
growth inhibition, cell cycle arrest, and chromosomal breakage analysis. 
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Results 
 
Twenty five SCC cell lines from sporadic cancer patients (15 head-and-neck and 10 
gynecological; Table 1) were examined for FA/BRCA pathway defects. Three 
HNSCC cell lines derived from FA patients were included as controls. The cell lines 
were examined for FANCD2, BRIP1/FANCJ, PALB2/FANCN, and BRCA2/FANCD1 
protein, by Western blotting. In contrast to the FA patient-derived tumor cell lines 
EUFA1131-T (FA-C), EUFA1365-T (FA-A), and EUFA974-T (FA-A), which expressed 
only the short form of FANCD2 (FANCD2-S), the gene-corrected EUFA1131-T 
(+FANCC) as well as all 25 sporadic SCC cell lines displayed the ubiquitinated form, 
FANCD2-L, in addition to the short form. This indicated that in all sporadic tumor cell 
lines studied the components functioning upstream of FANCD2 ubiquitination were 
intact (Figure 1). 
 
 
Figure 1. FANCD2 and BRCA2 protein expression. Whole-cell extracts were analyzed by 
direct Western blotting, using mouse monoclonal FANCD2 antibody and rabbit polyclonal 
BRCA2 antibody (Ab-2), which recognizes the amino acids between 3245 and 3418 of 
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human BRCA2. (a)The monoubiquitinated larger form of FANCD2 (FANCD-L) is detectable 
in sporadic HNSCC cell lines but lacking in the FA patient tumor-derived negative controls 
EUFA1131-T (FA-C), EUFA1365-T (FA-A), and EUFA974-T (FA-A). BRCA2 protein was 
undetectable in 1 sporadic HNSCC cell line, VU147-T. WT, wild type; D1, BRCA2-negative 
control; D2, FANCD2-negative control; A, FA-A; C, FA-C. (b) BRCA2 protein is detectable in 
all vulva and cervix tumor cell lines except in SCV-6, while all cell lines possess both forms of 
FANCD2. (c) BRCA2 protein was undetectable in cell lines SCV-6 and VU147-T with a rabbit 
BRCA2 antibody (Ab-2, upper panel), raised against the at C-terminus of the protein. After 
stripping and re-probing with a mouse BRCA2 antibody that recognized amino acids 1651-
1821 (Ab-1, lower panel), a weak band running slightly faster than full-length BRCA2 was 
detected in the VU147-T cells. 
 
 
BRCA2 deficiency 
In most sporadic HNSCC cell lines also downstream components appeared normal; 
examples of BRCA2 blots are shown in Figure 1a. However, in cell line VU147-T 
BRCA2 was undetectable, using a rabbit polyclonal BRCA2 antibody raised against 
the C-terminus of the protein (Ab-2). A similar observation was made in the 
gynecological cancer cell lines, where all cell lines appeared normal except for one 
vulva tumor cell line, SCV-6, in which we were unable to detect BRCA2 protein by 
the Ab-2 antibody (Figure 1b). Results from the Western blots for FANCD2, 
BRIP1/FANCJ, PALB2/FANCN, and BRCA2/FANCD1 are summarized in Table 1. 
Since most reported BRCA2 mutations result in a truncated protein (Tavtigian et al. 
1996) a mouse BRCA2 antibody (Ab-1) raised against the middle part of the BRCA2 
protein was used to detect potentially C-terminal truncated BRCA2 protein in SCV-6 
and VU147-T. As shown in Figure 1c, BRCA2 was – as before – undetectable in 
SCV-6 and VU147-T using Ab-2. However, after stripping the blot and re-probing with 
Ab-1, a weak band was detected in VU147-T suggesting a truncated BRCA2 protein. 
Su et al, (Su et al. 1998) reported that the detection of BRCA2 is improved when 
samples were denatured at lower temperature, 55 °C. However, these conditions did 
not improve the ability of antibody Ab-1 to detect wild-type BRCA2 in HSC93 cells, 
nor the truncated protein in VU147-T cells. In SCV-6 cells, BRCA2 remained 
undetectable (Figure 2). Detection of BRCA2 was neither improved by pretreating the 
cells with MMC, although this treatment increased the ratio FANCD2-L/-S, as 
reported before in other cell types. 
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Figure 2. Detection of BRCA2 protein under different conditions. (a) Sixty microgram (µg) 
aliquots of protein from whole cell lysates were analyzed using a mouse monoclonal antibody 
(Ab-1) following a denaturation temperature of 55 °C next to the routine 70 °C. BRCA2 
protein was still undetectable in SCV-6, although there was indication of improved detection 
in wild type HSC93 cells and truncated BRCA2 protein was detected in VU147-T. FANCD2 is 
shown on the same blot. (b) Cells were treated with the indicated concentrations of MMC 
and whole cell extracts from the same number of cells were analyzed by direct Western 
blotting using a rabbit BRCA2 antibody. BRCA2 protein remained undetectable in SCV-6, 
whereas FANCD2-L levels were elevated after MMC treatment. WT, wild type; D1, FA-D1. 
 
Genetic analysis of BRCA2 deficiency in VU147-T and SCV-6 cells 
VU147-T. Analysis of genomic DNA for copy number alterations by MLPA showed a 
heterozygous deletion of all BRCA2 exons (data not shown). A normal quantity 
normally sized BRCA2 transcript was detected by semiquantitative PCR of exon 27 
(Figure 3), suggesting that BRCA2 expression was normal at the mRNA level. 
Mutation screening on cDNA revealed a hemizygous nonsense mutation at 
10204A>T (p.K3326X), which results in deletion of 93 C-terminal amino acids. This 
sequence change is known as an unclassified variant or polymorphic stop (Mazoyer 
et al. 1996), and was evaluated as nonpathogenic using a mouse embryonic stem 
cell-based functional assay (Kuznetsov et al. 2007). However, this variant has 
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recently been associated with an increased risk of esophageal squamous cell 
carcinoma in the Turkmen population of Iran (Akbari et al. 2008), suggesting that the 
mutation may have pathogenic consequences.  
 
SCV-6. Deletion analysis by MLPA was carried out on genomic DNA from SCV-6. 
We detected a heterozygous deletion of all BRCA2 exons that also encompassed the 
promoter region (data not shown). RT-PCR of exon 27 indicated a normally sized 
BRCA2 transcript (Figure 3), which was present at a normal level as based on real-
time PCR (results not shown). To screen the second allele for mutations, the open 
reading frame and the 5’-untranslated region were sequenced. However, no 
pathogenic alterations were found. 
 
 
Figure 3. BRCA2 transcript in SCV-6 and VU147-T cells. PCR was carried out after BRCA2 
cDNA was synthesized (+, with reverse transcriptase; −, without reverse transcriptase). 
HSC93, wild type human lymphoblasts. 396 bp, PCR product corresponding to exon 27 of 
BRCA2. 
 
MMC sensitivity associated with BRCA2 deficiency 
Although the protein analysis suggested a deficiency in the levels of BRCA2 in 
VU147-T and SCV-6 cells, results of the genetic analysis did not necessarily imply 
complete loss of function. Cells derived from FA-D1 patients, who carry biallelic 
mutations in BRCA2 that cause a severe form of the disease, are known to be 
characterized by excessive chromosomal breakage and cell cycle delay in G2 when 
treated with MMC (Godthelp et al. 2006). We examined the cellular phenotype of 
VU147-T and SCV-6 cells by assessing MMC-induced growth inhibition, cell cycle 
delay, and chromosomal breakage. All three tests indicated a cellular phenotype in 
VU147-T and SCV-6 cells that was very similar to that of the FA tumor cell lines 
(Figure 4). These results indicated that the apparent absence of BRCA2 protein in 
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SCV-6 and the hemizygous truncating mutation with loss of the second allele in 
VU147-T are associated with a FA-like cellular phenotype. However, proof for a 
direct causal relationship would require correction of the phenotype by ectopic 
expression of BRCA2, which has thus far been technically unfeasible in our hands. 
 
 
 
 
 
 
 
a 
b 
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Figure 4. FA-like phenotype in SCV-6 and VU147-T cells. (a) MMC-induced growth inhibition 
in the BRCA2-deficient cell lines SCV-6 and VU147-T. The cell lines exhibit ~5-fold lower 
IC50 values than the gene-corrected EUFA1131-T+FANCC cells, similar to the uncorrected 
EUFA1131-T cells. (b) Cell cycle analysis after treatment with 50 or 100 nM MMC for 72 h 
shows excessive accumulation of cells in the G2/M phase in EUFA1131-T, VU147-T and 
SCV-6 cells compared to EUFA1131-T+FANCC. (c) Chromosomal breakage analysis. 
Elevated levels of chromosomal breakage is observed for EUFA1131-T, SCV-6, and VU147-
T cells, when compared to the gene-corrected EUFA1131-T+FANCC control and the HNSCC 
cell line VU120-T. BRCA1-deficient HCC1937 cells were also included as MMC-
hypersensitive controls. P-values for 2-sample Chi2 tests were <0.001, <0.001, and <0.002 
for the differences between EUFA1131-T, SCV-6, and VU147-T versus EUFA1131-
T+FANCC, respectively. 
c 
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BRCA1 deficiency 
Burkitt and Ljungman (Burkitt & Ljungman 2007) recently reported a FA-like 
phenotype in a subset of cisplatin-sensitive HNSCC cell lines, which was shown to 
be associated with deficient BRCA1 protein. Screening our cell lines for BRCA1 
protein by Western blotting revealed that the protein was undetectable in a HNSCC 
cell line, VU96-T, and a vulva tumor cell line, ME-180 (data not shown). These 3 cell 
lines were also found to exhibit hypersensitivity to MMC-induced cell cycle arrest in 
G2 (Table 1). However, after sequencing genomic DNA in these cell lines no 
pathogenic BRCA1 mutations could be detected. 
 
Functional screen for a FA-like phenotype 
Since the downstream part of the FA/BRCA pathway also depends on as yet 
unidentified proteins, we tested all remaining cell lines for MMC-induced cell cycle 
arrest. A MMC concentration was used that caused a strong accumulation in the G2 
phase of the cell cycle in EUFA-T (FA-C) cells, but hardly affected their gene-
corrected counterparts (EUFA-T+FANCC). By defining a FA-like response as the 
accumulation of >25% of cells in the G2 phase after 72 h exposure to 50 nM MMC, 
we observed that as many as 16 out of 25 SCC cell lines exhibited a FA-like 
response, which included the 4 cell lines that lacked detectable BRCA2 or BRCA1 
protein. Thus, in 12 cell lines the FA-like phenotype remains unexplained. These cell 
lines might be defective in as yet unidentified genes that play a role in the FA/BRCA 
pathway. 
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Table 1 Characteristics of SCC cell lines used in this study 
 
Cell line Gender Sitea G2 
arrestb 
D2-
Lc 
BRIP1 PALB2 BRCA2 BRCA1 FANCF 
methylation 
reference 
Head-and-neck tumors                                                 ----------           Western blot             ----------   
VU40-T F Tongue + + + + + + -- (Hermsen et al. 1996i) 
VU41-T M FoM - + + + + + -- (Hermsen et al. 1996h) 
VU78-T F Tongue +/-b + + + + + -- (Hermsen et al. 1996g) 
VU80-T M ToBase - + + + + + -- (Hermsen et al. 1996f) 
VU94-T F Tongue + + + + + + -- (Hermsen et al. 1996e) 
VU96-T M TrigRe + + + + + -- -- (Hermsen et al. 1996d) 
VU120-T F Tongue - + + + + + -- (Hermsen et al. 1996c) 
VU147-T F FoM + + + + -- + + (Hermsen et al. 1996b) 
UM-SCC-99-17 F U - + + + + + -- (Klaassen et al. 2002) 
UM-SCC-11B M Hypoph + + + + + + -- (Krause et al. 1981a) 
UM-SCC-22A F Hypoph + + + + + + -- (Krause et al. 1981b) 
UM-SCC-22B F n.m of 
22A 
+ + + + + + -- 
(Krause et al. 1981c) 
UM-SCC-35 U U + + + + + + -- (Weichselbaum et al. 1986) 
UM-SCC-OE M FoM + + + + + + -- (Hermsen et al. 1996a) 
UM-SCC-14C F FoM - + + + + + -- (Grenman et al. 1989) 
Gynecological tumors --  
SCV-1 F Vulva + + + + + + -- (Raitanen et al. 2004e) 
SCV-2 F Vulva + + + + + + -- (Raitanen et al. 2004f) 
SCV-3 F Vulva - + + + + + -- (Raitanen et al. 2004c) 
SCV-4 F Vulva + + + + + + -- (Raitanen et al. 2004d) 
SCV-6 F Vulva + + + + -- + -- (Raitanen et al. 2004b) 
SCV-7 F Vulva + + + + + + -- (Raitanen et al. 2004a) 
A431 F Vulva - + + + + + -- (Giard et al. 1973) 
ME-180 F Cervix + + + + + -- -- (Sykes et al. 1970) 
Caski F Cervix + + + + + + + (Pattillo et al. 1977) 
HeLa F Cervix - + + + + + -- (SCHERER et al. 1953) 
FA tumor cell lines (controls)    
EUFA1131-T 
(FA-C) 
F Oral + -- + + + + -- 
(van Zeeburg et al. 2005d) 
EUFA1131-T 
(+FANCC) 
  - + +    n.d. 
 
EUFA1365-T 
(FA-A) 
M Oral + -- n.d. n.d. + n.d. -- 
(van Zeeburg et al. 2005c) 
EUFA974 M Oral n.d. -- n.d. n.d. + n.d. n.d. (van Zeeburg et al. 2005b) 
 
aAbbreviations: FoM, floor of the mouth; ToBase, base of the tongue; TrigRe, trigonum 
retromolare; n.m., neck metastasis; U, unspecified. b +, >25%, -, <25% of the cells 
accumulated in the G2/M phase of the cell cycle after 3-d exposure to MMC at 50 nM 
(examples are shown in Figure 4). c +, present; –, undetectable. 
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Discussion 
 
In the present study 25 cell lines from sporadic tumor types that frequently occur in 
FA patients were screened by Western blotting for FANCD2 monoubiquitination and 
expression of BRCA2/FANCD1, BRIP1/FANCJ, PALB2/FANCN, and BRCA1. All cell 
lines were apparently capable of modifying FANCD2 by monoubiquitination, 
indicating that the upstream part of the FA pathway was functionally intact. However, 
a deficiency was observed in the downstream-acting BRCA2 protein in SCV-6 (vulva 
SCC) and VU147-T (HNSCC) cell lines. As expected for BRCA2-negative cells, SCV-
6 cells showed a dramatic increase in MMC-induced G2 phase arrest, chromosomal 
breakage, and growth inhibition, when compared to both wild type and other vulva-
derived cell lines that expressed full-length BRCA2 protein. VU147-T cells, which 
expressed a truncated BRCA2 protein, displayed a moderate MMC sensitivity in the 
chromosomal breakage assay. Further analysis of these two BRCA2-deficient cell 
lines showed that BRCA2 mRNA was present at a level comparable to other SCC 
cell lines. Sequencing of the BRCA2 cDNA identified a hemizygous nonsense 
mutation 10204A>T in VU147-T, a mutation that has been associated with 
predisposition for esophageal squamous cell carcinoma in the Turkmen population of 
Iran (Akbari et al. 2008). Our results thus raise the question whether this mutation 
might also predispose to head-and-neck cancer, although this may hold true only for 
certain ethnic backgrounds, since no such predisposition has been observed in 
European and North American BRCA2 mutation carriers (1999). 
The molecular cause underlying the apparently aberrant BRCA2 expression in a 
subset of our cell lines is still unclear. Although a heterozygous BRCA2 deletion in 
SCV-6 was observed, no other (epi)genetic aberrations were detected that could 
explain the absence of the BRCA2 protein in these cells. This observation suggests 
that additional mechanisms, besides genetic and epigenetic alterations, might 
abrogate BRCA2 protein expression or stability.  
Similar observations were made for BRCA1, which appeared undetectable by 
Western blotting in an oral tumor cell line (VU96-T) and a cervix SCC cell line (ME-
180). This abnormality was also associated with a hyper-responsiveness to MMC-
induced cell cycle arrest. Our findings concur with results recently reported by Burkitt 
and Ljungman (Burkitt & Ljungman 2007), who demonstrated BRCA1 deficiency to 
Chapter 8 
 
147 
be responsible for cisplatin sensitivity in a subset of HNSCC cell lines, although the 
authors did not report results from sequence analysis of the BRCA1 locus. We did 
sequence the gene in our 2 BRCA1-deficient cell lines, but failed to find any 
pathogenic alterations. Thus, a molecular explanation of the apparent absence of 
BRCA1 protein is still lacking. 
A striking result from our study is that as many as 16 out of 25 cell lines exhibited a 
FA-like phenotype, as assessed by MMC-induced cell cycle arrest, while only 4 of 
these cases could be correlated with a deficiency in BRCA1 or -2. In the remaining 
12 cell lines the underlying molecular mechanism is still to be elucidated. The 
mechanism may be based on deficiencies in as yet unidentified proteins acting 
downstream in the FA/BRCA or –related pathways. 
In conclusion, we found that 16 out of the 25 SCC cell lines studied exhibited a 
cellular phenotype consistent with a defective downstream component of the 
FA/BRCA pathway. However, in only 4 cell lines could the MMC-hypersensitive 
phenotype be associated with a demonstrable molecular abnormality in BRCA1 or -2, 
although further work is required to provide final proof for the association actually 
representing a causal relationship. For the remaining 12 cell lines no clue about the 
molecular basis underlying their FA-like phenotype is as yet available. In spite of this, 
our findings may have clinical significance. Bifunctional alkylating agents such as 
cisplatin in combination with inhibitors of the poly(ADP)ribose polymerase might offer 
a therapeutic option for treating tumors with a defective FA/BRCA pathway (Evers et 
al. 2008). Immunohistochemical staining for BRCA1 and -2 may help to recognize 
patients who might benefit from such treatment. 
 
 
Materials and methods 
 
Tumor cell lines. Twenty five cell lines derived from sporadic tumor patients were 
studied (Table 1). Fifteen HNSCC and 10 vulva/cervix tumor cell lines were from the 
Departments of Clinical Genetics and Otolaryngology/Head-Neck surgery, VU 
Medical Center, Amsterdam, and the Department of Obstetrics and Gynecology, 
Turku University Hospital, respectively. The following cell lines were used as controls 
in various experimental settings. Three HNSCC cell lines derived from FA patient oral 
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tumor biopsies were used as prototype FA-like tumor cells: EUFA-T (FA-C), VU1365-
T (FA-A), and VU974 (FA-A). Genetically corrected EUFA-T cells (EUFA-T + 
FANCC), obtained by transduction with a phoenix retroviral construct containing 
FANCC-GFP, were included as prototype for non-FA-like tumor cells. Human EBV-
immortalized lymphoblasts were derived from a healthy individual (HSC93) and from 
FA patients: EUFA1289 (FA-D2) and EUFA579 (FA-D1/BRCA2). AML cell line 
CHRF-288, which contains a silenced FANCF gene due to promoter 
hypermethylation, was used as a positive control for methylation analysis 
(Tischkowitz et al. 2003). HCC1937 tumor cells, obtained from the American Type 
Culture Collection, were included as BRCA1-deficient controls. 
 
 
Antibodies and Western blot. FANCD2(1-272) mouse monoclonal antibodies were used 
for the detection of FANCD2 (Santa Cruz Biotechnologies, Santa Cruz, California, 
USA). BACH1 rabbit antibodies were used to detect FANCJ. PALB21-200 rabbit 
antibodies were used to detect FANCN. BRCA1 mouse monoclonal antibody was 
used to detect BRCA1 (Santa Cruz Biotechnology, California, USA). BRCA2(1651-1821) 
(Ab-1) and BRCA2(3245-3418) (Ab-2) are mouse monoclonal and rabbit polyclonal 
antibodies, respectively (Merk Biosciences, Germany). For direct Western blot, cells 
from tumor cell lines were resuspended in lysis buffer (150 mM NaCl, 50 mM Tris-
HCl pH 8.0, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, supplemented 
with proteinase inhibitors aprotinin, pepstatin, leupeptin and pefablock). Protein 
lysates corresponding to 500,000 cells or the indicated amounts of protein, as 
determined with a Bio-Rad (Hercules, CA) protein assay, were denatured at 70 °C 
and/or 55 °C and loaded on a 3%-8% NuPAGE Tris-Acetate gradient gel (Invitrogen, 
Carlsbad, California, USA). After electrophoresis, proteins were transferred to an 
Immobilon-P membrane (Millipore, Bedford, Massachusetts, USA). The membrane 
was blocked with 5% fat-free milk in TBST (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 
0.1% Tween 20) and incubated with primary antibodies against FANCD2 (1:500) and 
BRCA2 (1:50) overnight. To visualize FANCD2 and BRCA2, blots were incubated 
with horseradish peroxidase-labelled secondary antibodies (Dako Diagnostics, 
Glostrup, Denmark) and detected using the ECL Western blot analysis system 
(Amersham Pharmacia Biotech, UK). Detection of other FA proteins by direct 
Western blot has been described elsewhere (de Winter et al. 2000). 
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RT-PCR and real-time RT-PCR. Total cellular RNA was isolated using TriReagent 
(Molecular Research Center, Cincinnati, OH) according to the manufacturer's 
instructions. cDNA synthesis was performed with Superscript II reverse transcriptase 
(Life Technology, Gaithersburg, MD), parallel to controls from which reverse 
transcriptase was omitted. The sequences of primers used to amplify exon 27 were 
as follows: BRCA2 (sense), 5'-TTCAGCCACCAAGGAGT-3'; BRCA2 (anti-sense), 5'-
GGCGACAATAAATTATTGAC-3'. Semi-quantitative PCR was performed as follows: 
94 °C for 2 minutes; 94 °C, 1 minute; 55 °C, 1 minute; 72 °C, 1 minute, for 35 cycles, 
and extended at 72 °C for a final 7 minutes.  
Real-time RT–PCR was performed using LightCycler FastStart DNA Master SYBR 
Green I kit (Roche Applied Science, Germany) with a Light Cycler apparatus. Each 
capillary contained a total reaction volume of 20 µl after the addition of primers (final 
concentration: 0.25 pM), MgCl2 (final concentration: 3.25 mM) and template cDNA (2 
µl of each) to the Master mix. PCR reaction was performed as: 94 °C for 5 min, then 
denaturation (95 °C for 0 s), annealing (59 °C for 10 s) and extension (72 °C for 12 s) 
for 60 cycles. After completion of the PCR amplification, a melting curve analysis was 
performed. The house keeping gene beta-2-microglobulin (B2M) was amplified at the 
same time and used as an internal control. Standard curves for BRCA2 and B2M 
were made using cDNA of HSC93 wild type lymphoblasts with 5-step dilutions as 
template. Calculation of ratios between target (BRCA2) and reference (B2M) genes 
according to their PCR efficiencies and crossing points has been described 
previously (Pfaffl et al. 2002). PCR products of BRCA2 and B2M were analyzed on a 
1.2% agarose gel. 
 
MLPA analysis and cDNA sequencing. Genomic DNA was isolated using QIAamp 
DNA Mini Kit (Qiagen, Hilden, Germany). Multiplex ligation-dependent probe 
amplification (MLPA), which detects gene deletions and amplifications, was 
performed as previously described (Hogervorst et al. 2003). Following reverse 
transcription, PCR reactions to amplify overlapping fragments of BRCA2 cDNA were 
performed. PCR products were purified and cycle sequencing performed using the 
ABI Big Dye cycle sequencing kit v3.1 according to the manufacturer's instructions, 
and products were analyzed on an ABI3100 machine for sequencing. 
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Mitomycin C-induced growth inhibition test. The growth-inhibiting effect of mitomycin 
C (MMC) was assessed by growing the cells in the presence of various 
concentrations of MMC over a period of time that allowed cells without added drug to 
undergo at least three population doublings. IC50 values are defined as the 
concentration of MMC causing 50% inhibition of growth. 
 
Flow cytometric analysis. Cells (150,000-200,000) were exposed for 72 h at 37 °C to 
MMC at 50 nM or 100 nM. DNA was stained with Hoechst, after which the cell cycle 
distribution was analyzed by flow cytometry using a Particle Analysing System (PAS) 
(Partec, Germany). 
 
Chromosomal breakage analysis. Spontaneous and MMC-induced chromatid-type 
aberrations were scored by visual inspection of Giemsa-stained metaphase spreads, 
as described previously (Joenje et al. 1981). 
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General discussion 
 
Several studies, including this thesis, have demonstrated the occurrence of a 
disrupted FA/BRCA pathway in a proportion of hereditary and sporadic malignancies. 
Patients with such malignancies might benefit from specific individualized treatment, 
designed to exploit the exquisite sensitivity of FA-like tumors to treatment with cross-
linking agents. Below, I will review the actual occurrence of FA-like malignancies in 
non-FA individuals, the methods of identification, and some of the various 
personalized treatment options. I will also briefly touch upon the phenomenon of 
resistance to chemotherapy, which is often observed after initial successful 
application of specific agents. 
 
 The important difference between familial/inherited and sporadic cancer in the 
present context is that in the inherited form a germ-line mutation in a DNA caretaker 
gene is present which facilitates the accumulation of oncogenic DNA alterations 
resulting in a high risk of cancer at a relatively young age. In the eventually arising 
tumor, the predisposing gene is typically found inactive, the unaffected allele often 
being deleted by ‘loss of heterozygosity’. The spontaneous mutation rate of an 
average gene is in the order of 10-6 to 10-8 per cell per division. With some 109 cells 
per gram tissue, heterozygous spontaneous mutations are likely to occur in most 
tissues. However, in the absence of a heterozygous germ-line mutation, the 
likelihood for both alleles to be hit by a mutation in a single cell would seem 
extremely small. Therefore, if inactivation of a caretaker gene were to play an 
important role in the genesis of a sporadic tumor, this inactivation is not likely to 
result from biallelic DNA sequence alterations, but rather from epigenetic gene 
silencing, which is a frequently observed phenomenon in tumor cells. 
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Inherited cancer 
 
Genes acting upstream in the pathway 
Carriership of a mutation in one of the ‘upstream’ FA genes does not appear to 
appreciably contribute to cancer susceptibility. If a cancer-predisposing effect were to 
result from heterozygous mutations in any of the upstream FA genes one might 
expect to observe a significant proportion of sporadic malignancies carrying mutated 
FANCB, which is X-linked and therefore present as only one active copy in a cell. 
Although comprehensive surveys have not been carried out so far, a recent screen in 
95 familial breast cancers has failed to record any case of FANCB mutation (Garcia 
et al. 2008). The fact that FA patients, who are homozygous for an ‘upstream’ defect, 
have an extremely high risk to develop malignancies seems to be at variance with 
the absence of an increased cancer risk in heterozygous carriers. A possible 
explanation may be that loss of the wild type allele as an early event in a somatic cell 
of a heterozygous carrier individual would create a situation in which an FA-defective 
cell exists in a non-FA tissue; in such a situation this cell may have little chance to 
survive due to its intrinsic growth disadvantage. Support for this argument is provided 
by the observation of female FANCB mutation carriers, who demonstrated complete 
skewed X-inactivation towards the mutated allele (Meetei et al. 2004). Whether 
germline mutations in the ‘central’ genes FANCI and FANCD2 are associated with 
increased cancer risk still remains to be examined in detail. 
 
Genes acting downstream in the pathway 
In contrast to mutations in the genes acting upstream in the FA pathway 
heterozygous germ-line mutations in the downstream-acting genes BRCA1 and 
BRCA2 are well known to impose an increased cancer risk, in particular breast and 
ovarian cancer. Heterozygous germ-line mutations in the remaining ‘downstream’ FA 
genes FANCJ and FANCN also confer an elevated risk for the development of breast 
cancer (Table 3), although to a lesser extent than mutations in BRCA1 and -2. In this 
case the homozygously affected cells resulting from inactivation of the wild type allele 
for some reason may have better survival chances than cells with an upstream 
defect. Alternatively, haploinsufficiency may be the conductive force towards cancer 
progression in BRCA heterozygously affected cells, consistent with their caretaker 
characteristics. In contrast to the widely accepted hypothesis that loss of the wild-
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type BRCA allele occurs in the development of breast cancer (Smith et al. 1992), it 
has recently been demonstrated that BRCA LOH is not required for BRCA-linked 
breast tumorigenesis (King et al. 2007). Either which way these genes are involved in 
tumorigenesis, it should encourage the search for additional FA genes that act 
downstream in the pathway, which may be relevant for both hereditary and sporadic 
cancer. 
 
 
Sporadic cancer 
 
FA pathway defects due to gene silencing 
Abrogation of the FA/BRCA pathway through epigenetic inactivation of FA 
genes has been demonstrated in a proportion of sporadic malignancies (Table 4, 
Introduction; Chapters 5 and 6). However, the proportion of sporadic malignancies 
with methylated FANCF promoter sequences is likely to be overestimated due to 
methodological flaws in the procedure that has been used to assess the promoter 
methylation status, as demonstrated in Chapter 7. Methylation of FANCF, FANCC 
and FANCL seems firmly established in sporadic leukemias, albeit at a low 
frequency, in the order of 5-10%. That promoter methylation is indeed associated 
with gene silencing has only been demonstrated for one AML (Chapter 5), one 
ovarian carcinoma cell line (Taniguchi et al. 2003), and one bladder cell line 
(Neveling et al. 2007). For the remaining cases this validation was not obtained, even 
though the cells’ phenotype was consistent with the genes actually being inactive. 
Interestingly, FANCF promoter methylation has also been observed in two squamous 
cell carcinoma cell lines (2 out of 25, Chapter 8), which showed normal FANCD2 
monoubiquitination, suggesting proficient FANCF expression. Whether FANCF 
promoter methylation is a coincidal event due to the localization of FANCF to a 
hypermethylation hotspot region (11p15) or a specific carcinogenesis promoting step 
causing genomic instability through the disruption of the FA/BRCA pathway, remains 
a subject of debate. 
The relevance for FA gene methylation screening in leukemic patients to 
predict tumor response to treatment may possibly be determined in a retrospective 
study using a large cohort of patients that either responded favorably or poor to 
cross-linking agents containing regimens. 
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Yet-to-be-identified molecular defects 
Based on direct mutation screening and protein analysis of DNA and cell lines 
obtained from unclassified FA patients, evidence for new FA subtypes, with both 
defects in the upstream and downstream parts of the FA/BRCA pathway has been 
presented in Chapter 2. Furthermore, in Chapter 8, the prevalence of FA/BRCA 
pathway deficiency was assayed in sporadic squamous cell carcinoma cell lines 
established from tumors that occur frequently in FA patients. The monoubiquitinated 
form of FANCD2 was present in all cell lines suggesting an intact FA core- and ID-
complex. However, deficient protein expression of BRCA2 was found in two cell 
lines. As expected for BRCA2 deficient cells, these cell lines were sensitive to MMC 
in terms of growth inhibition, cell cycle arrest, and chromosomal breakage. Analysis 
of the other cell lines demonstrated abnormal expression of BRCA1 in 3 instances, 
which appeared to associate with hyper-responsiveness to MMC-induced cell cycle 
arrest. However, no pathogenic genetic mutations or promoter methylation were 
found that could explain the absence of the BRCA1 and 2 proteins in these cell lines. 
This observation suggested the involvement of additional mechanisms in addition to 
mutations and promoter hypermethylation that might abrogate protein expression or 
stability. These findings are in agreement with results recently reported by Burkitt and 
Ljungman (Burkitt & Ljungman 2007) that demonstrated BRCA1 deficiency in a 
subset of cisplatin-sensitive HNSCC cell lines, where the molecular nature of this 
apparent defect could also not be explained. 
The aberrant levels of BRCA1/2 proteins might be explained by abnormal 
expression of interacting proteins that sustain BRCA1/2 stability, such as BRCA1-
associated RING domain 1 (BARD1) (Wu et al. 1996) for BRCA1, and the protein 
defective in ‘deleted in spilt hand/spilt foot’ (DSS1) (Li et al. 2006), FANCN (Xia et al. 
2006), and the inhibitor EMSY (Hughes-Davies et al. 2003) for BRCA2. However, 
normal levels of PALB2 protein were found and no mutation could be detected in 
DSS1, (and EMSY amplification remains to be analyzed). Alternatively, BRCA2 
silencing could result from other epigenetic silencing mechanisms like histone H3 
lysine 27 trimethylation, which can occur independent of promoter DNA methylation 
(Kondo et al. 2008), or inhibition of BRCA2 mRNA translation or mRNA degradation 
through microRNAs (Bartel 2004). 
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Interestingly, the majority of the analyzed cell lines that exhibited a FA/BRCA-
like phenotype as assessed by MMC-induced cell cycle arrest, could not be 
explained by an apparent defect in BRCA1 or BRCA2, suggesting deficiencies in as 
yet unidentified proteins acting downstream in the FA/BRCA or related pathways. 
Hence, these cell lines may serve as cloning vehicles for the identification of novel 
players in FA/BRCA pathway. 
FANCF promoter methylation has been reported for various types of 
malignancy suggesting inactivation of FA/BRCA pathway. The observation triggered 
many to support the proposition for an adapted adjuvant therapy treatment with 
cisplatin for tumors that harbor FANCF promoter methylation. Promoter methylation 
of FANCF is also reported in Chapter 8 for two squamous carcinoma cell lines, but 
did not seem to associate with gene silencing as FANCD2 monoubiquitination in 
these cells was normal. The partial methylation may suggest an early event resulting 
in the disruption of FA/BRCA pathway creating a mutator phenotype, followed by 
demethylation which would give a growth advantage to FANCF re-expressing cells 
during tumor development. Therefore, in order to exploit the FANCF promoter 
methylation as a potential predictor of tumor response to ICL agents, it is critical to 
ensure whether the methylation status is correlated with silencing. The clinical 
significance of FANCF promoter methylation for HNSCC patients that received 
cisplatin treatment is explored in Chapter 7, but did not demonstrate any predictive 
value. Moreover, a discrepancy in frequency of FANCF promoter methylation was 
observed between the data presented in Chapter 7 and that reported by Marsit et. al 
(2004), which might be explained by the used detection methods that may produce 
false-positive results (see chapter 7 for more detail). 
 
Identification of FA/BRCA tumors 
The generation of tools that could identify a functionally defective FA/BRCA 
pathway and hence may distinguish an ICL agent-sensitive tumor may demonstrate 
valuable implications for a more personalized therapy. The apparent disruption of the 
FA/BRCA pathway through BRCA1 and -2 impairment in cell lines may represent the 
condition of a proportion of tumors in situ. Furthermore, in Chapter 8 evidence for 
novel ‘downstream’ FA/BRCA key proteins has been shown based on hyper-
responsiveness to ICL agents. Therefore, immunohistochemical staining for BRCA1 
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and -2 and for yet to be identified proteins may help identify ICL agent-sensitive 
tumors. 
Recently, an assay has been demonstrated to measure the functional integrity 
of the FA/BRCA pathway in core biopsy samples from cancer patients. The 
technique is based on the evaluation of FANCD2, BRCA1, and RAD51 foci formation 
after irradiating the cells ex vivo (Powell & Kachnic 2008). This detection method may 
also be applicable on circulating tumor cells, isolated from the blood stream (Nagrath 
et al. 2007). 
A defect in any of the 8 FA core complex members or a component of the ID-
complex results in the failure to monoubiquitinate FANCD2 and FANCI at the lysine 
residues K561 and K523, respectively. The ability to specifically detect these 
modified forms might be exploited for the identification of a disrupted FA/BRCA 
pathway caused by a defective core- or ID-complex. Indeed, ongoing attempts are 
aimed to generate antibodies that distinctively detect the monoubiquitinated form of 
FANCD2 using branched peptide epitopes consisting of parts of FANCD2 protein 
flanking the K561 amino acid and a part of the ubiquitin molecule. The recently 
identified FANCD2 paralog, FANCI, may also be considered for the development of 
such specific antibodies. 
 
Treatment strategies for ‘FA/BRCA’ malignancies 
Chemotherapy treatment containing the ICL agent cisplatin or its derivatives, 
such as carboplatin and oxaliplatin has been used for various types of malignancies, 
including head and neck, testicular, breast, ovarian, cervical, lung, colorectal and 
lymphid tumors. The treated patients demonstrate dissimilar responses, while these 
chemotherapeutics can have severe side effects. Identifying patients that may 
optimally benefit from this specific treatment and excluding patients who may be 
subjected to ineffective treatment management with unnecessary burden is therefore 
very important. A higher response rate to platinum-based chemotherapy has been 
demonstrated in Jewish BRCA1/2 mutation carriers with ovarian cancer compared to 
non-hereditary ovarian cancer patients (Cass et al. 2003). In addition, patients with 
low/intermediate levels of BRCA1 mRNA were shown to have significantly improved 
overall survival following treatment with platinum-based chemotherapy as compared 
to patients with high levels of BRCA1 mRNA (Quinn et al. 2007). The observed 
sensitivity of BRCA1/2 cancer patients to ICL agents may also apply for cancer 
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patients who are carriers of mutations in other FA genes beside FANCD1/BRCA2. 
Retrospective examination of tumor biopsies from cancer patients who were 
subjected to treatment regimens containing ICLs may provide answers for this 
question. 
 
Synthetic lethality 
Synthetic lethality is explained as the occurrence of fatality in a cell when two 
genes or pathways are disrupted whereas inactivation of the individual gene or 
pathway has no effect on viability (Dobzhansky 1946). Recently, a synthetic lethal 
interaction has been described for the FA/BRCA pathway and ATM, where FA/BRCA 
deficient pancreatic cell lines were shown to be more sensitive to ATM inhibition as 
compared to their isogenic controls (Kennedy et al. 2007). Furthermore, Poly-ADP 
Ribose Polymerase (PARP) inhibitors, which have been shown to abrogate the base 
excision repair pathway (BER, involved in DNA single strand break repair), have 
been shown to cause selective cell killing in FA/BRCA deficient cells with defects in 
the FANCA, -C, -D1, and -D2 (Farmer et al. 2005; Bryant et al. 2005; McCabe et al. 
2006). In the context of cancer treatment of familial BRCA1/2 and sporadic cases, 
with a disrupted FA/BRCA pathway, these small molecules may have major 
therapeutic implications as the use of sub-lethal doses of the drug kills the malignant 
cells with a defective FA/BRCA pathway, leaving the normal cells unharmed. Indeed, 
PARP inhibitors are currently being tested in clinical trials on breast and ovarian 
cancer of BRCA mutation carriers. Preliminary data from phase I trials with ovarian 
cancer patients carrying BRCA1/2 mutations showed promising results in terms of 
anti-tumor activity based on radiological and biochemical observations (Yap et al. 
2007). Provided that a positive safety and efficacy of the described treatment 
approach is obtained for hereditary BRCA1/2 cancers, the approach might also be 
beneficial to sporadic tumors with a functionally impaired FA/BRCA pathway. 
Recently, several compounds have been identified to elicit a strong growth 
inhibition in FA/BRCA-deficient cells compared to their isogenic controls (Gallmeier et 
al. 2007). These compounds seemed to function in a mechanistically distinct manner 
as compared to ICLs and showed a synergistic effect when combined with ICLs. 
These observations warrant further investigation of these attractive candidate agents 
for the treatment of FA/BRCA-deficient tumors. 
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Acquired resistance in ‘FA/BRCA tumors’ 
Although tumors treated with platinum-based chemotherapy initially have a 
high response, most of them eventually become resistant, as is documented for 
ovarian tumors (Agarwal & Kaye 2003). Several mechanism of resistance can occur 
including, changes in cellular uptake and efflux of the drug, increased detoxification, 
alteration of the function or quantity of target, and increased repair of damaged DNA. 
Recently, resistant clones from a pancreatic cell line, which carries the protein-
truncating c.6174delT frameshift mutation, were developed by culturing the cells in 
media containing cisplatin or PARP inhibitors (Sakai et al. 2008; Edwards et al. 
2008). Resistance to both DNA damaging agents was found to result from intragenic 
mutations that restored the BRCA2 open reading frame (ORF), leading to expression 
of functional proteins. Examination of recurrent cancers from BRCA2-mutated 
ovarian carcinoma patients who received either cisplatin or carboplatin treatment 
demonstrated secondary BRCA2 ORF-restoring mutations (Sasaki & Tonomura 
1973; Edwards et al. 2008). Similar observations were made with recurrent BRCA1-
mutated ovarian cancers that were treated with platinum compounds, where four of 
the six recurrent platinum-resistant tumors had developed secondary genetic 
changes producing functional BRCA1 proteins (Swisher et al. 2008). Altogether, 
secondary mutations that restore the BRCA1/2 function suggest a major mechanism 
by which tumors acquire resistance to platinum-based chemotherapy. 
Spontaneous genetic alterations compensating for inherited disease-causing 
mutation have been described to occur in hematopoietic cells of FA patients 
belonging to subtypes FA-A and –C (Lo Ten Foe et al. 1997; Waisfisz et al. 1999; 
Gregory, Jr. et al. 2001; Gross et al. 2002; Hirschhorn 2003; Hamanoue et al. 2006), 
-D1 (Ikeda et al. 2003), and in a lymphoblastoid cell line established from a FA-N 
patient (Chapter 3). In FA patients, these reversion events, which might be the 
consequence of genetic instability, may provide proliferative advantage of the 
reverted cell lineages leading to improved bone marrow function. However, in the 
context of FA/BRCA-defective tumors in non-FA patients, the mutator phenotype as a 
result of the inability to maintain genomic stability may give rise to ICL and PARP 
inhibitor resistant subclones in the tumor due to increased single strand annealing 
(SSA) that compensates for the defective homologous recombination process 
(Jonnalagadda et al. 2005). In such cases, inhibition of the SSA process, e.g. by 
interfering with RAD52 may circumvent resistance. So far, secondary mutations as a 
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mechanism of resistance has only been demonstrated for tumors that carried 
frameshift mutations in BRCA1 and -2, suggesting additional mechanisms of 
resistance in tumors with no such mutations. 
 
Alternative approaches 
Given that tumor resistance to DNA damaging agents can occur through 
reactivation of the FA/BRCA pathway, approaches that specifically target the 
pathway may partly provide a solution to the problem. Small molecule inhibitors of 
the FA/BRCA pathway have been identified to sensitize breast and ovarian tumor 
cells to cisplatin, although their exact mechanism of action remains to be elucidated 
(Chirnomas et al. 2006). Among the potent inhibitors, the natural compound 
curcumin, was identified and is currently investigated for its sensitizing effect to 
cisplatin in animal models. Alternatively, targeting the FA/BRCA pathway in tumor 
cells could be achieved with viral delivery of dominant negative genes coding for 
enzyme components of the FA/BRCA pathway (Ferrer et al. 2004). This approach 
has been explored using an adenovirus over-expressing a FANCA variant, which 
disrupted the FANCD2-monoubiquitination ability in NSCLC cell lines. However, so 
far, moderate sensitization effects were reported (2 to 3 fold) mainly due to low 
infection efficiency. An improved bioengineering of viruses that target the tumor cells 
efficiently and specifically, which deliver more potent inhibitors of the FA/BRCA 
pathway may hold the answer for successful cancer gene therapy. 
 
Understanding the complex biological system of cancer is a prerequisite to 
ensure appropriate diagnosis, treatment and possibly prevention of the disease. The 
study of chromosomal instability disorders, among which FA, have increased our 
knowledge of mechanisms partly underlying cancer development, and at the same 
time provided us with possible treatment approaches that may enhance our chances 
in the battle against cancer. The goal of this thesis was to contribute to the effort of 
finding biomarkers, which may identify a subtype of tumors that may benefit from 
individualized treatment strategies. Evidence for additional key players in the 
FA/BRCA pathway has been presented and their identification may have valuable 
implications for both better understanding of the pathway as well as new targets for 
advanced treatment strategies. 
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Summary 
 
Cancer is characterized by uncontrolled cell growth and is caused by 
alterations in genes that regulate the cell cycle, apoptosis and communication 
between cells. These alterations are essentially due to misrepaired DNA damage, 
which may result from DNA replication errors as well as from chemically reactive 
agents produced by both endogenous and exogenous mechanisms. Yet, the 
spontaneous mutation rate in healthy individuals is unable to explain the life-time 
cancer risk. This is because cells are equipped with sophisticated molecular systems 
that are highly efficient in maintaining the integrity of the genome and keeping the 
mutation rate low. Failure of these systems to protect the genome increases the 
mutational load and increases the chance for growth-controlling genes to become 
dysregulated. That is precisely the case in individuals who suffer from genetic 
instability disorders, of which Fanconi anemia (FA) is a well-known example. 
FA is a rare recessively inherited disorder characterized by diverse clinical 
symptoms, including organ malformations, bone marrow failure and increased cancer 
risk. To date, 13 genes have been identified that, when mutated, can cause FA. 
Among these genes, the breast/ovarian cancer susceptibility gene, BRCA2, has been 
found defective in a subgroup of FA patients. The proteins encoded by the FA genes 
appear to function in a distinct biochemical pathway, the ‘FA/BRCA pathway’, which 
acts to stabilize the genome. A defect in this pathway is not lethal, but has profound 
consequences, both at the cellular and clinical levels. Cells with an FA/BRCA 
pathway defect exhibit an extremely high sensitivity to DNA cross-linking agents, 
such as the chemotherapeutic agents cisplatin and mitomycin C (MMC). 
The purpose of this thesis was two-fold. First, to expand our knowledge of the 
pathway by searching for novel genes that participate in the pathway (Chapters 2-4). 
Second, to explore the possible occurrence and significance of FA/BRCA pathway 
defects in sporadic cancer (Chapters 5-8). 
In Chapter 2 a comprehensive genetic subtyping approach for FA is presented that 
is primarily based on mutation screening, supplemented by protein expression 
analysis and by functional assays to test for pathogenicity of unclassified variants. A 
total of 80 unselected FA patients were analyzed, of which 73 could be successfully 
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subtyped. Ninety-two distinct mutations were detected, of which 56 were novel. All 
known genetic subtypes were represented, except D2, J, L, and M. Four patients 
could not be assigned to any of the known subtypes; these patients may represent 
novel subtypes. One of these patients had a defect downstream of the FANCD2 
monoubiquitination, whereas the remaining 3 were defective upstream of this step. 
The conclusion from this study was that direct mutation screening, in combination 
with functional tests, allows a molecular diagnosis of FA in the vast majority of 
patients. The patients that were unclassifiable by this approach likely represent novel 
genetic subtypes for which the underlying gene defect remains to be identified. 
Chapter 3 reports that for one of these patients the defect could be traced to a gene 
that was known to encode PALB2, a protein that is essential for the stabilization and 
localization of BRCA2. This subtype, which was named FA-N, is characterized by 
relatively severe clinical symptoms and extreme susceptibility to childhood cancers, 
similar to the FA-D1 subtype (mutated in BRCA2). Furthermore, as reported by 
others, individuals who carry a heterozygous mutation in this gene appear to have an 
increased risk to develop breast cancer. In Chapter 4, the occurrence of large 
PALB2 deletions, such as identified in the FA-N patient described in Chapter 3, was 
assessed in a large cohort (734) of familial breast cancer (FBC) patients but did not 
reveal the involvement of such aberrations in BC risk. 
The extreme proneness of FA patients to develop malignancies such as acute 
myeloid leukemia (AML) and squamous cell carcinoma of the head and neck region, 
suggested the involvement of the FA/BRCA deficiency as an underlying mechanism 
in a proportion of these ‘sporadic’ malignancies in the general population. In Chapter 
5, a functional disruption of the FA/BRCA pathway in a leukemic cell line was 
demonstrated to occur through promoter methylation of the FANCF gene, which 
codes for an essential component of the pathway. In contrast to gene-disrupting 
mutations, promoter methylation is another mechanism by which genes can be 
inactivated and is frequently observed for other genes in various types of 
malignancies. These FANCF deficient cells were hypersensitive to MMC, while 
reintroduction of the active FANCF gene into these cells restored resistance to MMC. 
Promoter methylation of two other FA genes, FANCC and FANCL, in cells from 
sporadic leukemia patients (AML and ALL) is described in Chapter 6. In these cases 
the methylation was also correlated with hypersensitivity to MMC. To investigate the 
possible predictive value of FANCF promoter methylation in head-and-neck 
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squamous cell carcinoma patients towards treatment strategies containing cisplatin, 
a panel of 22 patients of whom 11 responded favorably to the treatment were 
assessed for FANCF methylation in Chapter 7. In contrast to previous reports, 
promoter methylation was absent in all patients, which might partially be explained by 
the used detection method that is prone to produce false-positive results. 
In an attempt to assess the involvement of the FA/BRCA pathway defects in 
sporadic cancer, 25 cell lines derived from tumors that occur frequently in FA patients 
were evaluated for their FA/BRCA pathway status (Chapter 8). Interestingly, as 
many as 65% of the cell lines demonstrated FA-like behavior in terms of sensitivity to 
MMC, suggesting an abrogated FA/BRCA pathway. All cell lines appeared to be able 
to monoubiquitinate FANCD2, suggesting a defect downstream of this step. 
However, only in a small portion of the MMC-sensitive cell lines could this phenotype 
be correlated with molecular defects: BRCA2 protein was undetectable in two cell 
lines, while BRCA1 appeared to be absent in 3 cell lines. The molecular basis for 
these aberrations was unclear, since we were unable to find sequence alterations in 
these genes that could explain the protein deficiencies. However, inactivation of the 
FA/BRCA pathway in the remaining “FA-like cell lines” could not be attributed to any 
of the known FA proteins, suggesting the involvement of (a) novel FA protein(s). 
Further analysis of these cell lines may result in the identification of new important 
player(s) in the FA/BRCA pathway. These possible new FA genes may turn out to be 
frequent targets that are inactivated in the oncogenesis process and may thus also 
serve as predictors for cancer treatment response. 
In conclusion, the work presented in this thesis has contributed to the 
identification of a new breast cancer susceptibility gene, FANCN. Furthermore, 
evidence for novel FA genes yet to be identified has been presented. Identifying 
these genes will enhance our understanding of the FA/BRCA pathway. Given that 
inactivation of the FA/BRCA pathway renders cells hypersensitive to specific 
chemotherapeutic agents, identification of malignancies with such a defect may 
pinpoint patients that could benefit from adapted treatment strategies that exploit the 
Achilles heel of such malignancies: hypersensitivity to cross-linking agents. 
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Samenvatting 
 
Het hoofdkenmerk van kanker is ongebreidelde groei, die is ontstaan als 
gevolg van veranderingen in genen die een rol spelen bij de regulatie van de 
celcyclus, celdood en communicatie tussen cellen. Die veranderingen zijn 
veroorzaakt door het falen van DNA schadeherstelprocessen, die geacht worden 
beschadigingen in het erfelijk materiaal te repareren. DNA schade wordt bij 
voortduring aangebracht, als gevolg van bijvoorbeeld straling en chemische 
mutagentia. Spontane mutaties in het DNA komen weinig voor, omdat de cel er alles 
aan doet om de correcte genetische informatie te behouden, waarbij gebruik wordt 
gemaakt van ingewikkelde maar zeer efficiënte mechanismen die schade kunnen 
herstellen. Als zo’n mechanisme niet meer goed functioneert, kunnen mutaties zich 
ophopen en lopen de belangrijke genen die normale celgroei moeten garanderen 
gevaar om defect te raken, met als gevolg een verhoogd risico op het ontstaan van 
kanker. Deze situatie is van toepassing op patiënten die lijden aan een ‘genetisch 
instabiliteitssyndroom’, zoals Fanconi anemie (FA). 
FA is een zeldzame, recessief overervende, genetische ziekte met diverse 
klinische symptomen, waaronder aangeboren afwijkingen, beenmergfalen 
(aplastische anemie) en verhoogd risico op maligniteiten. Dertien verschillende 
genen kunnen – wanneer ze getroffen worden door mutaties – FA veroorzaken. 
Hierbij hoort ook het bekende borstkanker-predispositiegen BRCA2. De eiwitten, die 
door deze 13 genen worden gecodeerd, functioneren in een biochemische route, het 
‘FA/BRCA pad’, dat zorg draagt voor het intact houden van de genetische informatie. 
Een defect in dit pad is niet lethaal, maar heeft wel ernstige consequenties. Cellen 
met een defect in het FA/BRCA pad zijn genetisch instabiel en neigen daardoor tot 
ontwikkeling van kanker. Bovendien zijn dergelijke cellen extreem gevoelig voor 
stoffen die DNA cross-link schade kunnen veroorzaken, zoals de chemotherapeutica 
cisplatinum en mitomycine C (MMC).  
Het doel van deze studie was twee-voudig. Allereerst is getracht de kennis 
van het FA/BRCA pad uit te breiden door op zoek te gaan naar nieuwe genen, die 
deel uitmaken van dit pad (hoofdstukken 2-3). Daarnaast is onderzocht of en in 
hoeverre defecten in het FA/BRCA pad voorkomen bij sporadische gevallen van 
kanker (hoofdstukken 4-8). 
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Hoofdstuk 2 beschrijft een uitgebreide genetische analyse van 80 FA patiënten, 
primair gebaseerd op mutatiedetectie en aangevuld met een functionele analyse van 
de gevonden missense mutaties. Die analyse was nodig om onderscheid te maken 
tussen ongeclassificeerde varianten en echte ziekteverwekkende mutaties. Van de 
80 patiënten konden 73 eenduidig worden geclassificeerd als behorend tot een van 
de bekende subtypes. In totaal zijn 92 mutaties gevonden, waarvan er 56 nog niet 
eerder waren gerapporteerd. Alle bekende subtypes werden aangetroffen, behalve 
D2, J, L en M.  Vier patiënten konden niet aan één van de bekende subtypes worden 
toegerekend; deze patiënten zouden nieuwe subtypes kunnen vertegenwoordigen. 
Eén van deze patiënten had een defect downstream van de FANCD2 
monoubiquitinering, terwijl de overige 3 patiënten upstream van deze stap defect 
waren. De conclusie van deze studie was, dat mutatie detectie in combinatie met 
functionele testen een geschikte methode is om het moleculaire defect bij de 
overgrote meerderheid van FA patiënten te achterhalen. De patiënten die door deze 
methode niet konden worden geclassificeerd, vertegenwoordigen waarschijnlijk 
nieuwe genetische subtypes van de ziekte, waarvoor het onderliggende gendefect 
nog moet worden gevonden. Zoals beschreven in hoofdstuk 3, is dit gelukt voor één 
van de patiënten, bij wie een defect in PALB2 kon worden vastgesteld. Dit eiwit was 
al bekend als een partner eiwit van BRCA2 dat zorg draagt voor stabilisatie en 
correcte lokalisatie van BRCA2 in de cel. Patiënten behorend tot dit nieuwe 
genetische subtype, FA-N, lijden aan een relatief ernstige vorm van FA, waarbij 
sprake is van AML en solide tumoren op de vroege kinderleeftijd, hetgeen ook wordt 
waargenomen bij patiënten in de D1 groep, die een defect hebben in BRCA2. Uit het 
werk van anderen is bekend, dat draagsters van een mutatie in PALB2/FANCN een 
verhoogd risico hebben op het krijgen van borstkanker. In hoofdstuk 4 is getracht 
grote genetische deleties in het PALB2 gen, zoals die gevonden is in de FA-N patient 
welke beschreven is in hoodstuk 3, te onderzoeken op prevalentie in familiaire 
borstkanker gevallen. Geen enkel geval van de 734 geanalyseerd patiënten bleek 
zulke mutaties te hebben wat suggereert dat dergelijke gen afwijkingen geen 
verklaring bieden voor de erfelijke vorm van borstkanker. 
Het extreem hoge risico voor FA patiënten om maligniteiten te ontwikkelen 
zoals AML en plaveiselcel carcinomen, leidde tot de hypothese dat een defect in het 
FA/BRCA pad wellicht ook een rol zou kunnen spelen bij het ontstaan van dit type 
maligniteiten in de algemene populatie. Hiervan bleek in een aantal gevallen sprake 
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te zijn. In hoofdstuk 5 wordt een cellijn afgeleid uit een sporadische AML beschreven 
met een defect in het FA/BRCA pad. Dit defect berustte op een deficiëntie van het 
FANCF eiwit. Deze deficiënte was terug te voeren op downregulatie van het FANCF 
gen als gevolg van promoter methylering. Naast inactivering van genen door 
schrijffouten in de genetische code, kan inactivering ook optreden door het ‘op slot 
zetten’ van een gen middels methylering van de deoxycytidines in de promoter 
sequentie. Een dergelijke vorm van gen-inactivering wordt in tumorcellen veelvuldig 
aangetroffen en kan dus in bepaalde gevallen ook leiden tot uitschakeling van het 
FANCF gen. De cellen waarin dit fenomeen werd aangetroffen waren als gevolg 
hiervan hypergevoelig voor MMC, zoals ook bij cellen met een mutatie in een FA gen 
wordt waargenomen. Zoals mocht worden verwacht, kon deze gevoeligheid worden 
gecorrigeerd door introductie van een plasmide dat het normale FANCF eiwit tot 
expressie bracht. Uitbreiding van dit onderzoek leidde tot de ontdekking, beschreven 
in hoofdstuk 6, dat inactivering door promoter methylering ook bij andere FA genen 
wordt waargenomen in sporadische leukemieen. Zo werd FANCC methylering 
gevonden in 1 AML en 3 ALL gevallen, en 1 geval van FANCL methylering in een 
ALL. In al deze gevallen was er sprake van hypergevoeligheid voor MMC. De 
mogelijk voorspellende rol van FANCF promoter methylering in hoofd-hals- tumor 
patiënten op behandeling die cisplatin bevat is onderzocht in hoodstuk 7. In een 
groep van 22 patiënten met een dergelijke aandoening, waarvan de helft een goed 
response heeft gegeven op de behandeling, bleek geen enkele FANCF promoter 
methylering te hebben in tegenstelling tot eerdere studies. Een mogelijke verklaring 
kan liggen in de gebruikte methylerings detectie methode die gevoelig is voor het 
opleveren van vals-positieve resultaten. 
Het onderzoek werd uitgebreid naar 25 cellijnen afgeleid van solide tumoren, 
die bij FA patiënten veelvuldig voorkomen: plaveiselcel carcinomen in de mondholte 
en de vulva/cervix. Een verrassend groot aantal (16/25; 65%) bleek hypergevoelig te 
zijn voor MMC. Echter, in slechts een minderheid kon deze gevoeligheid 
gecorreleerd worden met een FA/BRCA defect, en wel in het downstream gedeelte 
van het FA/BRCA pad. In twee gevallen kon het eiwit BRCA2 niet gedetecteerd 
worden, terwijl in drie gevallen het eiwit BRCA1 leek te ontbreken. Het moleculaire 
defect dat aan deze afwijkingen ten grondslag ligt kon echter niet worden 
achterhaald. Bij alle 16 MMC-gevoelige tumorcellijnen werd een normale FANCD2 
monoubiquitinering vastgesteld, zodat er geen sprake was van een defect upstream 
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in het FA/BRCA pad. Bij elf van de gevoelige cellijnen kon het (downstream) defect 
niet worden opgehelderd. Verder onderzoek zal moeten uitwijzen of hier sprake is 
van een defect in nieuwe componenten van het FA/BRCA pad. 
Samenvattend kan gezegd worden dat het werk gepresenteerd in dit 
proefschrift heeft bijgedragen tot het identificeren van een nieuw gen (FANCN), dat 
participeert in het FA/BRCA pad van genoomprotectie, terwijl aanwijzingen zijn 
verkregen voor het bestaan van nog niet geïdentificeerde FA genen. Het vinden van 
die genen zal ons inzicht in het FA/BRCA pad kunnen verdiepen. Bovendien kunnen 
die genen nieuwe aanknopingspunten bieden voor betere diagnostiek en 
behandeling van kankerpatiënten.
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